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Abstract 
Lapatinib is a tyrosine kinase inhibitor of HER2 which blocks downstream signaling 
pathways in HER2 positive breast cancer cell lines, tumor xenografts and HER2 
positive breast cancer patients. However, pre-clinical and clinical studies have shown 
that HER2 positive patients can exhibit either innate or acquired lapatinib resistance. 
Previous work in our laboratory resulted in the generation of lapatinib-resistant SKBR3 
cells which exhibit decreased phosphorylation of eEF2 compared to parental cells. The 
aims of this study were to develop additional models of lapatinib resistance, characterise 
the cell lines and identify and validate alterations which may contribute to lapatinib 
resistance. 
HCC1954-L cells are a novel cell line model of acquired lapatinib resistance, developed 
through low-dose continuous conditioning with lapatinib. Using array CGH technology, 
HCC1954-L cells were found to have increased amplification and expression of 
STARD3. The decreased phosphorylation of eEF2 in SKBR3-L cells was found to be 
regulated by Ser359 phosphorylation of eEF2k in an mTOR-independent manner, 
suggesting a role for alterations in eEF2k and eEF2 in acquired lapatinib resistance. 
SILAC-proteomic analysis with SKBR3-par and SKBR3-L cells identified alterations in 
a number of different proteins of which CDK1, GAPDH, HER2, SELENBP1, SET and 
EBP1 were validated. Lapatinib conditioning of HCC1419 cells revealed a novel 
potential mechanism of lapatinib action – the induction of a senescent-like phenotype, 
which was reversed when lapatinib was removed from the media, suggesting a possible 
mechanism of lapatinib resistance, which may be dependent on p53 and p16 expression. 
Alterations in the phosphorylation of AKT, ERK, p70S6k and eEF2 correlated with 
lapatinib sensitivity in a panel of ~HER2-amplifed breast cancer cell lines.  
In conclusion, our data suggests several novel mechanisms of lapatinib resistance which 
warrant further investigation in in vivo models of HER2 positive breast cancer and 
ultimately in patients. 
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Chapter 1 
 
Introduction 
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1.1 Introduction 
Cancer is a term given to a group of diseases characterised by abnormal cell growth, 
increased rate of cell proliferation and decreased cell apoptosis. Cell 
division/proliferation is an essential function of cells and is strictly regulated by a 
variety of external signals, including contact with neighbouring cells, contact with the 
extracellular matrix, and secreted growth factors and hormones. Cancer begins when a 
single cell begins to divide abnormally, resulting in exponential growth of cancer cells 
which form a tumour or neoplasm [1].  
Breast cancer is the most prevalent form of invasive cancer, (excluding non-melanoma 
skin cancer), diagnosed in women in Ireland, with an average annual incidence of 2673, 
equating to 125.4 women per 100,000 (2007 – 2009). Breast cancer was second only to 
lung cancer as the leading cause of cancer death in Ireland in 2007 [2]. It was estimated 
that 230,480 women would be diagnosed with and 39,520 women would die of breast 
cancer in the USA in 2011 [3].  
1.2 Breast cancer subtypes  
Breast tumours consist of several pathological subtypes with different histological 
appearances of the malignant cells, different clinical presentations and outcomes, and 
the patients show a diverse range of responses to a given treatment [4]. Until recently, 
breast cancer was sub-classified on the basis of cellular morphology and the presence 
or absence of several receptors, namely the oestrogen receptor (ER), progesterone 
receptor (PR) and the epidermal growth factor receptor 2 (HER2) [5]. In recent years, 
gene expression studies using DNA micro-arrays have been used to further classify 
breast cancer subtypes based on the gene expression pathways of an intrinsic gene list 
of 496 genes. The variation in expression in this set of genes was used to group breast 
cancer tumour samples into various subtypes [6]. The identified subtypes differ in 
prognosis and the therapeutic targets they express [7]. Five distinct types of breast 
cancer have been identified using these techniques, including two ER-positive groups 
called luminal (A and B). Luminal tumours share features with luminal epithelial cells 
arising from the inner layer of the duct lining. A third group identified were called 
HER2 positive as they exhibited over-expression of HER2. A fourth group of tumours 
were found to have a high expression of basal epithelial-cell genes and a low 
expression of luminal epithelial-cell genes, this group is known as the normal type. The 
fifth subgroup is the basal-like; this group lacks expression of ER, PR and HER2. A 
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number of studies have shown that the HER-2 positive and the basal-like sub-types 
have a poorer prognosis than either luminal or normal-like tumours [8-10].  
1.3 Epidermal Growth Factor Receptor 2 (HER2) 
The HER2-neu (c-ERBB-2) proto-oncogene encodes HER2, a 185-kilodalton 
glycoprotein associated with tyrosine kinase activity [11]. The epidermal growth factor 
family of transmembrane receptors (ERBB or HER) are potent mediators of normal cell 
growth and development. This family of receptors has four known members EGFR 
(HER1 or ERBB1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4). The 
receptors are composed of an extracellular ligand binding domain, an α-helical 
transmembrane domain and an intracellular protein tyrosine kinase domain [12].  
1.3.1 Role of HER2 in normal development  
The HER receptors are widely expressed and functionally important in multiple tissues, 
particularly in mammalian development. HER2 plays a role in neuregulin (heregulin) 
signalling and is expressed in the developing nervous system [13]. HER2 plays a central 
role in the formation of the sympathetic nervous system, and HER2 mutant mouse 
embryos die at mid-gestation, soon after the effects of early defects in sympathetic 
nervous system development become apparent [14]. HER2 plays an essential role in the 
prevention of dilated cardiomyopathy as mice with a ventricular deletion of HER2 
displayed multiple independent parameters of dilated cardiomyopathy [15, 16]. 
1.3.2 HER2 in breast cancer 
HER2 is frequently overexpressed in breast cancer. The HER2 gene is either amplified 
or overexpressed at the protein level in approximately 25% of breast cancers [17]. 
Tumours are classed as HER2 positive if they achieve; immunohistochemistry (IHC) 
staining of 3+, a fluorescent in situ hybridisation (FISH) result of more than 6 HER2 
gene copies per nucleus or a FISH ratio of more than 2.2 [18]. The FISH ratio is 
calculated as the ratio of HER2 gene signals to chromosome 17 signals. HER2 status in 
breast cancer correlates positively with tumour size, lymph node status, high tumour 
grade, DNA aneuploidy, p53 mutation, high proliferative index, high urokinase-type 
plasminogen activator expression, and reduced ER and PR levels [19, 20]. HER2 
overexpression is associated with a poor clinical outcome [17]. 
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1.3.3 Activation of HER2 
HER receptors are activated by a number of ligands, referred to as EGF-related peptide 
growth factors [21]. These are produced as transmembrane precursors, and are 
processed and released by proteolysis. This cleavage, referred to as ectodomain 
shedding, is an important step in the control of ligand availability and receptor 
activation [22].  The known EGF ligands that bind to the HER receptors are EGF, 
transforming growth factor-α, amphiregulin, heparin-binding EGF, betacellulin, 
epiregulin, and heregulin [12, 23]. Ligand binding to HER receptors induces the 
formation of receptor homo- and heterodimers and the activation of the intrinsic kinase 
domain, resulting in phosphorylation on specific residues within the cytoplasmic tail. 
These phosphorylated residues serve as docking sites for a range of proteins, the 
recruitment of which leads to the activation of intracellular signalling pathways [12].  
Receptor dimerisation is essential for the function and signalling activity of these 
receptors. The receptors can form either hetero- or homodimers, and heterodimers have 
a greater signalling potency than homodimers. The HER2-HER3 heterodimer is 
considered the most potent HER-dimer with respect to the strength of interaction, ligand 
induced tyrosine phosphorylation and downstream signalling [24, 25]. The receptors 
normally exist as inactive monomers with the molecules folded in such a way as to 
prevent dimerisation [26].  
Ligand binding to the extracellular domain induces a conformational change in the 
receptor which exposes the dimerisation domain. After dimerisation, transactivation of 
the tyrosine kinase portion of the dimer occurs as each receptor activates its partner by 
phosphorylation leading to the activation of numerous downstream signalling cascades 
[Figure 1-1]. EGFR and HER4 both have an active kinase domain and known ligands to 
activate them [12]. Although HER3 can bind several ligands it is frequently reported to 
lack an active kinase domain rendering it incapable of binding ATP [27]. However, 
recent studies have shown that HER3 is locked in an inactive conformation and is 
capable of binding ATP yet remains catalytically inactive [28]. In the HER family, 
dimerisation of kinase domains occurs in an asymmetric conformation, leading to the 
allosteric activation of one kinase domain by the other [29]. The activating kinase 
domain does not have a catalytic role suggesting that the HER3 kinase domain may 
function as a highly specialised allosteric activator of other HER receptors [30]. HER2 
has an active kinase domain but no known ligand. It exhibits the strongest kinase 
activity of the HER family [31]. HER-2/HER-3 dimers are thought to be the most active 
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and potent signalling heterodimers of the family. In addition, HER-2-containing dimers 
undergo slower dissociation and endocytosis, and are more frequently recycled back to 
the cell surface, prolonging the potent signals [32, 33]. The potential ligand binding site 
in HER-2 also differs significantly from that of EGFR and HER-3, resulting in a 
receptor structure that is constitutively poised in an active conformation. It has also 
been reported that HER2 fails to form homodimers as a result of this altered structure 
[34]. The constitutively active formation of HER2 makes it the preferred partner for 
heterodimerisation [35].  
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Figure 1-1: (a) EGFR, HER3 and HER4 exist in a tethered “closed” conformation in 
which dimerisation is inhibited in the absence of ligand binding. HER2 has no known 
ligand and exists in an “open” conformation making it constitutively active and poised 
for dimerisation. (b) Ligand binding to HER receptors seems to induce a conformational 
change in the folded structure of the molecule that exposes the dimerisation domain, a 
required step for dimer formation and functional activation of EGFR, HER3 and HER4. 
The kinase domain interaction is asymmetric with the amino-terminal lobe of one 
tyrosine kinase interacting with the carboxy-terminal lobe of the other. Note, HER3 is 
depicted here as having an inactive kinase domain. [Reproduced from [36]]. 
1.4 HER2 signalling pathways 
The best characterised signalling pathways activated by the HER family are the 
phosphatidylinositol-3 kinase/AKT (PI3K/AKT) and the Ras/mitogen-activated protein 
kinase (Ras/MAPK) pathways [Figure 1-2]. 
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Figure 1-2: Activation of HER2 signalling pathway: HER2 is transported to the plasma 
membrane by heat shock protein (Hsp) 90. Ligand binding induces HER2 
heterodimerisation with EGFR, HER3 and HER4 activating the P13K/AKT, MAPK and 
PKC pathways, promoting proliferation and cell survival. Cleavage of HER2 by A 
Disintegrin and A Metalloprotease (ADAM) proteases produces an extracellular domain 
(ECD), which is shed, and a truncated membrane-bound p95 fragment which is capable 
of heterodimerisation and activates downstream signalling pathways. [Adapted from 
[37]].     
1.4.1 MAPK signalling pathway 
Each of the HER receptors contain at least one docking site for Src homology 2-
containing proto-oncogene (Shc) in the cytoplasmic tail of the receptor. Shc is the most 
common HER2 interacting protein and HER2 has 5 docking sites for Shc. Shc has 3 
known isoforms and it mediates signalling from numerous receptor tyrosine kinases 
(RTKs) [38]. Phosphorylation of Shc causes it to associate with Growth Factor Receptor 
Bound 2 (Grb2) [39]. Grb2 can also bind directly to HER2 at tyrosine 1139. In the 
cytosol, Grb2 is bound to the guanine nucleotide exchange factor Son-of-Sevenless, 
(named for its homolog in drosophila), (Sos). The Grb2-Sos complex binds to the 
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membrane bound protein Ras. Inactive Ras is bound to GDP, activated Grb2-Sos 
catalyses the exchange of GDP to GTP leading to the activation of Ras [40]. This allows 
Ras to bind several effector proteins, including B-Raf. Activated B-Raf phosphorylates 
and activates MEK1 (also known as MAPK kinase). This in turn activates the 
extracellular signal-related kinases ERK-1 and ERK-2 (p42/44 MAPK). This leads to 
activation of members of the activator protein 1 (AP-1) family, the best characterised of 
which are jun and fos. Once activated, jun and fos translocate to the nucleus where they 
form a complex and bind to an AP-1 motif of DNA. This leads to the expression of 
many genes which mediate cellular processes including proliferation, differentiation and 
cell survival [Figure 1-3].  
 
 
 
Figure 1-3: Schematic representation of growth factor receptor mediated activation of 
the MAPK signalling cascade. 
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1.4.2 PI3K/AKT signalling pathway 
Phosphatidylinositol-3 kinases, (PI3Ks), constitute a lipid kinase family characterised 
by their ability to phosphorylate an inositol ring 3’-hydroxyl (-OH) group in inositol 
phospholipids. Class-I PI3Ks are heterodimers composed of a catalytic subunit (p110) 
and an adaptor/regulatory subunit (p85). This class is further divided into the subclass 
IA, which is activated by RTKs and the subclass IB, which is activated by receptors 
coupled with G proteins. Activation of PI3K occurs through binding of its p85 
regulatory subunit to a phosphotyrosine residue on an RTK. While HER2 does not 
contain a docking site for PI3K, HER3 contains 6 PI3K docking sites in its intracellular 
domain [41]. PI3K can also bind to activated Ras-GTP which in turn activates PI3K. 
The p110 subunit of active PI3K binds to phosphatidylinositol-4,5-bisphosphate (PIP2), 
which is anchored to the lipid layer of the cell membrane by two fatty acids. PI3K 
phosphorylates PIP2 to phosphatidylinositol-3,4,5-trisphosphate (PIP3) [42]. PIP2 and 
PIP3 act as docking sites for proteins containing a pleckstrin homology (PH) domain. 
PH domains are found in many proteins, including the protein serine/threonine kinases 
3’-phosphoinositide-dependent kinase-1 (PDK1) and AKT/PKB, both central for the 
transforming effects of deregulated PI3K activity [43]. AKT binds to PIP3 resulting in 
its translocation to the plasma membrane where it is phosphorylated by PDK1 at Thr 
308. Full activation of AKT requires a second phosphorylation at Ser 473 which lies 
within in the hydrophobic motif (HM) near the C-terminal regulatory domain of AKT 
[44]. So far, at least 10 kinases have been suggested to function as HM kinases or a so-
called “PDK2”. These kinases include: mitogen-activated protein (MAP), kinase-
activated protein kinase 2 (MK2), integrin-linked kinase (ILK), p38 MAP kinase, 
protein kinase C (PKC), NEK6, the double-stranded DNA-dependent protein kinase 
(DNK-PK) and the ataxia telangiesctasia mutated (ATM) gene product [45]. However, 
recent studies now suggest that mammalian target of rapamycin complex 2 (mTORC2) 
is the exclusive kinase which phosphorylates AKT at Ser473 [44, 46-48]. Active AKT 
is released into the cytosol where it phosphorylates multiple effector proteins which 
mediate cell regulatory processes including apoptosis, protein synthesis and 
proliferation [Figure 1-4].  
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Figure 1-4: Schematic representation of the biological function of activated AKT. AKT 
regulates the activity of intracellular signalling proteins that trigger changes in the 
expression of proteins involved in cell survival, cell cycle and proliferation and protein 
synthesis [Reproduced from [49]]. 
 
1.4.3 Effects of activated AKT on cell regulatory processes 
1.4.3.1 Inhibition of apoptosis 
Active AKT phosphorylates the pro-apoptotic proteins Bcl-2 antagonist of cell death 
(BAD), pro-caspase 9 and members of the Forkhead family of transcription factors 
leading to their inactivation and subsequent inhibition of apoptosis [50]. AKT down 
regulates the pro-apoptotic protein p53 by activating mouse double minute 2 homolog 
(MDM2) which promotes p53 degradation [51]. AKT activation has also been linked to 
resistance to TNF-Related Apoptosis Inducing Ligand (TRAIL) induced apoptosis [52].  
1.4.3.2 Cell cycle progression and cell proliferation 
AKT inhibits glycogen synthase kinase-3 (GSK3) phosphorylation of β-catenin which 
results in the translocation of β-catenin to the nucleus where it induces the expression of 
Cyclin D leading to cell cycle progression [53]. AKT also phosphorylates p21
CIP1/WAF1
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and p27
KIP1
 which inhibits their anti-proliferative effects by retaining them in the 
cytoplasm [50]. These effects lead to cell cycle progression and cell proliferation.  
1.4.3.3 Inhibition of tumour suppressors  
AKT lowers the concentration of Forkhead Box Class O (FOXO) proteins, a family of 
tumour suppressors, via phosphorylation of FOXO proteins. Phosphorylated FOXO 
proteins are substrates of the enzyme ubiquitin ligase which transfers ubiquitin peptides 
onto the proteins causing them to be degraded by the proteosome. Therefore AKT 
blocks the FOXO tumour suppressive effect on cell proliferation [54-56].  
1.4.4 AKT and regulation of protein synthesis 
AKT plays a pivotal role in regulating protein synthesis through activation of the 
mammalian target of rapamycin (mTOR) pathway. mTOR forms two complexes, 
mTORC1 and mTORC2. mTORC1 is composed of mTOR, regulatory associated 
protein of mTOR (raptor), proline-rich AKT substrate of 40 kD (PRAS40) and 
mLST8/GβL [57]. mTORC2 is composed of mTOR, rapamycin-insensitive companion 
of mTOR (rictor) and mLST8/GβL. In addition to its role in the phosphorylation of 
AKT, mTORC2 is involved in the regulation of cell morphology and the cytoskeleton 
[58]. AKT activates Ras-homologue enriched in brain (Rheb) which results in the 
activation of mTORC1 [57]. Activated mTORC1 phosphorylates ribosomal S6 kinase 1 
(p70S6k) and eukaryotic initiation factor 4E-binding protein (4E-BP1). p70S6k, 
promotes increased mRNA translation by phosphorylating ribosomal protein S6, and 
promotes protein synthesis by phosphorylating eukaryotic elongation factor 2 kinase 
(eEF2k) which inhibits its negative regulation of eukaryotic elongation factor 2 (eEF2) 
[59, 60]. mTORC1 phosphorylation of 4E-BP1 results in the release of eukaryotic 
translation initiation factor 4E (eIF4E) which enhances mRNA translation [61]. The 
activation of mTOR signalling and its downstream pathways are illustrated in [Figure 1-
5]. 
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Figure 1-5: Schematic representation of AKT mediated activation of mTOR and 
subsequent downstream signalling pathways. Arrows represent activation while bars 
represent inhibition. This diagram has been adapted from [62]. 
 
1.5 Breast Cancer Treatment Strategies 
The treatment of breast cancer can be categorised as either conventional or targeted 
therapy. Conventional therapy includes surgery, radiation therapy and chemotherapy 
while targeted therapy utilises drugs which specifically target cancerous cells.  
1.2.1 Conventional Therapy 
Surgery is one of the oldest methods of localised breast cancer treatment, of which there 
are two distinct strategies, breast conserving therapy (BCT) and mastectomy. BCT is 
the treatment of primary breast cancer without the removal of the entire breast tissue, 
also known as a lumpectomy [63]. A mastectomy involves the removal of the breast 
Growth factor 
receptor
PI3K
AKT
PTEN
TSC
AMPK
LBK1
mTORC1
Bheb
mTORC2
P
PIP2
PIP3
P
PDK1
P
4E-BP1
eIF4E
P
p70S6k
P
S6
eEF2k
eEF2
P
P
 19 
 
(total mastectomy), the breast and auxiliary lymph nodes (modified radical mastectomy) 
or the breast, lymph nodes and pectoral muscles (radical mastectomy) [64]. Removal of 
the lymph nodes is not a curative measure but rather a means of determining if further 
treatment is required, as the presence of cancerous cells in the lymph nodes indicates a 
risk of metastasis, which is the movement or spread of cancer cells from one organ or 
tissue to another [65]. Randomised trials that compared mastectomy with BCT (with 
adjuvant radiotherapy) showed no difference in overall survival; however BCT is 
associated with a higher local recurrence rate [64].  
Radiation therapy, like surgery, is primarily used in the treatment of localised breast 
cancers. The primary action of radiation therapy is to damage DNA, either directly or by 
the generation of reactive chemical species (such as oxygen free radicals) within cells. 
Whole breast irradiation (WBI), in conjunction with breast conserving surgery, reduces 
the risk of early breast cancer recurrence, leads to a significant improvement in overall 
survival and has become a standard treatment in the care of early breast cancer. 
However, the long duration of conventional WBI regimens negatively impacts on 
quality of life. An alternative approach is to deliver radiation to a limited volume of 
tissue cavity only (partial breast irradiation) and delivering a larger than standard dose 
of radiation with each treatment (accelerated partial breast irradiation, APBI). APBI 
focuses treatment on the lumpectomy bed. Many methods of delivering APBI have been 
developed including: multi-catheter interstitial brachytherapy, MammoSite balloon 
catheter, single insertion multicatheter devices, 3D conformal external-beam radiation 
therapy, permanent seed implant and intraoperative techniques using electrons or low-
energy photons. Studies of APBI have demonstrated excellent local control and 
cosmetic outcomes in early-stage breast cancer patients [reviewed in [66], [67]]. 
Chemotherapy is the use of a chemical agent to kill cancer cells. The ultimate clinical 
effectiveness of any anticancer drug requires that it kill malignant cells in vivo at doses 
that allow enough cells in the patient’s critical tissues (bone marrow and gastrointestinal 
tract) to survive to ensure that recovery can occur [68]. In general, anticancer drugs are 
most useful against malignant tumours with a high proportion of dividing cells. Thus, in 
practical terms, chemotherapy alone is primarily effective against leukaemia and 
lymphomas only. The most common tumours however, including those of breast cancer, 
usually have a low proportion of dividing cells and therefore are less susceptible to 
treatment with chemotherapy alone. Surgery and radiation therapy can often eradicate 
primary or localised tumours but they are not effective once the cancer has metastasised 
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to other parts of the body [69]. A systemic therapy such as chemotherapy is required to 
control and eliminate metastatic cancer. Chemotherapy drugs often show increased 
effectiveness when used in combinations [70]. The combinations of chemotherapeutic 
agents used in the treatment of breast cancer are described in Table 1-1. As the mode of 
action of anticancer drugs is to attack cells which are dividing at an increased rate, they 
also attack non-cancerous cells of the body which naturally divide quickly, for example, 
the bone marrow, the lining of the mouth and intestines, hair follicles and blood cells. 
This results in a number of known side effects including; hair loss, mouth sores, loss of 
appetite, nausea/vomiting, infections (due to low white blood cell counts), excessive 
bruising and bleeding (due to low platelet counts) and fatigue (due to low red blood cell 
counts) [68]. Some chemotherapeutic agents are also associated with chemotherapy-
induced heart failure; many cancer survivors now have a higher risk of cardiovascular 
diseases than of recurrent cancer [71].  
Table 1-1: Chemotherapeutic regimens utilised in the treatment of breast cancer. 
Information adapted from [72].  
Abbreviation Components of chemotherapeutic regimen 
AC doxorubicin [Adriamycin]; cyclosphamide 
AC > T doxorubicin; cyclosphamide; paclitaxel [Taxol] 
CMF cyclosphamide; methotrexate; 5-fluorouracil 
FAC (CAF) 5-fluorouracil; doxorubicin; cyclosphamide 
FEC-100 5-fluorouracil; epirubicin; cyclosphamide 
GT gemcitabine; paclitaxel 
TAC docetaxel [Taxotere]; doxorubicin; cyclosphamide 
TC docetaxel; cyclosphamide 
EC epirubicin; cyclophosphamide 
AT doxorubicin; docetaxel 
 
1.2.2 Targeted Therapy 
Since the late 1950s the predominant modalities in the treatment of breast cancer have 
been surgery, radiation and chemotherapy. Chemotherapy and radiation work primarily 
by damaging proliferating cells at the level of DNA replication and inducing apoptotic 
cell death as a secondary response to that damage. However, chemotherapy exhibits a 
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lack of selectivity and a relatively high toxicity which has given rise to a need for novel 
drugs with a more specific action [73]. In the late 1980s new signalling networks that 
regulate cell proliferation and survival were discovered including: membrane growth 
factor receptors, cytoplasmic signalling molecules, nuclear cell cycle proteins, 
modulators of apoptosis and angiogenesis promoters [69, 74]. Since then, many new 
drugs have been developed which target these proteins. The first targeted therapy for 
breast cancer, tamoxifen, which targets the oestrogen receptor, was discovered over 40 
years ago [75]. The major classes of targeted therapeutic agents used in the treatment of 
breast cancer are, small molecule tyrosine kinase inhibitors (TKIs), selective oestrogen 
receptor modulators (SERMs), aromatase inhibitors and monoclonal antibodies (mAbs).  
1.6 HER2 targeted therapy – monoclonal antibodies 
HER2 positive breast cancer is associated with a poorer prognosis than HER2 negative 
breast cancer [17]. The discovery of trastuzumab, a monoclonal antibody which targets 
HER2 revolutionised the treatment of HER2 positive breast cancer.  
1.6.1 Trastuzumab 
Xenograft studies using HER2 positive driven tumours indicated that targeting these 
tumours with murine mAbs against HER2 was a viable treatment strategy. One of the 
most active murine mAbs, 4D5, was humanised to reduce immunogenicity yielding 
trastuzumab (Herceptin ®, Genentech), the first mAb approved for the treatment of 
breast cancer [76, 77] [Figure 1-6]. As a single agent trastuzumab achieved response 
rates of 26 – 34 % in HER2 positive metastatic breast cancer (MBC) patients and 11-15 
% response in HER2 positive MBC patients who had progressed after chemotherapy 
[78-80]. A phase III study of trastuzumab in combination with chemotherapy in HER2 
positive MBC patients resulted in a greater overall response rate (ORR), longer duration 
of response, longer survival and a 20 % decrease in the risk of death in patients treated 
with the combination compared to chemotherapy alone [81]. 
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Figure 1-6: Ribbon diagram of the human HER2 and trastuzumab complex 
[Reproduced from [25]]. 
 
The proposed mechanisms of action for trastuzumab include:  
1) Reduction of signalling through AKT and MAPK. Trastuzumab disrupts HER2-Src 
interactions which reduces PTEN phosphorylation thus increasing its activity. This 
results in a dephosphorylation of AKT and inhibition of proliferation [82].  
2) ECD-shedding: HER2 is cleaved by proteins containing A Disintegrin and A 
Metalloprotease domain (ADAMs), the extracellular domain is shed and the truncated 
kinase domain (p95-HER2) retains the ability to form heterodimers with HER3 [83] and 
can be phosphorylated by heregulin [84]. Trastuzumab inhibits ECD-shedding in vitro 
[85] and the serum ECD levels of HER2 are lower in trastuzumab treated patients 
compared to those not treated with trastuzumab [86].  
3) Trastuzumab sensitises cells to apoptotic agents: It is currently unclear as to whether 
or not trastuzumab induces apoptosis in tumours in vivo [87, 88] but it does sensitise 
tumour cells to apoptosis-inducing agents e.g. paclitaxel and etoposide [89].  
Trastuzumab also enhances TRAIL-induced apoptosis [90], and prevents cells from 
repairing DNA damage caused by chemotherapy (e.g. cisplatin) or irradiation [91]. 
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4) Inhibition of angiogenesis: HER2 overexpression correlates with elevated levels of 
vascular endothelial growth factor (VEGF) and increased angiogenesis [92]. 
Angiogenesis is the growth of new blood vessels from pre-existing ones and is essential 
to the continued growth of a tumour. In a mouse model of HER2 positive breast cancer, 
treatment with trastuzumab resulted in a decrease in VEGF and angiogenesis and a 
subsequent increase in the anti-angiogenesis factor thrombospondin-1 [93]. 
5) ADCC: Trastuzumab activates antibody-dependent cell-mediated cytotoxicity 
(ADCC) via recruitment of natural killer (NK) cells to the tumour. The NK cells express 
an Fcγ receptor (Fcγ-R) which binds to the Fc domain on trastuzumab. Trastuzumab 
showed lower activity in Fcγ-R-knockdown mouse compared to Fcγ-positive mice [94]. 
Response to trastuzumab was associated with increased ADCC activity in a neoadjuvant 
study of HER2 positive breast cancer [87]. A recent study also suggests that in breast 
cancer cells where HER2 is non-amplified but expressed at a low level, trastuzumab can 
bind resulting in an ADCC response [95].  
As of January 2012 there were 499 clinical trials incorporating trastuzumab on 
clinicaltrials.gov. Several novel agents are being investigated in combination with 
trastuzumab including Hsp90 inhibitors, P13K/AKT/mTOR inhibitors, VEGF 
inhibitors, IGF-IR inhibitors and aromatase inhibitors. In addition, combining 
trastuzumab with other inhibitors of HER2 is currently being extensively investigated.  
1.6.2 Pertuzumab 
Pertuzumab represents a second generation of humanised monoclonal antibodies 
targeting HER2. Pertuzumab binds to an epitope in HER2 which is distinct to the 
trastuzumab binding domain [24, 25]. In contrast to trastuzumab, pertuzumab is able to 
inhibit the formation of HER2/HER3 heterodimers and activation of downstream 
signalling cascades [96-98]. Pertuzumab has been tested in combination with 
trastuzumab and docetaxel in the Cleopatra study. The combination of pertuzumab plus 
trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, 
when used as first-line treatment for HER2-positive metastatic breast cancer, 
significantly prolonged progression-free survival (PFS) from 12.4 months in the control 
group to 18.5 months in the pertuzumab arm, with no increase in cardiac toxic effects 
[99]. Pertuzumab is also being investigated in the neo-adjuvant setting in the Neosphere 
trial. Patients given pertuzumab and trastuzumab plus docetaxel had a significantly 
improved pathological complete response (pCR) rate (45.8 %), compared with those 
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given trastuzumab plus docetaxel (29.0 %), without substantial differences in 
tolerability [100]. These studies suggest an on-going role for pertuzumab in 
combination with trastuzumab for the treatment of HER2 positive breast cancer.  
1.6.3 Trastuzumab-DMI 
Trastuzumab-DM1 (T-DM1) is a novel antibody drug conjugate, whereby trastuzumab 
is linked to a microtubule agent, DM1 (a derivative of maytansine) using a non-
reducible thioether linker. T-DM1 displayed superior activity compared to unconjugated 
trastuzumab [101]. The proposed mechanism of action of T-DM1 is to bind HER2 and 
enter the cell via endocytosis of HER2. T-DM1 then undergoes intralysosomal 
proteolytic degradation resulting in anti-tubulin associated cell death [101]. Single arm 
phase I and II trials confirmed T-DM1 had robust single-agent activity in patients with 
heavily pre-treated, HER2-positive metastatic breast cancer and that it was well 
tolerated at the recommended phase II dose (3.6 mg/kg every 3 weeks) [102, 103]. In a 
randomised phase II trial of T-DM1 versus trastuzumab and docetaxel in HER2-positive 
metastatic breast cancer, TDM-1 showed equivalent efficacy with clearly decreased 
toxicity [104] and an improvement in progression free survival [105]. T-DM1 can 
effectively inhibit the growth of HER2-positive cancer cells that are resistant to 
trastuzumab and lapatinib in vitro and in vivo [106-108]. Two large multicentre phase 
III clinical trials for T-DM1 are currently recruiting; MARIANNE and EMILIA. 
MARIANNE compares single agent T-DM1 with placebo, versus T-DM1 and 
pertuzumab, versus trastuzumab in combination with a taxane (docetaxel or paclitaxel) 
[109]. EMILIA compares single agent T-DM1 versus the combination of lapatinib and 
capecitabine in patients with metastatic breast cancer previously treated with 
anthracyclines, taxanes and trastuzumab [110].  
1.7 HER2 targeted therapy – tyrosine kinase inhibitors 
The development of trastuzumab revolutionised the treatment of HER2 positive breast 
cancer spurring on the development of another group of agents which target HER2, 
tyrosine kinase inhibitors (TKIs). TKIs differ from mAbs in several ways; TKIs can be 
administered orally versus intravenously for mAbs, TKIs bind the intracellular domain 
versus the extracellular domain for mAbs, the half-life of TKIs is usually shorter than 
that of mAbs, and mAbs are thought to be more specific than TKIs, as TKIs can 
frequently target more than one kinase [reviewed in [111]]. Table 1-2 summarises the 
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HER2-targeted therapies which are currently approved or under investigation for the 
treatment of HER2 positive breast cancer.  
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Table 1-2: The properties and current status of HER2-targeted therapies. TKI (rev) denotes a reversible TKI, TKI (irrev) denotes an irreversible TKI 
and mAb denotes a monoclonal antibody. 
Drug Company Properties Targets Current Status in HER2 breast cancer 
Trastuzumab Genentech mAb HER2 Approved  
Pertuzumab Roche mAb HER2 and HER2-
HER3 heterodimers 
Phase III: Docetaxel-trastuzumab ± pertuzumab 
T-DMI Genentech mAb conjugate HER2 Phase III: Trastuzumab-taxane vs T-DM1 ± pertuzumab   
Phase III: T-DM1 vs lapatinib-capectabine 
Lapatinib GlaxoSmithKline TKI (rev) EGFR HER2 Approved: lapatinib-capecitabine in  trastuzumab refractory MBC 
Phase III: Neo-adjuvant Lapatinib ± trastuzumab vs trastuzumab 
Phase III: Lapatinib ± trastuzumab vs trastuzumab 
Neratinib Pfizer TKI (irrev) EGFR HER2  Phase III: Neratinib vs placebo  
Afatinib Boehringer 
Ingelheim 
TKI (irrev) EGFR HER2 HER4 Phase III: Trastuzumab-vinorelbine vs Afatinib-vinorelbine 
MM-111 Merrimack bi-specific Ab HER2 HER3 Phase I: MM-111 ± trastuzumab 
U3-1287 (AMG888) U3-Pharma mAb HER3 Phase I/II: Trastuzumab-paclitaxel ± AMG888  
BMS-690514 Bristol-Myers 
Squibb 
TKI (rev) EGFR HER2 HER4 
VEGFR 
Phase II: letrozole-lapatinib vs letrozole-BMS-690514 
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1.7.1 Lapatinib 
Lapatinib (Tyverb ®, Tykerb ®) is an orally active, low molecular weight TKI [Figure 
1-7]. It is a selective, reversible inhibitor of EGFR and HER2; it binds to the ATP 
binding site of both receptors preventing signal transduction through both the MAPK 
and PI3K/AKT pathways, leading to an increase in apoptosis and decrease in cellular 
proliferation [112].  
1.7.1.1 Pharmacodynamics of lapatinib 
Lapatinib is a 4-anilinoquinazoline which binds selectively to EGFR and HER2. 
Lapatinib is one of the most specific kinase inhibitors approved for the treatment of 
cancer. When 20 kinase inhibitors (at 10 µM) were compared in an in vitro binding 
assay against a panel of 113 substrates, lapatinib was one of the most specific, targeting 
HER2 and EGFR with 10-fold greater affinity than any off-target substrates [113]. 
Lapatinib inhibits HER2 with an IC50 of 9.2 nM, EGFR with an IC50 of 10.8 nM, HER4 
with an IC50 of 0.367 µM and c-Src with an IC50 of 3.5 µM making lapatinib a highly 
selective HER2/EGFR inhibitor [114].  
.  
Figure 1-7: Chemical structure of lapatinib [Reproduced from [114]].  
Lapatinib has a moderate rate of absorption after oral administration with peak plasma 
concentrations at several hours post-treatment, and is assumed to have a low 
bioavailability. Lapatinib is extensively distributed in human tissues, including tumour 
tissues, has a large volume of distribution at least 3-fold exceeding the volume of body 
water and is extensively (about 95%) protein bound to α1-acid glycoprotein and 
albumin. Lapatinib undergoes metabolism via hepatic and intestinal cytochrome P450 
and is eliminated by biotransformation [reviewed in [115]]. The serum concentrations 
of lapatinib peak four hours after treatment, increase with increasing dose and achieve 
steady state in 6 to 7 days, suggesting an effective half-life of 24 hours. At the dose of 
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1,250 mg daily the peak plasma concentration of lapatinib in patients was 2.4 µg/ml (2.5 
µM), (ranging from 1.57 to 3.77 µg/ml) [116], and another study has shown that the 
steady-state trough concentrations of lapatinib range from 0.3 to 0.6 µg/ml (0.318 – 
0.636 µM) [117], [118].  
Lapatinib crosses the blood-brain barrier 
Overexpression of HER2 has been correlated with an increased risk of developing 
central nervous system (CNS) metastases [119, 120]. CNS may be a potential sanctuary 
site in patients with HER2-postive disease treated with trastuzumab, as evidence 
suggests that trastuzumab does not penetrate the blood-brain barrier; trastuzumab levels 
in cerebrospinal fluid were 300-fold lower than those in plasma [121]. Gefitinib, which 
is structurally similar to lapatinib, demonstrated objective response in brain metastases 
in patients with non-small cell lung cancer (NSCLC) [122], suggesting that TKIs can 
cross the blood-brain barrier. In a preclinical mouse model lapatinib inhibited the 
formation of brain metastasis and reduced the phosphorylation of HER2 in the brain 
metastasis [123]. Lapatinib as a single agent showed modest CNS activity in a phase II 
clinical trial in women with brain metastasis from HER2 positive breast cancer, who 
had been previously treated with trastuzumab [124] 
1.7.1.2 Early clinical trials with lapatinib 
Phase I trials evaluating the safety and pharmacokinetics of lapatinib were conducted in 
patients with advanced malignancies exhibiting overexpression of EGFR and/or HER2 
and provided evidence of lapatinib activity. These studies show that lapatinib is well 
tolerated at doses of up to 1600 mg/day. The predominant drug-related adverse events 
reported were diarrhoea and rash [117, 125]. Lapatinib was then examined in phase II 
trials, with a focus on breast cancer as most patients who exhibited a partial response to 
lapatinib in the phase I trials had breast cancer. As first-line therapy, lapatinib 
monotherapy resulted in objective response and clinical benefit rates of 24% and 43%, 
respectively in HER2-amplified locally advanced or metastatic breast cancer [126]. 
Lapatinib monotherapy also showed clinical activity and manageable toxicity in HER2-
overexpressing breast cancer patients who had progressed on trastuzumab [127], 
confirming the results of another study which also reported no activity in 
chemotherapy-refractory HER2-negative breast cancer [128]. Although lapatinib shows 
modest clinical activity as a monotherapy, it was the increased efficacy observed when 
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used in combination with capecitabine versus capecitabine alone that first lead to its 
approval as a breast cancer therapy. 
1.7.1.3 Lapatinib and capecitabine 
Lapatinib, in combination with capecitabine, was approved by the US Food and Drug 
Administration (FDA) on March 13, 2007, for the treatment of patients with advanced 
or HER2-overexpressing metastatic breast cancer previously treated with trastuzumab 
and an anthracycline, or taxane. Capecitabine (Xeloda ®, Roche) is an orally-
administered chemotherapeutic agent, that is enzymatically converted to 5-fluorouracil 
in the tumour, where it inhibits DNA synthesis and slows the growth of tumour tissue 
[129]. The efficacy of lapatinib in combination with capecitabine was first reported in a 
phase I study [130]. The pivotal trial, which led to regulatory approval of lapatinib, 
compared lapatinib plus capecitabine versus capecitabine alone, in HER2 positive, 
locally advanced or metastatic breast cancer, that had progressed after treatment with 
trastuzumab and an anthracycline, or taxane. The median time to progression was 8.4 
months in the lapatinib plus capecitabine group compared with 4.4 months in the 
monotherapy group, without any increased toxicity [131]. Updated results suggested a 
trend towards improved overall survival and a reduction in the risk for progression to 
central nervous system disease in the combination group [132]. A final analysis of the 
trial results suggest a 20 % decrease in the risk of death for patients treated with the 
combination versus capecitabine alone [133]. Lapatinib in combination with 
capecitabine is the first (and so far only) therapy to be approved for the treatment of 
HER2-positive breast cancer that is refractory to trastuzumab in the metastatic setting.  
1.7.1.4 Mechanism of action of lapatinib  
Lapatinib inhibits both MAPK-ERK1/2 and PI3K-AKT signalling in lapatinib-treated 
HER2 positive breast cancer cell lines, tumour xenografts and in clinical tumour 
biopsies obtained from women with HER2 positive breast cancer treated with lapatinib 
[112]. Several proposed mechanisms of action of lapatinib are out-lined below.  
Inhibition of HER2 and EGFR signalling 
Sensitivity to lapatinib is independent of the levels of EGFR in HER2 overexpressing 
breast cancer cells. This indicates that the effects of lapatinib are as a result of inhibition 
of HER2 signalling rather than a combination of EGFR and HER2 inhibition. In patient 
samples, lapatinib responsiveness was also correlated with HER2 expression but not 
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EGFR expression. HER2 overexpressing patients benefitted from lapatinib regardless of 
EGFR expression [112, 114, 117, 134]. 
Induction of stress response pathways 
As previously mentioned, HER2 is essential for cardiac development and function. 
Trastuzumab treatment is associated with increased incidence of cardiac-toxicity 
compared to chemotherapy alone [135], and anthracycline-trastuzumab combination 
therapy is associated with higher cardiac-toxicity compared to trastuzumab in 
combination with non-anthracycline-based chemotherapy [136]. In contrast, lapatinib 
treatment has been associated with a low-rate of cardiac toxicity [137]. GW2974, a 
lapatinib analogue, protects cardiac myocytes from apoptotic stimuli by activating 
AMP-regulated protein kinase (AMPK), which switches cells from an anabolic to a 
catabolic state of metabolism [138]. Trastuzumab does not activate AMPK which may 
explain, in part, why lapatinib is associated with a low incidence of cardiotoxicity 
compared to trastuzumab. This study suggests that activation of AMPK may be 
necessary to preferentially induce apoptosis in tumour cells while sparing cardiac cells 
[138].  
Inhibition of drug efflux pumps 
Drug efflux pumps are expressed in a broad spectrum of tissue, including cancerous 
tissue. Drug-efflux is largely mediated by the ATP-binding cassette (ABC) transporters 
p-glycoprotein (P-gp) and breast cancer-related protein BCRP [reviewed in [139]].  
Lapatinib synergises with SN-38, (the active metabolite or irinotecan, a topoisomerase 1 
inhibitor), leading to increased levels of apoptosis in a panel of breast, lung and 
testicular cancer cell lines [140].  The synergy between lapatinib and SN-38 was due to 
SN-38 intracellular accumulation via inhibition of BCRP by lapatinib. In addition, high 
dose lapatinib (10 µM) inhibited the efflux of mitoxantrone, a specific BCRP substrate, 
in a manner similar to fumitremorgin C, a BCRP inhibitor, suggesting that lapatinib is 
an inhibitor of BCRP [140]. Lapatinib treatment has also been shown to increase the 
expression of P-gp in a lung-cancer cell line with acquired resistance to paclitaxel, 
however the increased expression of P-gp was not associated with increase drug 
accumulation or activity [141].  
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Induction of apoptosis 
Early studies with lapatinib report a 23-fold increase in apoptosis in HER2-amplified 
cells following lapatinib treatment [112], and later studies, by the same group, show an 
even greater enhancement of apoptosis when lapatinib is combined with trastuzumab 
[142]. Increased apoptosis in lapatinib and trastuzumab treated cells also correlates with 
decreased levels of survivin [143]. Lapatinib-mediated apoptosis has also been 
associated with the upregulation of the pro-apoptotic protein Bcl-2 interacting mediator 
of cell death (BIM) through inhibition of the MAPK signalling pathway in breast cancer 
cells with HER2 amplification [144]. Lapatinib-mediated apoptosis can also be 
increased through inhibition of the anti-apoptotic protein, myeloid cell leukaemia 1 
(MCL-1) [145].  
Survivin is an inhibitor of apoptosis protein (IAP) which when overexpressed can 
protect breast cancer cells from apoptotic stimuli [146]. Lapatinib inhibits survivin 
expression in HER2-overexpressing breast cancer cells leading to an increase in 
apoptosis. In contrast, neither trastuzumab nor gefitinib resulted in a down-regulation of 
survivin. The down-regulation of survivin was also seen in tumour samples of HER2-
overexpressing breast cancer patients who participated in a phase 1 pilot study of 
lapatinib [147]. Failure to down-regulate survivin and/or increased accumulation of 
survivin in response to HER2 inhibition has been proposed as a possible mechanism of 
innate lapatinib and trastuzumab resistance [148].  
Cell cycle arrest 
Treatment of HER2 positive breast cancer cells with lapatinib results in cell cycle arrest, 
with cells accumulating in the G1 phase [114, 134]. Lapatinib treatment has also been 
shown to induce G1 arrest in gastric cancer [149], lung cancer [150] and in bladder 
cancer, specifically when used in combination with the chemotherapeutic regime 
gemcitabine, paclitaxel and cisplatin (GTC) [151].  
Autophagy 
Autophagy is a process involving the formation of membrane bound vacuoles 
containing lytic proteins which result in the degradation of cellular proteins and 
cytoplasmic organelles [152]. Treatment of breast cancer cells with lapatinib results in 
the induction of autophagy, which is dependent on the expression of eEF2k [153]. The 
authors of this study suggest that eEF2k-mediated autophagy plays a protective role for 
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breast cancer cells and that inhibition of autophagy in combination with lapatinib would 
result in a better therapeutic outcome. This is in contrast to another study showing that 
lapatinib in combination with a Bcl-2 inhibitor, obatoclax, caused synergistic cell killing 
by eliciting autophagic cell death indicating a non-protective role for autophagy in these 
cells [154]. Whether therapy-induced autophagy functions as a direct mechanism of cell 
death, or represents a self-defence mechanism for resisting therapy-mediated cell killing 
is still a matter for debate. The current belief is that autophagy is a cell survival 
mechanism activated in adverse conditions; continued exposure of the cells to adverse 
conditions may result in cell death, whereas alleviation of the conditions may result in 
cell survival [152]. The role of autophagy in response to lapatinib has not yet been fully 
elucidated.  
1.7.1.5 Lapatinib in clinical trials 
As of January 2012 there were 243 clinical trials with lapatinib listed on 
clinicaltrials.gov. The hypotheses, study design and results, where available, of several 
of the most interesting clinical trials, including those already completed and those still 
accruing, are summarised below. 
Lapatinib with paclitaxel 
Lapatinib in combination with paclitaxel, a microtubule interfering drug, has been 
evaluated as a first-line treatment for metastatic breast cancer (MBC). Patients with 
HER-2-negative or HER2-untested MBC did not benefit from the addition of lapatinib 
to paclitaxel. However, first-line therapy with paclitaxel-lapatinib significantly 
improved clinical outcomes in HER-2-positive patients [155]. First-line lapatinib and 
paclitaxel has shown ORR in previously untreated HER2-postive MBC patients [156]. 
Lapatinib in combination with paclitaxel has also shown clinical benefit in treatment-
naive patients with inflammatory breast cancer (IBC) [157]. Lapatinib is being 
evaluated in combination with paclitaxel and gemcitabine as a neoadjuvant treatment 
for HER2 positive breast cancer patients. A phase I dose escalation study has been 
published indicating that the combination is tolerable [158]. There are currently 35 
studies on clinicaltrials.gov examining combination of lapatinib and paclitaxel as a 
therapeutic intervention.  
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Lapatinib and docetaxel 
Lapatinib in combination with another chemotherapeutic agent, docetaxel, is also being 
investigated for the treatment of HER2 positive breast cancer. Initial phase I studies of 
lapatinib in combination with docetaxel indicate that the combination is well-tolerated 
[159]. A phase I/II study evaluating lapatinib in combination with docetaxel as first-line 
treatment for advanced or metastatic HER2 breast cancer is currently ongoing [160]. 
Docetaxel and lapatinib are being compared to docetaxel trastuzumab in several phase 
I/II clinical trials including: a phase II neo-adjuvant study assessing TCH (Docetaxel, 
Carboplatin and Trastuzumab), TCL (Docetaxel, Carboplatin and Lapatinib) and the 
Combination of TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) is 
currently underway in HER2 positive breast cancer patients [161]. 
Lapatinib with hormone therapy 
Crosstalk between HER2 and ER signalling has been implicated in resistance to ER 
targeted therapy [reviewed in [162]], providing a rationale for combining HER2 
inhibition with anti-ER based therapy. An initial phase I trial indicated the feasibility of 
safely combining lapatinib and letrozole [163]. Following this, a phase II trial 
comparing lapatinib plus letrozole, versus letrozole plus placebo resulted in significant 
improvement in PFS) in patients with ER positive and HER2-amplified MBC. The 
addition of lapatinib did not result in significant benefit in HER2-negative patients, 
however, it did result in a 23% reduction in the risk of progression [164, 165]. There are 
currently 14 clinical trials on clinicaltrials.gov evaluating lapatinib and letrozole as a 
therapeutic intervention in ER positive breast cancer which is either HER2 positive or 
HER2 negative. 
Lapatinib with trastuzumab 
Preclinical data suggests that lapatinib has a synergistic effect with used in combination 
with trastuzumab [134, 143]. A Phase III study evaluated the effects of lapatinib alone 
versus lapatinib plus trastuzumab in patients with HER2-postitve breast cancer who had 
progressed on trastuzumab and reported increased PFS and clinical benefit in the 
combination group compared to lapatinib alone [166]. The NeoALTTO trial, an 
international, multicentre, randomised phase III study, evaluating the efficacy of 
lapatinib plus paclitaxel versus trastuzumab plus paclitaxel versus concomitant lapatinib 
and trastuzumab plus paclitaxel, when given as neoadjuvant therapy in patients with 
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HER2 positive breast cancer has completed recruitment. First reported results showed 
that pCR was significantly higher in the combination of lapatinib and trastuzumab plus 
paclitaxel arm (51.3%) compared to either trastuzumab and paclitaxel (29.5 % (p < 
0.01)) or lapatinib and paclitaxel (24.7% (p < 0.01)) [167]. The ALTTO (Adjuvant 
Lapatinib and/or Trastuzumab Treatment Optimisation) trial was opened in April 2007 
and is comparing the activity of lapatinib alone, trastuzumab alone, trastuzumab 
followed by lapatinib, and concomitant lapatinib and trastuzumab. The study has 
recruited 8,381 patients and first reports on results are expected in 2013. Recently, the 
lapatinib-alone arm has been discontinued, as lapatinib alone failed to meet the pre-
specified criteria of non-inferiority to trastuzumab alone with respect to disease-free 
survival [168].  
Lapatinib is also being examined in clinical trials with angiogenesis inhibitors, 
P13K/mTOR inhibitors, inhibitors of topoisomerase 1, and multiple cytotoxic agents 
including epirubicin, temozolamide, carboplatin, docetaxel, vinorelbine and 
gemcitabine [from www.clinicaltrials.gov]. 
1.7.2 Neratinib 
Second-generation tyrosine kinase inhibitors include HKI-272 (neratinib) an irreversible 
inhibitor of EGFR and HER2. Neratinib inhibits HER2 with an IC50 of 59 nM and 
EGFR with an IC50 of 92 nM. Neratinib inhibits HER2 phosphorylation and removal of 
neratinib from the cells does not restore phosphorylation of HER2, thus the inhibition is 
irreversible [169]. In a phase II study, neratinib monotherapy showed clinical benefit 
among patients with HER2-positive breast cancer who were pre-treated with 
trastuzumab, the median PFS was 23 weeks and the objective response rate was 24 %. 
This study also evaluated neratinib as a monotherapy in HER2-positive breast cancer 
patients who had not been pre-treated with trastuzumab, interestingly the PFS doubled 
to 40 weeks and the objective response rate rose to 56 % [170]. Neratinib-monotherapy 
is being evaluated in a phase III trial in HER2 positive breast cancer following adjuvant 
trastuzumab therapy [171]. Neratinib is currently in multiple clinical trials including; a 
phase I/II study in combination with paclitaxel [172], in combination with trastuzumab 
[173], a phase II studying comparing neratinib and paclitaxel versus trastuzumab and 
paclitaxel (NEFERTT) [174] and a phase II study evaluating neratinib versus lapatinib 
and capecitabine in HER2 positive advanced breast cancer [175].   
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1.7.3 Afatinib 
BIBW-2992 (afatinib) is also an irreversible inhibitor of EGFR, HER2 and HER4, with 
an IC50 of 14 nM for HER2 and 0.5 nM for EGFR [176, 177]. Afatinib is being 
examined extensively as a treatment for lung cancer in the LUX-Lung program, and 
early results indicate that afatinib significantly prolongs PFS compared with placebo in 
pretreated patients with clinically acquired resistance to gefitinib or erlotinib [178, 179]. 
Afatinib has also been shown to overcome acquired resistance to cetuximab, an EGFR 
monoclonal antibody [180]. Afatinib is also being investigated in several trials in HER2 
positive patients including; alone and in combination with paclitaxel or vinorelbine in 
patients who have progressed on prior HER2-targeted therapy [181], as a single agent 
versus lapatinib or trastuzumab in HER2 positive treatment naïve patients [182] and 
also in HER2 positive IBC [183]. A phase III trial of afatinib in combination with 
vinorelbine compared to trastuzumab and vinorelbine is currently underway in 
trastuzumab refractory breast cancer [184].   
1.7.4 Other novel HER-targeting agents in preclinical and clinical development 
In addition to the HER2-targeting agents already described, there are several agents 
which target the HER family, which are currently in pre-clinical and clinical 
development. MM-111 is a bi-specific HER2/HER3 antibody which forms a trimeric 
complex with HER2 and HER3, effectively inhibiting HER3 signalling.  MM-111 also 
inhibited the growth of cell line and xenograft models of HER2 positive breast cancer 
[185]. MM-111 is currently being investigated as a monotherapy for HER2-postive 
trastuzumab refractory breast cancer [186] and in combination with trastuzumab or 
lapatinib [187].  U3-1287 (AMG888) is a monoclonal antibody which targets HER3 and 
is currently in phase 1/11 trial in combination with trastuzumab and paclitaxel for the 
treatment of newly diagnosed HER2-positive MBC [188]. BMS-690514 is a reversible 
TKI inhibitor of EGFR, HER2, HER4 and VEGFR that has been shown to be effective 
in the treatment of erlotinib-resistant NSCLC cell lines [189]. BMS-690514 is currently 
being evaluated in combination with letrozole for the treatment of endocrine-resistant 
HER2 positive and negative breast cancer patients [188].  
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1.8 Resistance to HER2 targeted therapy 
1.8.1 Mechanisms of resistance to trastuzumab 
Although some patients with MBC respond to trastuzumab, most patients develop 
resistance to trastuzumab, while others fail to respond to trastuzumab at all [190]. The 
mechanisms of either the de novo or acquired resistance to trastuzumab are not fully 
understood but several potential mechanisms have been proposed.  
1.8.1.1 Loss of PTEN / P13K mutation 
Phosphatase and tensin homologue gene (PTEN) is a tumour suppressor which 
functions to prevent the activation of the P13K/AKT pathway, and loss of PTEN occurs 
in approximately 50 % of breast cancers [191]. Mutations in the P13KCA genes, which 
encode P13K, have been reported in approximately 30 % of breast cancers [192, 193].  
The effect of PTEN loss or P13K mutation is the hyperactivation of the P13K/AKT 
pathway. Loss of PTEN has been implicated trastuzumab resistance in vitro and in vivo, 
and loss of PTEN is a predictive marker for trastuzumab resistance [82, 194]. In vitro 
expression of mutant P13KCA in HER2-amplified breast cancer cell lines confers 
resistance to trastuzumab [195], and PI3KCA mutations were associated with shorter 
time to progression in trastuzumab-treated breast cancer patients [193].  
1.8.1.2 p95-HER2 expression 
Truncation of HER2 is believed to be a prominent mechanism of trastuzumab resistance 
and truncated HER2 is commonly referred to as p95-HER2 [reviewed in [196]]. p95-
HER2 can be generated in two ways; via cleavage or expression of splice variants. 
ADAM10, a disintergin and a metalloproteinase, mediates the cleavage of the 
extracellular domain (ECD) of HER2 leaving p95-HER2 bound to the membrane [197]. 
In addition, a role has been suggested for alternative mRNA splicing in the production 
of p95-HER2 [198]. p95-HER2 has been shown to be an independent prognostic factor 
in breast cancer, defining a subgroup of HER2 positive breast cancer patients with a 
significantly worse prognosis [199]. Retrospective studies have shown that p95-HER2 
levels in breast cancer tumours correlate with trastuzumab resistance [200, 201]. 
Although these results suggest that the presence of p95-HER2 should be considered 
when determining the treatment of a HER2 positive patient however, the detection of 
p95-HER2 through current techniques is a controversial issue. The above mentioned 
studies use Western blotting [199], or immunofluorescence using two different 
 37 
 
antibodies [200, 201] to detect p95-HER2. To date a clinically applicable assay for the 
detection of p95 has yet to be developed.  
1.8.1.3 Ligand-dependant activation of HER3 
HER2-HER3 heterodimers can be activated in a ligand-dependent or independent 
manner. Trastuzumab inhibits the ligand-independent activity of HER2-HER3 
heterodimer but has no effect on ligand-stimulated HER2-HER3 heterodimer formation 
[202]. Ligand stimulation of breast cancer cells with heregulin can overcome the 
inhibitory effects of trastuzumab [203]. Knockdown of HER3 with shRNA resensitised 
trastuzumab-resistant cells to trastuzumab [204].  Increased expression of HER3 has 
been shown in a cell line model of trastuzumab resistance [205]. However, neither the 
expression nor phosphorylation of HER3 correlates with response to trastuzumab in a 
panel of breast cancer cell lines [194] or trastuzumab-treated breast cancer patients 
[206], suggesting that trastuzumab resistance may be mediated by lack of HER2-HER3 
heterodimer inhibition rather than HER3 expression alone.  
1.8.1.5 Crosstalk with IGF-IR 
Increased expression of insulin-like growth factor receptor 1 (IGF-IR) correlated with 
diminished trastuzumab activity in HER2-amplified breast cancer cell lines [207]. 
HER2 heterodimerised with IGF-IR in trastuzumab-resistant cells, but the same effect 
was not seen in trastuzumab sensitive cells, and inhibition of IGF-IR activity increased 
the sensitivity of trastuzumab-resistant cells to trastuzumab [208]. A further study 
showed that heterodimerisation of HER2 with IGF-IR may not be limited to 
trastuzumab-resistant cells, and therefore may not be a causative factor in the 
development of trastuzumab resistance. In addition, the study showed increased 
expression of IGF-IR in a cell line model of acquired trastuzumab resistance and also 
shows enhanced activity of trastuzumab in combination with anti-IGF-IR therapy in 
trastuzumab sensitive cells [209]. A recent study implicates the formation of a 
heterotrimeric complex of HER2-HER3-IGF-IR in trastuzumab-resistant cells, and 
knockdown of HER3 or IGF-IR overcomes trastuzumab resistance [204]. Altered 
secretion of IGF-binding proteins has also been associated with trastuzumab resistance 
[210]. However, expression of IGF-IR does not predict response to trastuzumab therapy 
in patients with metastatic HER2 positive breast cancer [206, 211].  
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1.8.1.6 Other mechanisms implicated in trastuzumab resistance  
Several other pathways and proteins have also been implicated in trastuzumab 
resistance. Briefly, these include; the inability of trastuzumab to inhibit EGFR 
signalling [212], the over-expression and/or amplification of  cyclin E [213], Met 
receptor [214], EphA2 [215], the upregulation of miR-21[216], escape from ADCC 
[217], dysregulated glucose metabolism [218], and epitope masking via expression of 
mucin 4 (MUC4) [219], or CD44/hyaluronan complex [220, 221], both of which mask 
the HER2 binding site preventing trastuzumab binding to HER2.  
1.8.2 Lapatinib overcomes trastuzumab resistance  
As previously discussed, a synergistic interaction between trastuzumab and lapatinib 
has been seen in HER2-amplified cell lines [134, 143] and in clinical trials [167]. In 
addition, breast cancer cell lines exhibiting either de novo or acquired trastuzumab 
resistance remain sensitive to HER2 inhibition with lapatinib [134, 194], indicating that 
the mechanisms of lapatinib and trastuzumab resistance are non-overlapping. Several of 
the proposed mechanisms of trastuzumab resistance do not seem to apply to lapatinib, 
these include: 
1.8.2.1 Loss of PTEN / mutations in PI3K 
Loss of PTEN or PI3KCA mutations correlates with trastuzumab resistance. However, 
in preclinical studies, and clinical studies of women with HER2 positive breast cancer 
treated with lapatinib, the activity of lapatinib did not correlate with PTEN status [194, 
222, 223]. In contrast to these studies, loss of PTEN and/or P13KCA mutations have 
been implicated in lapatinib resistance in cell line and xenograft models of HER2 
positive breast cancer [224]. In addition, in HER2 positive patients treated with 
lapatinib and capecitabine, P13K activation, defined as loss of PTEN or PI3K mutation, 
was associated with lower clinical benefit and a lower ORR [224, 225]. Analysis of 
results from the NeoALTTO and ALTTO trials will hopefully determine the role of 
these alterations in trastuzumab and lapatinib resistance. 
1.8.2.2 Lapatinib inhibits p95-HER2 activity 
Trastuzumab does not inhibit p95-HER2. Cell line and xenograft models of p95-HER2 
expression were resistant to trastuzumab however, they remain sensitive to lapatinib 
[200]. Lapatinib, as a monotherapy or in combination with capecitabine, was equally 
effective in patients with p95-HER2 positive and p95-HER2 negative HER2-positive 
breast tumours [226]. This is most likely due to the fact that p95-HER2 retains the 
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active kinase domain of HER2 and loss of the extracellular trastuzumab-binding domain 
does not inhibit the functionality or activity of the kinase domain [227].  
1.8.2.3 Alterations in IGF-IR expression/activity 
Alterations in IGF-IR have been implicated in trastuzumab resistance, however, 
treatment of trastuzumab-resistant cells with lapatinib resulted in inhibition of IGF-IR 
signalling and induction of apoptosis, even in the presence of IGF-1 [228]. 
  
1.8.3 Mechanisms of resistance to lapatinib 
Since lapatinib gained FDA approval for the treatment of trastuzumab refractory HER2-
positve breast cancer in 2007, there has been increased interest in determining its 
mechanisms of action, biomarkers of activity and also elucidating mechanisms of both 
de novo and acquired resistance. The mechanisms which have been proposed for 
lapatinib resistance are outlined below, and summarised in Table 1-3. 
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Table 1-3: Published cell line models of acquired lapatinib resistance, the method and concentration used to condition the cells and the proposed 
mechanism of lapatinib resistance. * denotes greater than peak plasma concentration (2.5 µM) 
Cell line Conditioning method Lapatinib conc. Profiling technique  Resistance mechanism Ref. 
BT474 single cell cloning  5 µM * Affymetrix array Upregulation of ER signalling [229] 
BT474, SKBR3 single cell cloning  5 µM * Affymetrix array Activation of RelA [230] 
SUM190 
 
continuous exposure (0.25 – 2.5 µM) Immunoblotting Overexpression of XIAP [231] 
BT474 single cell cloning 3 µM * phospho-tyrosine 
immunoblotting 
Overexpression of AXL [232] 
HCT116 continuous exposure 10 µM * Immunoblotting Increased expression of MCL-1 [233] 
HCC1954 
BT474 
continuous exposure (0.1 – 1 µM) Immunoblotting Increased expression of β1-
integrin 
[234] 
SKBR3, MDA-MB-361, 
UACC893 
BT474, HCC1954,  
SUM190 
continuous exposure increasing conc. up to: 
1 µM or 2 µM  
phospho-proteomic 
profiling 
Increased SRC kinase activity [235] 
BT474, UACC812 continuous exposure (0.1 – 1 µM) Immunoblotting Upregulation of ER signalling  [236] 
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1.8.3.1 Upregulation of ER signalling 
Increased dependence on ER signalling has been described in an acquired model of 
lapatinib resistance [229]. ER signalling plays an essential role in breast cancer as over 
60 % of breast cancers are ER positive [237]. FOXO3a is a member of the Forkhead 
family of transcription factors and it enhances ER transcriptional activity and its 
activation is regulated by AKT [238]. A comparison of the gene expression profiles of 
acquired lapatinib-resistant BT474 cells and sensitive BT474 cells revealed increased 
expression of several genes relating to ER signalling including FOXO3a, suggesting a 
switch from dependence on HER2 for signalling and survival to co-dependence on 
HER2 and ER. Combining lapatinib with ER inhibition prevented the emergence of 
lapatinib-resistant BT474 cells. Importantly, this study also reported increased ER 
signalling in tumour biopsies from lapatinib treated breast cancer patients [229]. 
Another study, which examined the effect of acquired lapatinib resistance on ER 
signalling, found that acquired lapatinib resistance was associated with increased ER or 
its downstream products in BT474 and UACC812, HER2-postive, ER positive cell lines 
with acquired lapatinib resistance. They also showed following ER upregulation that 
prolonged conditioning with lapatinib causes a switch from ER dependence back to 
HER2 dependence in a BT474 model of acquired lapatinib resistance [236]. In a 
different BT474 model of acquired lapatinib resistance, the resistant cells exhibited 
increased expression of ER and were sensitive to inhibition with a combination of 
lapatinib and fulvestrant [232]. In contrast to these studies, an ER-positive, HER2-
postive SUM190 cell line model of acquired lapatinib resistance exhibited decreased 
expression of FOXO3a [231]. In a HCT116 colon cancer model of acquired lapatinib 
resistance, which is HER2-positive and ER-positive, resistance to lapatinib was not 
associated with increased ER expression nor was the resistance overcome by the 
addition of tamoxifen to lapatinib [233].  
1.8.3.2 Overexpression of AXL 
By examining a BT474 model of acquired lapatinib resistance, the overexpression of 
AXL protein was detected using phospho-tyrosine immunoblotting and identified using 
mass spectrometry and proposed as a mechanism of acquired lapatinib resistance [232]. 
AXL is a membrane-bound receptor tyrosine kinase containing a kinase domain closely 
related to MET and an extracellular domain resembling that of neural cell adhesion 
molecules. AXL activation is linked to several signal transduction pathways, including 
AKT, MAP kinases and NF-κB [Reviewed in [239, 240]]. AXL expression has been 
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reported in breast cancer cell lines [241] and also in human glioma carcinomas, where 
expression correlates with poorer prognosis [242]. Inhibition of AXL restored 
sensitivity to lapatinib in the lapatinib-resistant cells [232]. This study provides a 
mechanism by which HER2 positive, ER-positive breast cancer cells acquire resistance 
to lapatinib by increased expression of AXL. 
1.8.3.3 Overexpression of MCL-1 
Overexpression of myeloid cell factor-1 (MCL-1) has been reported in a HCT116 colon 
cancer cell line with acquired resistance to lapatinib [233]. The B-cell lymphoma-2 
(BCL-2) family of proteins consists of 25 pro- and anti-apoptotic proteins that regulate 
the intrinsic/mitochondrial apoptosis pathway. Anti-apoptotic proteins, including MCL-
1 associate with pro-apoptotic proteins, including BAX and BAK. When BAX and 
BAK are released from the complex with anti-apoptotic proteins they form pores in the 
mitochondrial membrane which allow for the release of cytochrome C and AIF leading 
to apoptosis. Tumour cells take advantage of this pathway to maintain survival via 
several mechanisms including: loss of expression of pro-apoptotic proteins (eg. BAX): 
and/or over-expression of anti-apoptotic proteins (eg. MCL-1) [reviewed in [243]]. The 
HCT116 colon cancer cell line with acquired lapatinib resistance had increased 
expression of MCL-1, decreased expression of BAX and decreased activation of BAX 
and BAK. Unlike sensitive cells, the lapatinib-resistant cells did not express activated 
BAX following either serum starvation or lapatinib treatment. Knockdown of MCL-1 in 
lapatinib-resistant cells enhanced lapatinib activity and this enhancement was abrogated 
by knockdown of BAX [233, 244]. Inhibition of MCL-1 has also been examined, in 
combination with lapatinib, in SKBR3 and BT474 breast cancer cell lines, whereby 
treatment with cyclin-dependent kinase (CDK) inhibitors resulted in reduced MCL-1 
expression and enhanced lethality of lapatinib. Treatment of cells with the MCL-1 
inhibitor, obatoclax, also enhanced the lethality of lapatinib in a synergistic fashion. 
Overexpression of MCL-1 or knockdown of BAX and BAK suppressed the enhanced 
lethality. This effect was also reproduced in vivo using xenograft models of BT474 cells 
[145]. Collectively, these studies suggest a mechanism whereby lapatinib resistance 
results in overexpression of MCL-1 rendering cells less susceptible to BAX/BAK-
dependent apoptosis and tumour cell death.  
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1.8.3.4 Overexpression of XIAP 
Acquired lapatinib resistance has been associated with overexpression of X inhibitor of 
apoptosis protein (XIAP) in a SUM190 model of HER2 positive IBC [231]. XIAP is an 
inhibitor of apoptosis protein (IAP) that binds to and inhibits the activation of 
procaspase-9, procaspase-7 and procaspase-3 leading to inhibition of both intrinsic and 
extrinsic apoptotic pathways. In addition to its caspase-binding function, XIAP 
regulates the activity of AKT, NF-κB and survivin. XIAP is overexpressed in tumour 
tissue compared to normal tissue including breast tumours and has been linked to 
therapeutic resistance in cervical, ovarian and prostate cancers [reviewed in [245]]. 
Expression of XIAP correlates with shorter overall survival and may act as an 
independent prognostic biomarker for invasive ductal carcinoma [246]. The SUM190 
lapatinib-resistant cells had approx. 3-fold higher expression of XIAP compared to 
sensitive parental cells and stable expression of XIAP, using a lentiviral system, 
induced resistance to lapatinib in the parental SUM190 cells [231]. Downregulation of 
XIAP using embelin, a small molecule inhibitor which abrogates the XIAP/procaspase-
9 interaction, resulted in decreased viability of SUM190 lapatinib-resistant cells. This 
suggests that XIAP is required for the survival of lapatinib-resistant cells and that XIAP 
represents a rational target for IBC patients with resistance to lapatinib [231].  
1.8.3.5 Upregulation of SRC family kinases 
Phospho-proteomic profiling of lapatinib-resistant cells suggested increased SRC (or a 
SRC family kinase) activity in a study of acquired lapatinib resistance [235]. The SRC 
family of tyrosine kinases has nine members including, YES, LYN and c-SRC (SRC). 
SRC has been implicated in pathways regulating proliferation, angiogensis, invasion 
and metastasis, and bone metabolism [reviewed in [247]]. Increased expression and 
activity of YES was observed in BT474 and UACC893 cell line models of acquired 
lapatinib resistance, and increased expression and activity of LYN was observed in a 
HCC1954 cell line model of acquired lapatinib resistance [235]. Treatment of the 
lapatinib-resistant cells with saracatinib (AZD0530) or dasatinib, both ATP competitive 
small molecule SRC inhibitors, resulted in inhibition of SRC phosphorylation, partial 
inhibition of AKT phosphorylation and inhibition of cell growth in both cell lines. 
Combined treatment of lapatinib sensitive breast cancer cell lines with lapatinib and 
saracatinib prevented the emergence of lapatinib-resistant cells. Importantly this study 
also showed that the expression of several SRC family members were upregulated in a 
small cohort of primary HER2 positive tumours following lapatinib treatment [235]. 
 44 
 
1.8.3.6 Activation of RelA 
Using a BT474 cell line model of acquired lapatinib resistance, calcium-dependent 
activation of RelA has recently been associated with lapatinib resistance [230]. RelA is 
a subunit of NF-κB, which functions to protect cells from apoptosis. NF-κB functions to 
activate anti-apoptotic proteins which negate the pro-apoptotic effects of therapeutic 
agents [reviewed in [248]]. Lapatinib treatment triggered a cytoprotective stress 
response in SKBR3 and BT474 HER2-postive lapatinib-sensitive breast cancer cell 
lines, which was mediated by activation of RelA. Inhibition of RelA not only enhanced 
the apoptotic effects of lapatinib in BT474 and SKBR3 cells, but could overcome 
lapatinib resistance in a BT474 model of acquired lapatinib resistance [230]. There was 
also a small yet significant change in RelA expression between lapatinib responders and 
non-responders in lapatinib treated HER2-postive breast tumour samples [230].  
1.8.3.7 Up-regulation of β1-integrin-mediated signalling 
By examining HCC1954 and BT474 cell line models of acquired lapatinib resistance, 
the upregulation of several kinases which lie downstream of β1-integrin have been 
implicated in lapatinib resistance [234]. β1-intergrin is a critical mediator of breast 
cancer initiation and progression [249], has been associated with EGFR expression 
[250] and linked to therapeutic resistance in multiple cancer types.  Notably, β1-integrin 
has been suggested as a predictive indicator for patients with de novo resistance to 
trastuzumab [251]. Acquired lapatinib resistance, in HCC1954 and BT474 lapatinib-
resistant cells, was associated with increased expression of focal adhesion kinase (FAK) 
and SRC, downstream of β1-integrin [234]. In addition, inhibition of β1-integin 
significantly inhibited the growth of lapatinib-resistant HCC1954 and BT474 cells but 
did not significantly affect sensitive cells, suggesting a role of β1-integrin in acquired 
resistance to lapatinib.       
1.8.3.8 Failure to downregulate survivin 
Survivin is an IAP which when overexpressed can protect breast cancer cells from 
apoptotic stimuli [146]. One of the mechanisms of lapatinib action is the down-
regulation of survivin. Failure to downregulate survivin was associated with lapatinib 
resistance in JIMT-1 cells, which represents a HER2-amplified cell line model of innate 
lapatinib resistance [148]. Thus, this suggests that constitutive activation of survivin 
protects the cells from lapatinib-mediated apoptosis. Knockdown of survivin in 
combination with HER2 inhibition suppressed proliferation and colony formation of the 
lapatinib-resistant cells [148].   
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1.8.3.9 Induction of autophagy 
Induction of autophagy in response to lapatinib treatment has been proposed as a 
potential mechanism for lapatinib resistance [252]. Interestingly induction of autophagy 
has also been suggested as a mechanism of action for lapatinib in lapatinib sensitive 
breast cancer cells [154]. The role of autophagy in lapatinib resistance has yet to be 
fully explored or confirmed. 
1.8.3.10 Upregulation of Grb7 
Growth factor receptor-bound 7 (Grb7) is an adaptor protein which is frequently co-
amplified with HER2 [253]. Lapatinib induces upregulation of Grb7 in cancer cells in 
vitro and in vivo. P13K signalling normally represses Grb7. Inhibition of AKT by 
lapatinib leads to Grb7 de-repression, and thus increased Grb7 expression. Knockdown 
of Grb7 reduces breast cancer cell viability and increases the activity of lapatinib [254]. 
This study suggests that Grb7 upregulation is a potentially adverse consequence of 
HER2 inhibition and that preventing Grb7 accumulation and or/its interaction with 
RTKs may increase the benefit of lapatinib. 
1.8.3.10 Decreased phosphorylation of eEF2 
Unpublished data from our laboratory identified eukaryotic elongation factor 2 (eEF2) 
as a protein whose phosphorylation is significantly altered in a model of acquired 
lapatinib resistance [255]. eEF2 is a monomeric GTPase that plays an essential role in 
regulating protein synthesis. Phosphorylation of eEF2 which results in its inactivation 
can occur through various different pathways, including the mTOR pathway [reviewed 
in [60, 256]]. A number of phosphorylated forms of eEF2 were significantly decreased 
in lapatinib-resistance SKBR3 cells compared to lapatinib-sensitive SKBR3 cells [255]. 
This suggests that altered phosphorylation of eEF2 may play a role in lapatinib 
resistance.  
1.9 Quantitative methods used to identify alterations in lapatinib-resistant models 
Various different techniques were utilised to identify the alterations discussed above, 
including; either unbiased pathway [233, 244]  or selective [231] immunoblotting 
analysis; immunoblotting coupled with mass-spectrometry-based peptide sequencing 
[232]; phospho-tyrosine proteomics [235] and human affymetrix oligonucleotide array 
platform [229]. Below, the quantitative methods utilised in this study to identify 
alterations in models of acquired lapatinib resistance are discussed.  
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1.9.1 Array Comparative Genome Hybridisation analysis (aCGH) 
aCGH analysis, also known as molecular karyotyping, is a technique used to identify 
copy number variations (CNV) in a genomic-wide screen [reviewed in [257]]. This 
technique utilises genomic DNA probes, known as oligos, which are robotically spotted 
and immobilised onto glass microscope slides, known as arrays. DNA from the test 
material (e.g. resistant cell line), is labelled with a green fluorescent dye (Cy3) and 
combined with the control material (e.g. sensitive cell line), which has been labelled 
with red fluorescent dye (Cy5). The 2 samples are co-hybridised to the array and the 
resulting ratio of fluorescence intensities is proportional to the copy numbers of DNA 
sequences in the test and control genomes. The areas on the slide that appear green 
indicate extra chromosomal material (duplication) in the test sample at that particular 
region. Areas on the slide that appear red indicate relatively less test DNA (deletion) in 
the sample at that specific spot [Figure 1-8]. aCGH analysis has been used as a tool to 
identify alterations in a broad spectrum of different cancer types including; ovarian 
cancer [258, 259],  prostate cancer [260], melanoma [261], lung cancer [262], 
lymphoma [263] and breast cancer [264, 265]. It has also been used to identify 
alterations in newly developed models of trastuzumab resistance [266, 267]. To date 
aCGH technology has not been used to identify genomic alterations in a model of 
acquired lapatinib resistance.   
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Figure 1-8: Principles of the aCGH technology. (a) DNA from the sample to be tested 
is Cy3 labelled and the control sample is Cy5 labelled. The samples are mixed and co-
hybridised to the array. (b) The slides are scanned into image files using a specific 
microarray scanner (c). An output of scanning depicts hundreds of spots with different 
ratios of the fluorescence intensities. (d). Sample output of aCGH analysis showing 
alterations on a specific chromosome. [Image and legend reproduced from [257]]. 
1.9.2 SILAC proteomic based technology 
Stable Isotope Labelling of Amino acids in Cell culture (SILAC) is a proteomic 
labelling strategy which utilises the metabolic machinery of cells to incorporate isotope 
labelled amino acids into the proteins of the cells [for review and protocol [268]]. With 
SILAC, the entire proteome of a given cell population is metabolically labelled with 
“heavy”, non-radioactive isotopic variants of amino acids, usually [U-13C6]-L-Lysine, 
which alters the weight of the peptide fragments by 6 Daltons, thus making it 
distinguishable from a second non-labelled cell line by mass spectrometry (MS). 
Therefore two or more distinctly SILAC-labelled cell-populations can be mixed and 
analysed in one MS experiment which allows for accurate quantitation of proteins from 
different cellular states. A conventional SILAC workflow involves culturing one 
population of cells in media containing the heavy amino acid, and the second population 
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of cells in media containing non-isotope labelled lysine [Figure 1-9]. The cells are 
grown in their respective media for a minimum of 6 doublings to allow for full 
incorporation (≥ 95 %) of the heavy lysine, after which time the two populations are 
combined, analysed by mass-spectroscopy (MS). The signal intensities from the heavy 
labelled and non-labelled samples provide a quantitative comparison of their abundance 
in the mixed population [268].   
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Figure 1-9: Overview of SILAC protocol. The SILAC experiment consists of two 
distinct phases - (a) an adaptation and (b) an experimental phase. (a) During the 
adaptation phase, cells are grown in light and heavy SILAC media until the heavy cells 
have fully incorporated the heavy amino acids (red star). This allows the two SILAC 
cell pools to be fully distinguishable by MS (black dot and red star, indicating light and 
heavy SILAC peptides, respectively) and can then be mixed and processed as a single 
sample. The adaptation phase can include the expansion of cells to reach the required 
number of dishes for the experiment. (b) In the second phase, the two cell populations 
are mixed, digested to peptides as a single pool and analysed by MS for protein 
identification and quantification [Image and legend reproduced from [268]]. 
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1.9.2.1 Advantages of SILAC labelling over traditional methods 
SILAC is advantageous over traditional gel based proteomic methods such as 
Difference In-Gel Electrophoresis (DIGE) for several reasons. DIGE allows samples to 
be mixed and separated on a  two dimensional gel for the identification of alterations in 
the expression levels of proteins, however, this technique is associated with greater run-
to-run variability compared to SILAC.  The lower variability associated with SILAC 
allows smaller statistically significant differences in protein abundance to be detected 
and requires fewer repetitions making the technique more high throughput [269]. One of 
the main differences between the capabilities of DIGE and SILAC is that DIGE is 
incapable of identifying co-migrating proteins. DIGE image software assumes a spot on 
a gel is homogeneous but it has been shown that some spots may contain multiple 
proteins. As there is a limit on the maximum number of spots that can be observed on a 
typical DIGE gel, many proteins will inevitably co-migrate to the same spot position, 
thus confounding their accurate quantitation and mass spectrometric identification 
[270]. A major limitation of DIGE is inefficient detection of low abundant proteins, 
proteins with high or low molecular weights and hydrophobic proteins. Proteins with 
these characteristics are important in receptor tyrosine kinase signalling pathways and 
are therefore of particular interest in cancer cell models.  
1.9.2.2 SILAC labelling coupled with phospho-tyrosine enrichment 
Post-translational modification events, such as phosphorylation, account for 
approximately 10 % of total protein in the cell, which results in a large number of non-
phosphorylated peptides being present with a smaller population of phosphorylation 
peptides. This adds unwanted complexity to the MS analysis which can mask signals 
from the low abundant phospho-peptides behind the higher abundant non-
phosphorylated peptides. Therefore robust separation and enrichment strategies for 
purification of phosphorylated peptides from non-phosphorylated peptides are highly 
beneficial. There are several enrichment techniques that can be coupled with SILAC 
analysis to yield more specific results [reviewed in [271]]. Antibody based purification 
methods utilise specific targeted antibodies to immunoprecipitate proteins of interest. 
By utilising either a protein specific or phospho-site specific antibody information about 
other phospho-sites on the protein of interest can be obtained and it can also give 
information about the binding partners of the phospho-protein of interest. One antibody 
based approach for the enrichment of phospho-peptides is to examine tyrosine 
phosphorylation sites. Phosphoproteomic approaches generally reveal only small 
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numbers of tyrosine phosphorylation sites, due to the low level of phospho-tyrosine 
sites compared to phospho-serine and phospho-threonine residues. Using 
immunoaffinity purification and reverse-phase chromatography, this technique allows 
the investigator to obtain a global overview of tyrosine phosphorylation in the cell, 
covering many classes of proteins without preconceived biases about where tyrosine 
phosphorylation sites will be found [272].  
1.9.2.3 SILAC proteomics - a cancer research tool 
SILAC proteomic based techniques have been used to identify alterations at the protein 
level in various different cancer types including; lung [273], melanoma [274], ovarian 
[269], prostate [275], and breast cancer [276-278]. SILAC labelling has been used to 
compare normal breast epithelial cells to HER2 positive amplified cells extracted from 
HER2 transfected mice [278]. SILAC proteomic techniques have also been used to 
identify alterations in cell lines models of lapatinib resistance [235].  
1.9.2.4 Limitations of SILAC proteomics 
There are several limitations to SILAC-based proteomics; 1) SILAC is an unsuitable 
method for performing proteomic analysis on clinical samples due to the requirement 
for metabolic labelling, 2) Incorporation of the metabolic label is dependent on the rate 
of intracellular protein turn-over requiring optimisation on a cell line to cell line basis, 
3) and the cost of media containing isotopically-labelled amino acids is high which is a 
deterrent to performing multiple comparisons with additional replicates. 
1.10 Summary 
Lapatinib is approved for the treatment of metastatic HER2 positive breast cancer and 
although it provides effective treatment for some patients, many patients fail to respond 
to lapatinib or develop resistant after an initial period of response. Thus, resistance to 
lapatinib is a significant clinical issue and identifying mechanism of how tumours 
become resistant to lapatinib would aid in the development of therapeutic strategies to 
prevent the onset of resistance. In this study, we developed a number of cell line models 
of HER2-positive lapatinib-resistant breast cancer and applied genomic and proteomic 
profiling techniques to investigate mechanism of lapatinib resistance. 
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1.11 Study Aims 
The aims of this study were as follows: 
1. To develop new cell line models of acquired lapatinib resistance – developing 
additional models of lapatinib resistance may help identify mechanisms of 
resistance that are present in a subset of HER2 positive breast cancers, thus 
helping to predict the subset of patients likely to present with the same 
mechanism of resistance. There are very few published cell line models of 
acquired lapatinib resistance and many of these cell lines were conditioned with 
lapatinib concentrations in excess of the peak plasma concentration of lapatinib 
achievable in patients.  
 
2. To characterise the resistant phenotype of acquired lapatinib resistance cells – 
extensive characterisation in the form of growth assays, drug sensitivity assays 
and immunoblotting for members of key signalling pathways provides a context 
additional alterations to be examined and allows for the comparison of newly 
developed cell lines to previously published models  
 
3. To utilise aCGH and SILAC proteomic based technology to identify alterations 
in acquired lapatinib-resistant cells – global profiling techniques suggest 
alterations at the genomic and proteomic level which may predict lapatinib 
resistance for provide a target for the treatment of lapatinib-resistant breast 
cancer  
 
4. To examine the role of eEF2 phosphorylation in lapatinib resistance – previous 
phospho-proteomic work in our laboratory identified that the phosphorylation of 
eEF2 was decreased in acquired lapatinib-resistant cells, thus identifying the 
mechanism(s) responsible for the decreased phosphorylation of eEF2 may 
provide a target for the treatment of lapatinib-resistant breast cancer 
 
5. To explore alterations in HER2 signalling innate lapatinib-resistant cells - many 
patients exhibit innate resistance to lapatinib and by examining alterations in the 
key signalling pathways using a panel of HER2-positive breast cancer cells 
lines, some of which exhibit innate lapatinib resistance, biomarkers which may 
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predict or correlate with response could be found which could improve the 
outcome for these patients. 
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Chapter 2 
 
Materials and Methods 
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2.1 Cell lines, cell culture and reagents 
Nineteen human breast cancer cell lines were used in this study, including 17 
established cell lines, a lapatinib-conditioned HER2 overexpressing breast cancer cell 
line (SKBR3-L), which was selected for long-term growth in drug-containing medium 
and its parent cell line (SKBR3-par). The cell lines BT474, HCC1419, HCC1954 and 
SKBR3 were obtained from the American Type Culture Collection (ATCC).  
UACC812, HCC202, HCC2218, HCC1569, EFM-192A, SUM225, SUM190, ZR-75, 
UACC893, UACC732, MDA-MB-361 and MDA-MB-453 and were obtained from the 
University of California Los Angeles, USA. JIMT-1 cells were purchased from the 
German Collection of Microorganisms and Cell Cultures (DSMZ). The growth 
conditions for each cell line are described in Table 2-1. SKBR3-L cells were generated 
by Dr Brigid Browne through continuous culturing of SKBR3 cells in RPMI 
supplemented with 250 nM lapatinib for 6 months [255]. All cell lines were routinely 
tested for the presence of mycoplasma, and found to be negative. Lapatinib (Tykerb ®) 
was obtained from GlaxoSmithKline, NVP-AEW541 from Novartis, BMS-536924 from 
Bristol-Myers Squibb, gefitinib was purchased from Sequoia Research Products, 
LY294002 from Merck, and U0126 and NH125 from Calbiochem. Unless otherwise 
specified, all reagents were of laboratory or electrophoresis grade. All cell culture 
procedures were performed as per the guidelines set out in NICB SOPs [#001-01, #002-
02 and #003-01]. In addition, mitochondrial DNA from all cell lines, including newly 
developed lapatinib-resistant cell lines, was sequenced to confirm their correct identify 
[this was performed in collaboration with Dr. Neil O’Brien and Dr. Charles Ginther in 
UCLA]. 
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Table 2-1: Growth media, foetal calf serum (FCS) and supplements for each of the cell 
lines used in this study 
Cell line Media FCS Supplements 
BT474 RPMI 1640 10% None 
EFM-192A RPMI 1640 10% None 
SKBR3 RPMI 1640 10% None 
HCC1419 RPMI 1640 10% None 
MDA-MB-453 RPMI 1640 10% None 
HCC1954 RPMI 1640 10% None 
JIMT-1 DMEM 10% glutamine 
1
 
UACC812 L-15 15% glutamine 
MDA-MB-361 L-15 15% glutamine 
SUM190 DMEM-F12 10% 10 μg/mL insulin, 1 μg/mL hydrocortisone 
SUM225 DMEM-F12 10% 10 μg/mL insulin, 1 μg/mL hydrocortisone 
HCC1569 RPMI 1640 10% glutamine, D-glucose 
2
, sodium pyruvate 
3
 
ZR75-30 RPMI 1640 10% glutamine, D-glucose, sodium pyruvate 
HCC202 RPMI 1640 10% glutamine, D-glucose, sodium pyruvate 
HCC2218 RPMI 1640 10% glutamine, D-glucose, sodium pyruvate 
UACC732 MEM 10% glutamine,  1% MEM nonessential amino 
acids, sodium pyruvate 
UACC893 L-15 15% glutamine, 20ng/ml EGF, 10 µg/ml insulin,  
10 µg/ml glutathione 
                                                 
1
 2 mmol/L glutamine 
2
 1 µmol/L sodium pyruvate 
3
 4.5 g/L D-glucose 
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2.2 Preparation of cell lysates 
Cells were grown in duplicate wells in 6-well plates and whole cell lysates were 
prepared as follows: cells were washed twice with cold phosphate buffered saline 
solution (PBS) and 150 µl/well RIPA buffer ((Sigma, R0278) 5 mM Tris-HCl pH 7.4, 
1% NP-40, 0.1% SDS, 150 mM NaCl, 1% Triton x-100) containing 1x Protease 
Inhibitor cocktail (Calbiochem, 539131), 2 mM PMSF (Sigma, P7626), and 1 mM 
sodium orthovanadate (Sigma, 6508), was added and cells were incubated on ice for 20 
minutes. Cells were scraped into lysis buffer. The lysis buffer was collected and 
centrifuged at 16,100 x g for 10 minutes at 4 
o
C. The pellets were discarded and the 
supernatants collected and stored at -80
o
C. Protein quantification was performed using 
the BCA quantitation kit (Pierce, 23227). 
2.3 Immunoblotting  
Protein (30 µg) was electrophoretically resolved on 7.5 % (Lonza, 59501) or 10 % 
(Lonza, 59502) denaturing polyacrylamide gels. The resolved proteins were then 
transferred to nitrocellulose membranes (Invitrogen, IB3010-01) using the iBlot transfer 
system (Invitrogen, IB1001).  Protein transfer was visually confirmed using Ponceau S 
staining (Sigma, P7170). Membranes were blocked with skimmed-milk powder (Bio-
Rad, 170-6404) in PBS-tween (Sigma, P1379) (0.1%), and incubated overnight at 4 
o
C 
with primary antibodies. The blotting conditions for each antibody used in this study are 
described in Table 2-2. Proteins were visualised using horseradish peroxidase-
conjugated anti-mouse, anti-goat or anti-rabbit antibodies (Sigma – see Table 2-2 for 
full details) and ECL plus reagent (GE Healthcare, RPN2132). Membranes were 
washed with 0.1 % PBS-tween 3 times for 10 minutes each, both prior to and following 
incubation with secondary antibodies. Protein bands were detected using the Typhoon 
9400 (Amersham Biosciences) system. Densitometry was performed using the 
ImageQuant software ((version 5.2), (Amersham Biosciences)) on biological triplicate 
immunoblots and the results were normalised using α-tubulin as a loading control. 
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Table 2-2: List of antibodies, blotting conditions, secondary antibodies, companies and catalogue numbers for all antibodies used in the study; where 
PBS-T is PBS-Tween, PTG is ProteinTech Group, SCB is Santa Cruz Biotechnology and CST is Cell Signalling Technology.  MDA-MB-468 positive 
control lysate was provided by Dr. Brendan Corkery, and Hela cell lysate was purchased from BD transduction laboratories, (611449). 
Antibody Phospho-site dilution blotting conditions Secondary + ve control company Cat no. 
anti-Rabbit secondary  1:1000 2.5 % milk / 0.1 % PBS-T   Sigma A6154 
anti-mouse secondary  1:1000 2.5 % milk / 0.1 % PBS-T   Sigma A6782 
anti-goat secondary  1:500 2.5 % milk / 0.1 % PBS-T   Sigma A5420 
α-tubulin  1:1000 2.5 % milk / 0.1 % PBS-T Mouse  Sigma T6199 
anti-HER2  1:1000 5 % milk / 0.1 % PBS-T Mouse BT474 Calbiochem OP15 
anti-phospho-HER2 Tyr1221/1222 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit BT474 CST #2249 
anti-EGFR  1:250 2.5 % milk / 0.1 % PBS-T Mouse MDA-MB-468 Neomarkers MS-665-P 
anti-phospho-EGFR Tyr1173 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit MDA-MB-468 CST #4407 
anti-HER3  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit BT474 CST #4754 
anti-phospho-HER3 Tyr1289 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit BT474 CST #4791 
anti-HER4  1:500 1 % milk / 0.1 % PBS-T Rabbit MCF7 CST #4795 
anti-AKT  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit SKBR3 CST #9272 
anti-phospho-AKT Ser473 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit SKBR3 CST #9271 
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Table 2-2: Continued 
Antibody Phospho-site dilution blotting conditions Secondary + ve control company Cat no. 
anti-ERK  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit SKBR3 CST #9102 
anti-phospho-ERK Thr202/Tyr204 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit SKBR3 CST #9101 
anti-XIAP  1:1000 2.5 % milk / 0.1 % PBS-T Mouse SUM190 BD Biosciences 610717 
anti-ER   1:200 3 % milk / 0.1 % PBS-T Mouse MCF7 SCB sc-8002 
anti-SRC  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit MCF7 CST #2108 
anti-phospho-SRC Tyr416 1:500 1 % milk / 0.1 % PBS-T Rabbit MCF7 Millipore 05-677 
anti-MCL-1  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit A549 CST #4572 
anti-IGF1R  1:500 5 % milk / 0.1 % PBS-T Rabbit BT474 SCB sc-713 
anti-phospho-IGF1R Thr1131 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit BT474 CST #3021 
anti-eEF2  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit MDA-MB-453 CST #2332 
anti-phospho-eEF2 Thr56 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit MDA-MB-453 CST #2331 
anti-p70S6K  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit UACC732 CST #2708 
anti-phospho-p70S6K Thr389 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit UACC732 CST #9234 
anti-eEF2k  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit HELA CST #3692 
anti-phospho-eEF2k Ser366 1:1000 2.5 % milk / 0.1 % PBS-T Rabbit HELA CST #3691 
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Table 2-2: Continued 
Antibody Phospho-site dilution blotting conditions Secondary + ve control company Cat no. 
anti-phospho-eEF2k Ser359 1:200 2.5 % milk / 0.1 % PBS-T Rabbit HELA SCB sc-21644 
anti-phospho-eEF2k Ser396 1:200 2.5 % milk / 0.1 % PBS-T Rabbit HELA SCB sc-21646 
anti-mTOR  1:500 1 % milk / 0.1 % PBS-T Rabbit MDA-MB-453 CST #2983 
anti-phospho-mTOR Ser2448 1:500 1 % milk / 0.1 % PBS-T Rabbit MDA-MB-453 CST #2971 
anti-EPB1  1:1000 2.5 % milk / 0.1 % PBS-T Goat HELA SCB sc-68478 
anti-CDKI  1:500 2.5 % milk / 0.1 % PBS-T Rabbit MCF7 CST #9112 
anti-phospho-CDK1 Tyr15 1:500 2.5 % milk / 0.1 % PBS-T Rabbit MCF7 CST #4539 
anti-GAPDH  1:1000 2.5 % milk / 0.1 % PBS-T Mouse MCF7 R&D systems mab5718 
anti-SELENBP1  1:1000 2.5 % milk / 0.1 % PBS-T Goat MCF7 SCB sc-160788 
anti-SET protein  1:1000 2.5 % milk / 0.1 % PBS-T Goat HELA SCB sc-5655 
anti-STARD3  1:1000 2.5 % milk / 0.1 % PBS-T Rabbit MCF7 PTG   20292-1-AP 
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2.4 Proliferation Assays 
Cells were seeded into 96-well plates at the following densities, 3000 cells/well SKBR3 
cells, 2000 cells/well HCC1954 cells and 5000 cells/well HCC1419 cells. After 24 
hours, cells were treated with the appropriate media supplemented with 10 % FCS with 
or without serial dilutions of lapatinib, NVPAEW541, BMS-536924, gefitinib, NH125 
or rapamycin. Proliferation was measured after five days using the acid phosphatase 
assay. For the acid phosphatase assay, media was removed and each well rinsed with 
PBS; 100 μl of acid phosphatase substrate (10 mM p-nitrophenol phosphate (Sigma, 
1040) in 0.1 M sodium acetate (Sigma, S2899), 0.1% triton X-100 (BDH, 9002-93-1), 
pH 5.5) was then added to each well followed by incubation at 37
o
C for 60 minutes, at 
which time 50 μl of NaOH (Sigma, S5881) was added to each well and the absorbance 
was read at 405 nm with 620 nm as a reference. Proliferation or inhibition of 
proliferation was calculated relative to untreated controls. Each assay was carried out in 
triplicate. 
2.5 Growth inhibition – cell count method 
HCC1954 and HCC1419 cells were seeded into 24-well plates. Once the cells reached 
approx. 40% confluence, cells were treated with a range of lapatinib concentrations: 
100, 200 and 300 nM for HCC1419 cells and 750, 1000 and 1250 nM for HCC1954 
cells. Following 4 days of treatment, the media was removed from the cells, they were 
washed with PBS and 100 µL of trypsin was added to each well. Once the cells had 
detached, 100 µL of media containing 10 % FCS was added to each well. In a round-
bottom 96-well plate, 100 µL of cell suspension was added to 100 µL of ViaCount 
reagent (Millipore, 4000-040). Cell counts were performed using the Guava EasyCyte 
((version 5.3), (Millipore)) in triplicate and proliferation or inhibition of proliferation 
was calculated relative to untreated controls.  
2.6 Lapatinib conditioning of cell lines 
HCC1419 and HCC1954 cells were conditioned with lapatinib. Four day growth assays 
(described in section 2.5) were performed to determine the concentration of lapatinib to 
condition cells with. Each cell line was grown in duplicate T75 flasks containing either 
control media or conditioned media, and media was replaced twice weekly for 6 
months. HCC1419 cells were conditioned with 250 nM lapatinib and HCC1954 cells 
with 1000 nM lapatinib. The effects of lapatinib conditioning on the cells were 
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examined by monitoring cell morphology and sensitivity to lapatinib at 4-weekly 
intervals during the conditioning process.   
2.7 Doubling time assays 
Doubling time assays were performed by seeding 3000 cells into each well of a 24 well 
plate. After 24 hours, cells were treated with and without 100 nM trastuzumab or 100 
nM lapatinib. Cell counts were performed at day 0, 3, 5 and 7 as follows: the media was 
removed from the cells, they were washed with PBS and 100 µL of trypsin was added to 
each well. Once the cells had detached 100 µL of media, containing 10 % FCS was 
added to each well. In a round-bottom 96-well plate, 100 µL of cell suspension was 
added to 100 µL of ViaCount reagent (Millipore, 4000-040). Cell counts were 
performed using the Guava EasyCyte ((version 5.2) (Millipore)) in both technical and 
biological triplicate. Doubling times were calculated between days 5 and 7, while the 
cells were growing exponentially, using the formula; 
Doubling time   
(      )(     )
(             )
 
where Tt is the end time point and T0 is the beginning time point (days), which in this 
case were 7 and 5, respectively.  
2.8 Drug withdrawal assays 
Drug withdrawal assays were performed by culturing lapatinib-conditioned cells for an 
extended period of time (up to 4 months) in the absence of lapatinib. Proliferation 
assays, to assess the sensitivity of the cells to lapatinib, were performed at 4 week 
intervals using the acid phosphatase method, as described in section 2.4.  
2.9 HER2 fluorescent in situ hybridisation analysis 
2.9.1 Preparation of cell donor paraffin blocks 
Cells (5 x 10
6
) were re-suspended in 10 ml of a 10 % (v/v) neutral-buffered formalin 
solution, containing formaldehyde solution (Sigma, 252549), sodium dihydrogen 
phosphate (Fisher Scientific, 7558-79-4) and disodium hydrogen phosphate (Fisher 
Scientific, 7558-80-7), and incubated overnight at room temperature. Cells were 
pelleted by centrifugation at 500 x g for 10 minutes, washed with PBS and re-pelleted. 
Cells were re-suspended in a 0.8 % agarose (Sigma, A9539) solution and transferred to 
a 1.5 ml microcentrifuge tube, from which the tapered end had been removed. The 
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agarose plug was left to solidify within the tube, removed via the cap end and 
transferred to an embedding cassette (Fisher Scientific, 15-200-402E). The cassettes 
were placed in a slide bath and were washed for 1 hour each in the following solutions: 
ultra-high purity (UHP) water, 50 % ethanol (Merck, 100983), 70 % ethanol, 90 % 
ethanol, 100 % ethanol. This was followed by 2x 1 hour washes in 100 % xylene 
(Applichem, A0663), before being placed into melted paraffin (McCormick Scientific, 
561006) for 2 hours. Using the Leica EG1150H machine the cassettes were placed in 
plastic moulds (SKS Science, M475), embedded with paraffin and left to cool. Once the 
paraffin was set the cell culture blocks were stored at 4 °C prior to sectioning.  
2.9.1 Sectioning and de-paraffinisation of slides 
Sectioning of cell culture blocks and subsequent FISH analysis were carried out by Ms. 
Alison Prendergast (St. Vincent’s University Hospital, Dublin). An overview of the 
procedure is outlined below. Sections (4 µm) were cut from the cell blocks, mounted on 
silanised slides and incubated overnight at 56 °C. Slides were de-paraffinised using a 
Paraffin pre-treatment kit (Abbott, 32-801200). All buffers were supplied with the kit 
unless otherwise specified. Briefly, slides were immersed in 0.2 M hydrochloric acid 
(HCL) (Fluka, 382887) for 20 minutes at room temperature and then washed with wash 
buffer with agitation for 5 minutes. Slides were immersed in pre-treatment solution at 
80 °C for 30 minutes, washed in wash buffer with agitation for 5 minutes, then 
incubated with protease solution at 37 °C for 30 minutes before repeating wash step. 
Slides were immersed in 4 % neutral buffered formalin solution (containing 
formaldehyde solution (Sigma, 252549), sodium dihydrogen phosphate (Fisher 
Scientific, 7558-79-4) and disodium hydrogen phosphate (Fisher Scientific, 7558-80-
7)), at room temperature for 10 minutes and the wash step was repeated. Slides were 
dehydrated by consecutive 1 minute washes in 70 %, 85 % and 100 % ethanol (Merck, 
100983) and air dried at 37 °C.  
2.9.2 PathVysion HER-2 DNA Probe Hybridisation 
All subsequent steps were performed using the PathVysion HER-2 DNA Probe Kit 
(Abbott, 02-J01-030), and all reagents were supplied with the kit unless otherwise 
specified. LSI HER-2/neu SpectrumOrange/CEP 17 SpectrumGreen DNA Probe 
mixture (10 µl) was applied to each slide and covered with a coverslip, sealed and 
placed in a humidified hybridisation chamber (HYBrite) overnight. Slides were then 
immersed in post-hybridisation wash buffer at room temperature to remove the 
coverslip and then immersed in post-hybridisation wash buffer, which had been pre-
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heated to 74 °C, for 2 minutes with gentle agitation, transferred to a 70 % ethanol 
(Merck, 100983) solution for 20 seconds and air dried at 37 °C. DAPI counterstain (10 
µl) was applied to the slides. Slides were covered with a coverslip, sealed and stored at 
4 °C prior to signal enumeration.  
2.9.3 HER2/CEP17 ratio enumeration 
Signal enumeration was performed using a fluorescence microscope equipped with 
appropriate excitation and emission filters allowing visualisation of the intense orange 
and green fluorescent signals. The filters required for signal enumeration are DAPI, 
FITC and TRITC. Normal and amplified Vysis ProbeChek HER-2/neu control slides 
were included and they met the acceptable range for HER2/CEP17 ratio (Normal 0.75-
1.25; Amplified 1.60-2.00) (Abbott, 02-J05-030, 02-J04-030). Enumeration was 
performed on 60 interphase nuclei giving a HER2/CEP17 ratio for each nucleus, 
yielding a ratio of the HER-2/neu gene to chromosome 17 copy number. Images of the 
FITC stain, TRITC stain and DAPI stain were taken and overlaid to create a composite 
image using the fluorescence microscope.  
2.10 Senescence associated β-galactosidase activity assay 
The activity of β-galactosidase was measured using a β-galactosidase staining kit (Cell 
Signalling Technology, #9860). Briefly, media was removed from the cells, followed by 
2 washes with PBS and cells were then incubated with fixative solution (containing 2 % 
formaldehyde and 0.2 % glutaraldehyde in UHP water) for 15 minutes at room 
temperature. Following 2 washes with PBS, staining solution is added. The staining 
solution contains 40 mM citric acid/sodium phosphate (pH 6.0) , 0.15 M NaCl, 2 mM 
MgCl, to which 10 µl/ml of both 500 nM potassium ferrocyanide solution, 500 nM 
potassium ferricyanide solution and 50 µl/ml of 20 mg/ml X-gal (5-bromo-4-chloro-3-
indolyl-βD-galactopyranoside powder) dissolved in N-N-dimethylformamide (DMF) 
was added.  Note, all reagents for fixative and staining solutions were supplied with the 
kit. The volumes of each fixative solution and staining solution required per well and 
per flask are described in Table 2-3. The cells were incubated in staining solution at 37 
°C overnight. After incubation cells were washed twice with PBS and then examined 
for the presence of blue staining within cells, indicating activity of β-galactosidase. 
Triplicate representative images were taken of each treatment condition using unbiased 
cell selection and all experiments were repeated in biological triplicate. Treatment of 
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cells with 50 µM bromodeoxyuridine (BrdU) (Sigma, B5002) was used as a positive 
control for β-galactosidase activity.  
Table 2-3: Volumes of fixative and staining solutions required for each different cell 
culture vessel used for experiments involving β-galactosidase staining. 
Cell culture vessel Volume of solution required 
24-well plate 500 µl / well 
6-well plate 1 ml / well 
T25 flask 2.5 ml / flask 
T75 flask 4 ml / flask 
 
2.11 RNA extraction 
RNA was extracted from HCC1419 and SKBR3 cells using the following method. 
Media was removed from the cells and they were washed twice with PBS. Tri-reagent 
(Sigma, 93289) was added to the flask (1 ml / T75), cells were scraped into the Tri-
reagent using cell scrapers, and the RNA lysates was stored at -80 °C until required. To 
extract RNA from the lysate, lysates were thawed on ice and 200 µl/ml of chloroform 
(Lab-Scan Analytical Systems, AR1027E) was added. Samples were mixed by 
inversion (5 times) and left to sit at room temperature for 15 minutes. Samples were 
then centrifuged at 15,700 x g for 15 minutes at 4 °C, resulting in the separation of the 
sample into 3 distinct layers. The top, clear layer of the sample was removed to a new 
eppendorf to which 500 µL of ice-cold isopropanol (Fluka, 34965) was added. Samples 
were mixed by inversion (5 times) and left to sit at room temperature for 10 minutes. 
The samples were then centrifuged at 13,400 x g for 30 minutes at 4 °C and the 
supernatant then removed. Following this, 750 µl of 75 % ethanol (Merck, 100983) was 
added to the samples, samples were vortexed to detach the pellet and centrifuged at 
16,100 x g for 5 minutes at 4 °C. The supernatant was removed and discarded and the 
ethanol wash step repeated. The pellet was then re-suspended in 20 µl of RNase-free 
water (Ambion, 9932) and left to sit at room temperature for 20 minutes. Samples were 
then stored at -80 °C or on ice for immediate use. 
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2.12 Reverse transcription polymerase chain reaction (RT-PCR) 
The concentration of total RNA in extracted samples was determined using the Nano-
Drop Spectrophotometer (Thermo Scientific). Stock solutions of 2 µg /10 µl were made 
by diluting RNA-extracts with RNase-free water (Ambion, 9932). Using a high capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, 4368814), a 2X master mix 
solution was prepared as per Table 2-4. For each reaction, 10 µl of RNA sample and 10 
µL of master mix were combined in PCR tubes, briefly centrifuged to spin down 
contents and loaded into the thermo-cycler (G-STORM) and the reverse transcription 
run as per Table 2-5. The samples were then stored at 4 °C, for immediate use, or at -80 
°C until required. Controls were included at this point; non-target control (NTC) which 
was prepared without the RNA template, and a minus reverse transcriptase control (-
RTC) which was prepared without the reverse transcriptase enzyme. 
Table 2-4: Components of master mix for RT-PCR experiments 
Component Volume / Reaction (µl) 
10X RT buffer 2.0 
25X dNTP Mix (100 mM) 0.8 
MultiScribe 
TM
 Reverse transcriptase 1.0 
RNase-free water 4.2 
10X  RT random primers 2.0 
Total per reaction 10.0 
 
Table 2-5: Thermo-cycler steps, indicating the temperature and duration, for RT-PCR 
experiment 
Step Temperature (°C) Time (minutes) 
1 25 10 
2 37 120 
3 85 5 
4 4 hold 
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2.13 Quantitative real-time polymerase chain reaction (qrt-PCR) 
Using cDNA obtained from the RT-PCR step, qrt-PCR for the following assays was 
performed; p15 (Applied Biosystems, HS00793225_m1), p16 (Applied Biosystems, 
HS04189686_m1), p21 (Applied Biosystems, HS00355782_m1) and p27 (Applied 
Biosystems, HS00153277_m1), with GADPH (Applied Biosystems, HS02758991_g1) 
as an endogenous control. Briefly, the cDNA samples were diluted with 30 µl of 
RNase-free water (Ambion, 9932) and 2 µl of this stock was added to a 96-well PCR 
reaction plate (Applied Biosystems, 4346906) and combined with 18 µl of assay master 
mix. The assay master mix consisted of 10 µl of Taqman Universal PCR Master Mix 
(Applied Biosystems, 4364340), 7 µl of RNase-free water (Ambion, 9932) and 1 µl of 
the specific assay (primer), per reaction. The PCR plate was then sealed using Optical 
Adhesive film strips (Applied Biosystems, 4360954). The qrt-PCR reaction was 
performed on the ABI7900HT fast system using Sequence Detection System (SDS) 
automated controller software (version 2.2) (Applied Biosystems). The procedure for 
qrt-PCR was 10 minutes at 95 °C followed by 40 cycles of 15 seconds at 95 °C and then 
1 minute at 60 °C. Once complete the cycle threshold (Ct) values were exported to 
Excel and relative RNA expression levels calculated using the DeltaCt method where 
ΔCt was the Ct value of the sample minus the Ct value of the endogenous control. The 
ΔΔCt values were calculated as the ΔCt of the test sample minus the ΔCt of the 
calibration sample (e.g. treated minus control). The relative quantity ratios (RQ) of each 
sample were calculated using the equation: 
                               (       )        (       )      
Where, Ct,X is the cycle threshold of the gene of interest and Ct,R is the cycle threshold 
of the endogenous reference gene. 
2.14 Array Comparative Genome Hybridisation analysis (aCGH) 
The following aCGH experimental protocol was used, and supplied, by Dr. Lee 
Anderson (UCLA) who carried out the aCGH experiments described in this study.  
Genomic DNA was extracted from cell lines using the DNeasy Kit (Qiagen) with the 
following modifications: 70 % ethanol was substituted for Buffer AW2 in the final 
wash, and DNA was eluted in 50 µl of sterile water (Invitrogen). The concentration and 
quality of the DNA were measured by NanoDrop and by electrophoresis in 1 % agarose. 
Labelling and hybridisation of Agilent 105K oligonucleotide CGH arrays was 
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performed according to the manufacturer’s protocol for Human Genome CGH 105A 
Oligo Microarray Kit, Version 5.0 (Agilent Technologies). Briefly, 1 µg of test cell line 
and 1 µg of the control cell line were digested with Alu I and Rsa I restriction enzymes 
(Promega) for 2 hours, then labelled with Cy5-dUTP (test cell line) and Cy3-dUTP 
(control cell line) using the Agilent Genomic DNA Enzymatic Labelling Kit for 2 hours 
at 37 ºC followed by 14-18 hours at room temperature. Unincorporated nucleotides 
were removed using Amicon spin filter units (Millipore), and incorporation and yield 
were measured with the NanoDrop Spectrophotometer. Labelled test and control cell 
line DNAs were combined, annealed with COT-1 DNA (Invitrogen) and 10X Blocking 
Agent (Agilent Technologies) for 30 minutes at 37 ºC after boiling, then hybridised to 
Agilent 105A arrays for 40 hours at 65 ºC according to the manufacturer’s instructions. 
After hybridisation, arrays were washed according to Procedure B (which includes an 
ozone blocking wash), and scanned using an Agilent Scanner (G2565BA). Files were 
extracted using Agilent Feature Extraction software (version 9.5) with the default CGH 
protocol.  Extracted arrays with a DRL Spread < 0.3 were included in the analysis. CGH 
Analytics software (version 4.0.85) (Agilent Technologies) was used for copy number 
analysis, employing the ADM2 algorithm (Threshold 5), with Fuzzy Zero and 
Centralization corrections to minimise background noise. All map positions were based 
on the March 2006 NCBI36/hg18 genome assembly. A minimum of 3 consecutive 
probes was required to define a region as amplified or deleted. The data was also 
filtered by requiring a minimum absolute average log
2
 ratio of 0.58. All data was 
inspected visually using the interactive view. Log
2
 ratios larger than 1 were considered 
amplified and log
2
 ratios larger than 2 highly amplified, log
2
 ratios smaller than -1 were 
considered hemizygous deletions and log
2
 ratios smaller than -2 were considered 
homozygous deletions. 
2.15 Stable Isotope Labelling with Amino acids in Cell culture (SILAC) – based 
proteomic profiling of cell lines 
Labelling of cells with [U-
13
C
6
]-L-Lysine (heavy) amino acid was performed using 
SILAC RPMI 1640-Flex media (Invitrogen, MS10031) and media were made up using 
the kit components, as per Table 2-6.  L-Arginine, L-Lysine HCL and [U-
13
C
6
]-L-
Lysine were re-suspended in 1 ml of basal un-supplemented media prior to addition. 
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Table 2-6: Media components of heavy and light SILAC RPMI 1640-Flex media 
Reagent Volume (ml) 
 Heavy SILAC media Light SILAC media 
RPMI 1640-Flex 877.5 ml 877.5 ml 
Glucose solution (200 g/L) 10 ml 10 ml 
L-Glutamine 200mM (100X) 10 ml 10 ml 
Phenol Red solution (10 g/L) 0.5 ml 0.5 ml 
Dialysed Fetal Calf Serum (ml/L) 100 ml 100 ml 
L-Arginine (100 mg) 1 ml 1 ml 
L-Lysine HCL (100 mg)  -  1 ml 
[U-
13
C
6
]-L-Lysine (100 mg)  1 ml -  
Total volume  1000 ml 1000 ml 
 
2.15.1 SILAC labelling and protein extraction 
SKBR3-par cells were cultured in heavy SILAC media and SKBR3-L cells cultured in 
light SILAC media. Three biologically different passages of SKBR3-par and SKBR3-L 
cells were grown independently of each other and termed replicates 1, 2 and 3. Each 
biological replicate for each cell line consisted of twelve T175 cm
2
 flasks of cells, 
which was calculated to give an approx. total cell number per replicate of 2 x 10
8
 cells. 
The cells were grown for approx. 15 days in the SILAC media which allowed for 
maximum labelled amino acid incorporation and enabled the cells to reach 80% 
confluence. At this stage each of the 3 replicates for each cell line was split in half; 6 of 
the flasks were fed with the appropriate SILAC media while the other 6 flasks were 
treated with SILAC media containing 1 µM lapatinib. After exactly 24 hours, the cells 
in 6 of the flasks were lysed using RIPA buffer and stored at -80 °C for protein 
validation. The remaining 60 flasks were lysed using cell lysis buffer supplied as a 
component of the downstream purification kit, Phospho-Scan (Cell-Signaling 
Technology, #7900). Note, unless otherwise specified all reagents for downstream 
purification were supplied in this kit. This lysis buffer consisted of: 1 ml of 10X lysis 
buffer mix ((20 mM HEPES (pH 8.0), 9M urea, 1 mM sodium orthovanadate, 2.5 mM 
sodium pyrophosphate, 1 mM b-glcerophosphate)), 5.4 g urea and 0.2 ml of sodium 
vanadate in 10 ml of mass spectrometry (MS) grade water (Fisher Scientific, 
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W/0112/15). To lyse the cells, 5 ml of lysis buffer solution was added to one flask and 
cells scraped into buffer, the same buffer solution containing lysed cells was added to 
the second flask (of the same biological replicate) the second flask of cells was scraped 
into the lyse buffer and so on – until the cells from all 5 flasks were contained in the 
same 5 ml of lysis buffer. All samples were prepared in this manner. The lysates were 
then cooled on ice for 15 minutes and sonicated at 15W output with 2 bursts of 30 
seconds each. The samples were cooled on ice between bursts. The samples were then 
cleared by centrifugation at 20,000 x g for 15 minutes and the supernatant collected and 
stored at -80 °C. 
2.15.2 Phospho-tyrosine enrichment of SILAC labelled samples 
Protein concentration was determined using the BCA assay (Pierce, 23227), and 
comparison samples were mixed at a 1:1 ratio based on protein concentration to yield 6 
samples with a total of 30 mg of protein each. The downstream processing of one such 
sample is outlined below. Carboxamidomethylation of proteins was performed to 
inactivate enzymatic activity, by adding 1/10 volume of 45 mM dithiothreitol (DTT) to 
the supernatant and incubating at 60 °C for 20 minutes. The solution was then cooled to 
room temperature and then 100 mM idoacetamide, at an equal volume to that of DTT, 
was added and the solution was incubated in the dark at room temperature for 15 
minutes. Lysates were then diluted 4-fold (e.g. a 10 ml lysate was diluted with 1 ml 
DTT, 1 ml iodoacetamine, 3 ml of 10X lysis buffer mix and 25 ml of MS grade water 
(Fisher Scientific, W/0112/15) – yielding a 40 ml lysate). A small aliquot (100 µl) of the 
solution was removed and stored at -80 °C. After dilution, 400 µl of a 1 mg/ml trypsin-
TPCK solution was added to each sample and digested overnight at room temperature. 
The digestion was assessed by resolving 20 µl of digested and undigested sample on 10 
% gels and staining with colloidal Comassie blue reagent (Pierce, 24590) – undigested 
samples yield multiple protein bands whereas digested samples do not. The peptide 
solution was then acidified to contain 1 % trifluoracetic acid (TFA) (Pierce, 28904), left 
to stand at room temperature for 10 minutes, centrifuged for 5 minutes at 1,800 x g and 
decanted into a new tube. The solution was then purified using Sek-Pak C18 columns; 
the column was connected to a 10 cc syringe, pre-wet with 5 mls of 100 % Acetonitrile 
(ACN) (Sigma, 34967), washed with 7 ml of 0.1 % TFA, loaded with the lysate, washed 
with 12 ml of 0.1 % TFA and peptides were eluted using 6 ml (3 x 2 ml) of a 0.1% 
TFA, 40% ACN solution. The eluted peptides were stored at -80 °C overnight and then 
lyophilised for 2 days, to remove all traces of TFA. The lyophilised peptides were re-
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suspended in 1.4 ml of IAP buffer ((50 mM MOPS (pH 7.2), 10 mM sodium phosphate, 
50 mM NaCl)), and left to stand for 5 minutes at room temperature followed by 30 
minutes of gentle shaking. The re-suspended peptides were then sonicated at 15W 
output with 2 bursts of 10 seconds each. The pH of the re-suspended peptides was 
checked using pH indicator strips (Santa Cruz, sc-3667), and if found to be acidic, the 
pH was adjusted to pH 7.0 using a concentrated Tris (Sigma, 93352) solution, which 
had not been adjusted for pH. The neutral re-suspended peptide solution was cleared by 
centrifugation for 5 minutes at 1,800 x g at room temperature and transferred to a micro-
centrifuge tube containing 80 µl of phopsho-tyrosine mouse monoclonal antibody (P-
Tyr-100) beads. The mixture was incubated for 2 hours, on a rotator at 4 °C and then 
centrifuged at 1,500 x g for 1 minute at 4 °C and the supernatant was discarded. All 
subsequent steps were performed on ice. A wash step was performed; IAP buffer (1 ml) 
was added to the beads, mixed by inversion (5 times), centrifuged at 1,500 x g for 1 
minute at 4 °C and the supernatant removed and discarded. The IAP wash step was 
repeated a further 2 times followed by 2 washes (as above) with MS-grade water. The 
peptides were eluted from the beads using a two-step process;   using first 55 µL of 0.15 
% TFA was added to the beads, mixed by gentle tapping, left to stand for 10 minutes at 
room temperature, centrifuged at 1,500 x g for 1 minute and the supernatant removed to 
a new micro-centrifuge tube. The above step was repeated with 45 µl of 0.15 % TFA 
and the supernatant combined with the first eluate and mixed. The eluate was divided 
into 7 aliquots of 14 µl each. A ZipTip (included with kit) was pre-wet with 10 µl of 40 
% ACN, 0.1% TFA twice, equilibrated by washing the tip with 4 x 10 µl washes of 0.1 
TFA and pipettes were bound to the tip by drawing each of the 7 aliquots fully into the 
tip and pipetting each aliquot 10 times. The tip was washed 4 times with 10 µl each of 
0.1 % TFA and peptides eluted with 20 µl of 40% ACN, 0.1 % TFA by pipetting 4 
times up and down and transferring to a new micro-centrifuge tube. The eluted samples 
were then dried to completion under vacuum and transferred to the Mass Spectrometry 
Facility (UCLA Pasarow Mass Spectrometry Laboratory), where they were stored at -80 
°C prior to analysis.  
2.15.3 Analysis of total protein from SILAC-labelled samples 
A comparison of the expression of total protein between cell lines was performed by 
mixing 10 µg of sample from each cell line and resolving the mixed samples on a 10 % 
gel (Lonza, 59501). The gel was stained with colloidal Comassie blue reagent (Pierce, 
24590) for 1 hour, and destained with a 40 % methanol (Sigma, 34860), 5 % acetic acid 
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(Sigma, 45754) solution overnight. Each lane on the gel was cut into 32 gel bands with 
a fresh disposable scalpel blade, and each band was further cut into 6 pieces. The gel 
pieces were transferred to a MS format 96-well plate, washed with MS-grade water 
(Fisher Scientific, W/0112/15), suspended in 70 µl of 200 mM ammonium bicarbonate 
(NH4HCO3) (Sigma, 09830) and incubated for 10 minutes at 37 °C in a thermoshaker 
(Thermo-Scientific) at 400 x g. This was followed by a series of wash steps each carried 
out for 10 minutes at 400 x g at 37 °C; 100 µl of 200 mM NH4HCO3, ACN (2:3); 
followed by 100 µl of 50 mM NH4HCO3  and then 100 µl of 100 % ACN. The gel 
pieces were incubated in 50 µl of 10 mM DTT (Sigma, 43817) in 100 mM NH4HCO3 
for 60 minutes at 400 x g at 56 °C, liquid removed and replaced with 50 µl of 50 mM 
iodoacetamide (Sigma, L1149) in 100 mM NH4HCO3  at 400 x g for 30 minutes at 
room temperature in the dark. This was followed by; a 15 minute incubation with 150 µl 
of 100mM NH4HCO3 at 400 x g and 37 °C; a 15 minute incubation with 150 µl of 
100mM NH4HCO3/ACN (1:1) at 400 x g and 37 °C and then a 10 minute incubation 
with 100 µl of 100 % ACN at 400 x g and 37 °C. Following removal of ACN the 
samples were incubated with 30 µl of gold grade trypsin (12.5 ng/µl) (Promega, V5280) 
at 37°C overnight. The liquid was transferred to a new plate and the gel pieces were 
incubated with 100 µL of extraction buffer (5 % formic acid (Sigma, 06440))/ACN 1:2)  
for 10 minutes at 400 x g and 37 °C. The liquid from each was added to the new plate 
and this extraction step was repeated and extracts were pooled. The plate was 
transferred to a vacuum centrifuge and dried down. The dried down samples were then 
transferred to the Mass Spectrometry Department (DCU) where they were stored at -20 
°C prior to analysis. 
2.15.4 Mass Spectrometry 
The phospho-enriched samples were analysed by Dr. Julian Whitelegge (UCLA) and 
the total protein samples by Mr. Michael Henry (DCU) using the below method. 
Digested samples were re-suspended in 0.1% TFA, 2% ACN and analysed by nanoLC-
MS/MS using an Ultimate 3000 system (Dionex) coupled to a nanospray LTQ Orbitrap 
mass spectrometer (Thermo Fisher Scientific), using a linear acetonitrile gradient from 
0% to 65% ACN over 45 minutes. Buffers used for nano LC separation contained 0.1% 
Formic acid as the ion pairing reagent. The flow rate was 300 nL/minute. The LTQ 
Orbitrap was operated in data-dependent acquisition mode with Xcalibur software. 
Survey scan MS data were acquired in the Orbitrap on the 300–2000 m/z mass range 
with the resolution set to a value of 60,000 at 400 m/z . The five most intense ions per 
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survey scan were selected for MS/MS fragmentation and the resulting fragments were 
analysed in the linear trap. Collision energy was set to 35%. Dynamic exclusion was 
employed within 60 seconds. Full scan mass spectra were recorded in profile mode and 
tandem mass spectra in centroid mode. 
2.15.5 Peptide/Protein Identification 
The resulting RAW files of MS data from both the phospho- and total protein 
experiments were analysed using TurboSEQUEST software (Bioworks Browser 
(version 3.3.1), Thermo Fisher Scientific)) using the UniProt_SwissProt_Human 
database (downloaded in March 2011). The following filters were applied: for charge 
state 1, XCorr > 1.5; for charge state 2, XCorr > 2.0; for charge state 3, XCorr > 2.5; for 
charge state 4, XCorr > 3.0. Modification of peptides: carbamidomethylation of cysteines 
and SILAC modification of +6.0204 Daltons on Lysine, were set. Peptide probability 
was set as p ≤ 0.05 giving 95 % confidence of peptide identification. Protein 
identifications were accepted if they had at least 2 unique identified peptides. SILAC 
ratios of heavy to light (H/L) amino acid were calculated using the in-built SILAC 
search function. For each protein identified with a SILAC ratio a manual examination of 
MS and MS/MS data was performed to ensure accurate identification of both heavy and 
light lysine containing peptides. Lists of identified phospho- and total proteins and their 
corresponding SILAC ratios were exported to Excel. 
2.15.6 Statistical cut-off for identified proteins 
For an identified protein to be considered significant and subject to further analysis, it 
had to meet the following criteria: i) only proteins which were identified in all three 
biological comparisons were considered for inclusion; ii) proteins had to have a 
corresponding SILAC ratio (and have manually verified heavy and light peptide 
identifications); iii) deviation of the ratio across the 3 biological replicates ≤ 20 %; iv) 
SILAC ratios indicating a fold change ≥ 1.2-fold. A shortlist of proteins which met 
these statistical requirements were then generated and subjected to bioinformatical 
analysis.  
2.15.6.1 Panther 
Shortlisted proteins were analysed using PANTHER Classification System [available 
from www.pantherdb.org]. The PANTHER (Protein ANalysis THrough Evolutionary 
Relationships) Classification System is a unique resource that classifies genes by their 
functions, using published scientific experimental evidence and evolutionary 
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relationships to predict function even in the absence of direct experimental evidence 
[279]. The shortlisted proteins were analysed for; Molecular Pathways, Molecular 
function, Biological Processes, Protein Class and Cellular Component.  
2.17.6.2 Pathway studio 
Protein function, regulation and interaction were investigated by analysing shortlisted 
proteins in Pathway Studio 8.0 (Ariadne Genomics). This software was used to build 
protein networks based on in silico literature mining. When features of interest were 
identified the literature for that node was assessed. 
2.16 Statistics 
Drug IC50 values were calculated using CalcuSyn (version 1.1.0.0) software. Analysis 
of the difference of comparisons in protein levels and response to treatment was 
performed using the Student t-test (two-tailed with unequal variance). Bi-variant 
scattergraphs and Spearman rank correlations were performed using StatView (version 
5.0.1) (SAS institute Inc.). The cut-off for statistical significance was set as p ≤ 0.05.  
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Chapter 3 
 
Development of HCC1954-L, a HER2 positive cell line model of 
acquired lapatinib resistance 
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3.1 Introduction  
Lapatinib, the dual EGFR and HER2 tyrosine kinase inhibitor has shown promising 
results in clinical trials. However, resistance to lapatinib is an emerging clinical 
problem. Patients can exhibit either de novo (innate) or acquired resistance to lapatinib, 
the mechanisms of which are currently poorly understood and the number of cell line 
models of resistance available is limited. To investigate mechanisms of acquired 
resistance to lapatinib, a cell line model of acquired lapatinib resistance was developed 
using the HER2 amplified breast cancer cell line HCC1954, which is sensitive to 
lapatinib. The development and characterisation of the resistant cell line is detailed in 
this chapter. 
 
3.2 Development of a cell line model of acquired lapatinib resistance 
3.2.1 Lapatinib-conditioning of HCC1954 cells 
HCC1954 cells overexpress HER2 and thus represent a cell line model of HER2 
positive breast cancer. HCC1954 cells are resistant to trastuzumab but are moderately 
sensitive to lapatinib with an IC50 of 0.430 ± 0.027 µM [Figure 3-1]. A lapatinib dose 
response assay was performed in order to select the concentration of lapatinib which 
would result in 70 % growth inhibition over a 4 day treatment. Treatment of HCC1954 
cells with 1 µM lapatinib inhibited the growth of the cells by 71.5 ± 1.2 % compared to 
untreated controls (p = 0.004) [Figure 3-2]. Therefore, lapatinib conditioning of 
HCC1954 cells was initiated with twice weekly treatments of 1 µM lapatinib. 
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Figure 3-1: Proliferation of HCC1954 cells following a 5-day treatment with lapatinib 
(0 – 5 µM). Growth is expressed relative to untreated control cells. Error bars represent 
the standard deviation of triplicate experiments.  
 
 
Figure 3-2: HCC1954 cells treated with varying concentrations of lapatinib over a four 
day period. Cell counts were performed using ViaCount reagent and Guava Software 
and expressed relative to control untreated cells. Error bars denote the standard 
deviation of triplicate cell counts from triplicate experiments. Percentages shown on 
graph represent the percentage of growth inhibition compared to control cells across 
three independent experiments. Student’s t-test was performed to determine significant 
differences between treatments and control: * denotes p < 0.05; ** denotes p < 0.01.   
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3.2.2 Lapatinib-conditioning: 3 months 
HCC1954 cells were seeded into two flasks, one flask was left untreated but was 
passaged alongside the treatment flask, and these cells were named HCC1954-par cells. 
The other flask of cells was treated with 1 µM twice weekly and throughout the 
conditioning process and characterisation these cells were referred to as HCC1954-L. 
During the conditioning process, the morphology of both cell lines and the sensitivity of 
the cell lines to lapatinib was monitored. The morphology of HCC1954-L cells did not 
alter during the first 3 months of lapatinib conditioning [Figure 3-3]. After 3 months of 
conditioning, the sensitivity of the cells to lapatinib was tested. The lapatinib IC50 for 
HCC1954-par cells was 0.42 ± 0.01 µM, which is similar to the original HCC1954 
cells. The lapatinib IC50 for HCC1954-L cells was 0.75 ± 0.07 µM [Figure 3-4]. This 
represents 1.8-fold change decrease in sensitivity to lapatinib. At this stage of the 
conditioning process the lapatinib IC50 of HCC1954-L cells had not yet reached the 
critical threshold for resistance (1 µM), however they had begun to actively proliferate 
in the presence of lapatinib. The concentration of lapatinib was therefore increased from 
1 µM to 1.25 µM and conditioning continued with this concentration for a further 3 
months.   
 
 
 
Figure 3-3: Images of (A) HCC1954-par and (B) HCC1954-L cells after 3 months of 
lapatinib conditioning at 100X magnification. 
 
A B
HCC1954-par (3 months) HCC1954-L (3 months) 
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Figure 3-4: After 3 months conditioning with 1 µM lapatinib the proliferation of 
HCC1954-par and HCC1954-L cells following a 5-day treatment with lapatinib (0 – 2.5 
µM) was measured. Growth is expressed relative to untreated control cells. Error bars 
represent the standard deviation of triplicate experiments.  
 
3.3 Characterisation of HCC1954-L cells 
3.3.1 HCC1954-L cells are resistant to lapatinib 
After 6 months of lapatinib conditioning, the sensitivity of the cells was again tested. 
The lapatinib IC50 for HCC1954-par was 0.42 ± 0.02 µM whereas the lapatinib IC50 for 
HCC1954-L cells was 2.67 ± 0.08 µM (p = 0.01) [Figure 3-5]. This represents 6.1-fold 
decrease in sensitivity to lapatinib. HCC1954-L cells were deemed to be resistant to 
lapatinib as the lapatinib IC50 was above the 1 µM threshold for sensitivity [194]. The 
resistant cells also exhibited distinct morphological alterations compared to the parental 
cell line. These differences were indicated by more distinct colony boundaries and a 
flatter cell shape [Figure 3-6]. 
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Figure 3-5: After 6 months conditioning with lapatinib the proliferation of HCC1954-
par and HCC1954-L cells following a 5 day treatment with lapatinib (0 – 5 µM) was 
measured. Growth is expressed relative to untreated control cells. Error bars represent 
the standard deviation of triplicate experiments.  
 
 
 
Figure 3-6:  Images of (A) HCC1954-par and (B) HCC1954-L cells after 6 months of 
lapatinib conditioning at 200X magnification. 
3.3.2 Assessing the stability of acquired lapatinib resistance 
To establish a reliable cell line model of lapatinib resistance, the phenotype must be 
stable when the cell line is frozen and re-thawed. To asses this, frozen stocks of the 
HCC1954 par and HCC1954-L cells were prepared in foetal calf serum containing 5 % 
DMSO. After a minimum of 48 hours in liquid nitrogen, the frozen stocks were thawed 
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and the viability of the stocks assessed by microscopy. The cells were then passaged a 
minimum of 3 times before lapatinib sensitivity assays were repeated [Figure 3-7]. The 
lapatinib IC50 was 0.44 ± 0.02 µM in the parental cells while the lapatinib IC50 in 
HCC1954-L cells was 2.73 ± 0.05 µM. This indicates that the HCC1954-L cells retain 
their resistant phenotype following a freeze/thaw cycle. 
 
 
Figure 3-7: Sensitivity of HCC1954-par and HCC1954-L cells to lapatinib following a 
freeze-thaw cycle. Proliferation of cells was assessed following 5 days treatment with 
lapatinib (0 – 5 µM). Growth is expressed relative to untreated control cells.  Error bars 
represent the standard deviation of triplicate experiments.  
 
In order to assess the long-term stability of the resistant phenotype, drug withdrawal 
assays were performed. Lapatinib was removed from the HCC1954-L cells and the 
sensitivity of the cells to lapatinib was tested at 4 week intervals for a period of 12 
weeks, the results at each interval are illustrated in Figure 3-8. Following 12 weeks 
growth in the absence of lapatinib the lapatinib IC50 of the parental cells was 0.43 ± 0.05 
µM while the lapatinib IC50 of HCC1954-L cells was 2.63 ± 0.16 µM. There was no 
significant difference between the initial lapatinib IC50 for either the parental or resistant 
cell line and the lapatinib IC50 for the cell lines after 12 weeks growth in the absence of 
lapatinib [Table 3-1].  
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Figure 3-8: Lapatinib IC50 values for HCC1954-par and HCC1954-L cells following 1, 
2 and 3 months growth in the absence of lapatinib. IC50s were calculated following a 5 
day lapatinib treatment (0 – 5 µM). Error bars represent the standard deviation of 
triplicate experiments.   
 
Table 3-1: IC50 values (± standard deviation of triplicate experiments) for lapatinib in 
HCC1954 par and HCC1954-L cells after 1 month, 2 months and 3 months growth in 
the absence of lapatinib. 
IC50 (µM) HCC1954-par HCC1954-L 
Initial 0.424 ± 0.018 2.674 ± 0.083 
1 month 0.440 ± 0.051 2.655 ± 0.202 
2 months 0.416 ± 0.035 2.706 ± 0.273 
3 months 0.430 ± 0.045 2.626 ± 0.157 
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3.3.3 Effect of HER2 inhibition on doubling time of HCC1954-par and HCC1954-L 
cells 
The effect of lapatinib and trastuzumab on the growth rate of HCC1954-par and 
HCC1954-L cells was investigated used cell counting. Cells were counted at days 0, 3, 
5, and 7 using ViaCount Reagent and the Guava system. Treatment of both cell lines 
with lapatinib or trastuzumab resulted in lower cell counts compared to untreated 
control cells [Figure 3-9]. 
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Figure 3-9: Proliferation of (A) HCC1954-par and (B) HCC1954-L cells treated with 1 
µM lapatinib or 15 µg/ml trastuzumab for 7 days. Cells were plated in 24-well plates 
and proliferation was measured at days 0, 3, 5 and 7 by cell counting. Error bars 
represent standard deviation of triplicate experiments. 
 
These cell counts were used to calculate the doubling times of each cell line, under each 
treatment condition using the formula detailed in [section 2.7]. HCC1954-par cells have 
a doubling time of 29.8 ± 1.0 hours. Compared to this the doubling time of HCC1954-L 
cells, 48.5 ± 2.6 hours, was significantly increased (p = 0.0026). Lapatinib treatment 
increased the doubling time of both cells lines, in HCC1954-par cells the doubling time 
significantly increased from 29.8 ± 1.0 hours in the control to 83.0 ± 3.6 hours (p = 
0.0007) in the lapatinib treated cells. In HCC1954-L cells, lapatinib did not significantly 
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increase the doubling time (48.5 ± 2.6 hours in the control to 57.2 ± 7.1 hours in the 
lapatinib treated cells, p = 0.1544). Trastuzumab treatment also increased the doubling 
time of both cells lines, in HCC1954-par cells the doubling time significantly increased 
from 29.8 ± 1.0 hours in the control to 43.2 ± 3.9 hours (p = 0.0213) in the trastuzumab 
treated cells. In HCC1954-L cells, the doubling time increased from 48.5 ± 2.6 hours in 
the control to 55.1 ± 5.1 hours in the lapatinib treated cells, however this increase was 
not statistically significant (p = 0.1381) [Table 3-2]. 
 
Table 3-2: Doubling times (hours) of conditioned HCC1954 cells with and without 
lapatinib (Lap) (1 µM) or trastuzumab (Trast) (15 µg/ml) treatment (± standard 
deviation of triplicate experiments). The fold change in cell growth in response to 
treatment is expressed relative to the control untreated cells for each cell line. 
Cell line  Control Lap Trast 
HCC1954-par Doubling time (hrs) 29.8 ± 1.0 83.0 ± 3.6 43.2 ± 3.9 
 Fold change relative to control  2.8 1.5 
HCC1954-L Doubling time (hrs) 48.5 ± 2.6 57.2 ± 7.1 55.1 ± 5.1 
 Fold change relative to control  1.2 1.1 
 
3.4 Array Comparative Genomic Hybridisation (CGH) analysis of HCC1954-L 
cells 
Array CGH analysis is used to examine alterations, either amplifications or deletions of 
genes at the chromosome level. HCC1954-L cells were compared to the parental cell 
line using array CGH technology. This work was carried out in collaboration with Dr. 
Lee Anderson, UCLA. Briefly, DNA is fragmented and fluorescently labelled and 
hybridised to Agilent arrays, fluorescent signals are detected by a microarray scanner 
and results are viewed as a common karyogram revealing copy number changes. 
HCC1954-L cells displayed 14 unique aberrations compared to HCC1954-par cells; 
these aberrations are listed in Table 3-3, and the gene descriptions are listed in Table 3-
4.  
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Table 3-3: List of aberrations, chromosome and cytoband position, number of annealed probes, degree of amplification of deletion, p-value and 
corresponding gene names for HCC1954-L cells compared with HCC1954-par   
Aberr 
No. 
Chr Cytoband Start Stop #Probes Amp. Del. pval Gene Names 
1 chr1 p12 1.18E+08 1.18E+08 25 0.523 0.000 4.30E-70 MAN1A2, FAM46C, GDAP2, WDR3, SPAG17 
2 chr4 q22.3 9.80E+07 9.82E+07 3 0.996 0.000 1.02E-10  
3 chr4 q26 1.15E+08 1.16E+08 28 0.738 0.000 9.25E-25 ARSJ, UGT8, NDST4 
4 chr4 q27 1.21E+08 1.23E+08 51 0.609 0.000 2.37E-14 MAD2L1, PRDM5, C4orf31, TNIP3, GPR103, ANXA5, 
TMEM155 
5 chr11 p14.3 2.37E+07 2.58E+07 42 0.525 0.000 3.98E-42 LUZP2 
6 chr12 p12.2-
p12.1 
2.01E+07 2.25E+07 94 0.777 0.000 0.00E+00 PDE3A, SLCO1C1, SLCO1B3, LST-3TM12, SLCO1B1, 
SLCO1A2, IAPP, PYROXD1, RECQL, GOLT1B, 
C12orf39, GYS2, LDHB, KCNJ8, ABCC9, CMAS, 
ST8SIA1, KIAA0528 
7 chr12 q23.1 9.88E+07 9.91E+07 10 0.747 0.000 6.01E-24 ANKS1B, UHRF1BP1L 
8 chr13 q12.11 1.84E+07 1.85E+07 3 0.504 0.000 1.93E-09  
9 chr17 q12 3.43E+07 3.45E+07 11 0.000 -0.52 7.04E-09 LASP1, FBXO47, PLXDC1 
10 chr17 q12 3.49E+07 3.54E+07 33 0.720 0.000 1.47E-
248 
CRKRS, NEUROD2, PPP1R1B, STARD3, TCAP, 
PNMT, PERLD1, ERBB2, C17orf37, GRB7, IKZF3, 
ZPBP2, GSDML, ORMDL3, GSDM1 
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11 chr18 q12.3-
q21.1 
4.17E+07 4.25E+07 39 0.000 -0.52 3.01E-11 KIAA1632, PSTPIP2, ATP5A1, CCDC5, C18orf25, 
RNF165 
12 chr20 q11.22 3.17E+07 3.18E+07 5 0.580 0.000 9.51E-19 PXMP4, ZNF341 
13 chr20 q11.22 3.30E+07 3.32E+07 11 0.547 0.000 8.21E-35 MYH7B, TRPC4AP, EDEM2, PROCR 
14 chr20 q11.22 3.34E+07 3.35E+07 6 0.518 0.000 5.36E-18 UQCC, GDF5, CEP250 
15 chr22 q13.32-
q13.33 
4.77E+07 4.83E+07 20 0.605 0.000 1.04E-08  
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Table 3-4: List of names and descriptions of genes altered in HCC1954-L compared to 
HCC1954-par. 
Gene Name Description of Gene 
MAN1A2  mannosidase, alpha, class 1A, member 2 
FAM46C  family with sequence similarity 46, member C 
GDAP2  ganglioside induced differentiation associated protein 2 
WDR3  WD repeat domain 3 
SPAG17 sperm associated antigen 17 
ARSJ  arylsulfatase family, member J 
UGT8 UDP glycosyltransferase 8 
DST4 STE20 family protein kinase 
MAD2L1  MAD2 mitotic arrest deficient-like 1 (yeast) 
PRDM5 PR domain containing 5 
C4orf31 neuron-derived neurotrophic factor 
TNIP3   TNFAIP3 interacting protein 3 
GPR103  pyroglutamylated RFamide peptide receptor 
ANXA5 annexin A5 
TMEM155 transmembrane protein 155 
LUZP2 leucine zipper protein 2 
PDE3A  phosphodiesterase 3A, cGMP-inhibited 
SLCO1C1  solute carrier organic anion transporter family, member 1C1 
SLCO1B3 solute carrier organic anion transporter family, member 1B3 
LST-3TM12  organic anion transporter LST-3b 
SLCO1B1   solute carrier organic anion transporter family, member 1B1 
SLCO1A2 solute carrier organic anion transporter family, member 1A2 
IAPP islet amyloid polypeptide 
PYROXD1 pyridine nucleotide-disulphide oxidoreductase domain 1 
RECQL RecQ protein-like (DNA helicase Q1-like) 
GOLT1B golgi transport 1B 
C12orf39 chromosome 12 open reading frame 39 
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Table 3-5: Continued 
Gene Name Description of Gene 
GYS2 glycogen synthase 2 (liver) 
LDHB  lactate dehydrogenase B 
KCNJ8 potassium inwardly-rectifying channel, subfamily J, member 8 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 
CMAS cytidine monophosphate N-acetylneuraminic acid synthetase 
ST8SIA1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 
KIAA0528 novel C2 domain containing protein 
ANKS1B ankyrin repeat and sterile alpha motif domain containing 1B 
UHRF1BP1L UHRF1 binding protein 1-like 
LASP1 LIM and SH3 protein 1 
FBXO47  F-box protein 47 
PLXDC1 plexin domain containing 1 
CRKRS cyclin-dependent kinase 12 
NEUROD2  neurogenic differentiation 2 
PPP1R1B protein phosphatase 1, regulatory (inhibitor) subunit 1B 
STARD3 StAR-related lipid transfer (START) domain containing 3 
TCAP titin-cap (telethonin) 
PNMT phenylethanolamine N-methyltransferase 
PERLD1 post-GPI attachment to proteins 3 
ERBB2 Epidermal growth factor receptor 2  
C17orf37 migration and invasion enhancer 1 
GRB7 growth factor receptor-bound protein 7 
IKZF3 IKAROS family zinc finger 3 
ZPBP2 zona pellucida binding protein 2 
GSDML  gasdermin B 
ORMDL3  ORM1-like 3 (S. cerevisiae) 
GSDM1 gasdermin A 
 90 
 
Table 3-6: Continued 
Gene Name Description of Gene 
KIAA1632 ectopic P-granules autophagy protein 5 homolog (C. elegans) 
PSTPIP2 proline-serine-threonine phosphatase interacting protein 2 
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha 
subunit 1, cardiac muscle 
CCDC5 HAUS augmin-like complex, subunit 1 
C18orf25 chromosome 18 open reading frame 25 
RNF165 ring finger protein 165 
PXMP4 peroxisomal membrane protein 4, 24kDa 
ZNF341 zinc finger protein 341 
MYH7B myosin, heavy chain 7B, cardiac muscle, beta 
TRPC4AP transient receptor potential cation channel, subfamily C, member 4 
associated protein 
EDEM2 ER degradation enhancer, mannosidase alpha-like 2 
PROCR protein C receptor, endothelial 
UQCC ubiquinol-cytochrome c reductase complex chaperone 
GDF5 growth differentiation factor 5 
CEP250 centrosomal protein 250kDa 
 
3.4.1 Increased amplification of chr17q12 
HCC1954-L cells have increased amplification of chr17q12 compared to HCC1954-L 
cells [Figure 3-10]. Amplification of this region is associated with the amplification of 
several genes including HER2, STARD3, Grb7 and gasdermin. The expression levels of 
HER2 and STARD3 was used to determine whether amplification of this region 
corresponded with increased protein expression.  
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Figure 3-10: Representation of increased amplification of chr17q12 in HCC1954-L 
cells compared to HCC1954-par cells. 
 
3.4.2 Validation of increased HER2 amplification 
The increased amplification of HER2 in HCC1954-L cells compared to HCC1954-par 
cells was confirmed using Western blotting. HCC1954-L cells exhibit a small but 
significant 1.2-fold (p=0.02) increase in HER2 expression compared to parental cells 
[Figure 3-11]. The increased amplification of HER2 was also examined using 
Fluorescent In-situ Hybridisation (FISH) analysis, carried out in collaboration with 
Alison Prendergast, St. Vincent’s University Hospital. Briefly paraffin blocks of 
HCC1954-par and HCC1954-L cells were sectioned and analysed for HER2 using the 
PathVysion HER-2 DNA Probe Kit. The HER2 FISH ratio (HER2/CEP17) for 
HCC1954-par cells was 3.80 while HCC1954-L cells have a HER2 FISH ratio of 4.04.  
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Figure 3-11: (A) Immunoblotting for HER2 in HCC1954-par and HCC1954-L cells. α-
tubulin was used as a loading control. Images are representative of triplicate 
experiments. Densitometry analysis of triplicate immunoblots was performed using 
ImageQuant software. * denotes p ≤ 0.05 (B) Image of HCC1954-par cells stained for 
HER2 using the PathVysion HER-2 DNA Probe Kit. 
 
3.4.3 Validation of increased STARD3 amplification 
STARD3 (StAR-related lipid transfer (START) domain containing 3) was also 
associated with a dramatic increase in STARD3 protein expression. STARD3, often 
referred to as MLN64 (metastatic lymph node 64), was initially identified from a breast-
cancer-derived metastatic lymph node cDNA library as a gene that was overexpressed 
and amplified in breast cancer [280]. Immunoblotting for STARD3 was performed to 
examine whether the increased amplification of STARD3 in HCC1954-L cells 
compared to HCC1954-par cells corresponded with increased expression at the protein 
level. STARD3 expression was 29.7-fold higher in HCC1954-L cells compared to 
HCC1954-par cells, in which expression of STARD3 was barely detectable [Figure 3-
12]. 
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Figure 3-12: Immunoblotting for STARD3 in HCC1954-par and HCC1954-L cells. α-
tubulin was used as a loading control. Images are representative of triplicate 
experiments. Densitometry analysis of triplicate immunoblots was performed using 
ImageQuant software. * denotes p ≤ 0.05. 
 
3.5 Analysis of signalling pathways downstream of HER2 
To determine if the increased amplification of HER2 in HCC1954-L cells compared to 
HCC1954-par cells contributes to lapatinib resistance in these cells, the phosphorylation 
of HER2 and other key HER signalling molecules were examined. 
 
3.5.1 Expression of HER family members 
HCC1954-L cells express higher levels of HER2 compared to HCC1954-par cells (p = 
0.008) [Figure 3-13]. Treatment of HCC1954-par cells with 1 µM lapatinib for 24 hours 
results in a slight, yet statistically significant increase in HER2 (p = 0.04), and a 
significant decrease in phospho-HER2 levels (p = 0.03). Treatment of HCC1954-L cells 
with 1 µM lapatinib resulted in a significant decrease in phospho-HER2 levels (p = 
0.04) and a small increase in HER2 which failed to reach statistical significance (p = 
0.05). There was a small decrease in phospho-HER2 in HCC1954-L cells compared to 
HCC1954-par cells, however, when the levels of phospho-HER2 were normalised to 
total HER2 this decrease failed to reach statistical significance (p = 0.42).  
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Figure 3-13: Immunoblotting for phospho- (Tyr1221/1222) and total HER2 in 
HCC1954-par and HCC1954-L cells treated with 1 µM lapatinib for 24 hours. α-tubulin 
was used as a loading control on each gel. Images are representative of triplicate 
experiments. Densitometry analysis of triplicate immunoblots was performed using 
ImageQuant software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001. 
 
There was no significant difference in the levels of EGFR or HER3 between HCC1954-
par and HCC1954-L cells. Treatment of HCC1954-par cells with 1 µM lapatinib did not 
significantly alter the levels of HER3 or EGFR [Figure 3-14]. However, treatment of 
HCC1954-L cells with 1 µM lapatinib resulted in a significant increase in HER3 levels 
(p = 0.0248). Phospho-HER3 levels were barely detectable and phospho-EGFR levels 
were undetectable by Western blot, in HCC1954-par and HCC1954-L cells. Positive 
controls for phospho-HER3 (BT474 cells) and phospho-EGFR (MDA-MB-468 cells) 
were detected (not shown). 
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Figure 3-14: Immunoblotting for phospho- and total HER3, and phospho- and total 
EGFR in HCC1954-par and HCC1954-L cells treated with 1 µM lapatinib for 24 hours. 
α-tubulin was used as a loading control on each gel. Images are representative of 
triplicate experiments. Densitometry analysis of triplicate immunoblots was performed 
using ImageQuant software. * denotes p ≤ 0.05. 
 
3.5.2 Alterations in P13K/AKT and MAPK signalling pathways 
Phospho-AKT levels were significantly decreased in HCC1954-par (p = 0.01) and 
HCC1954-L (p = 0.04) cells following 24 hour treatment with 1 µM lapatinib [Figure 3-
15]. Lapatinib treatment resulted in a similar decrease in the levels of phospho-ERK in 
HCC1954-par (p = 0.0001) and HCC1954-L (p = 0.003) cells. HCC1954-L cells had 
higher levels of both phospho-AKT (p = 0.04) and phospho-ERK (p = 0.01) compared 
to HCC1954-par cells, with no significant change in the levels of total AKT or ERK.  
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Figure 3-15: Immunoblotting for phospho- (Ser473) and total AKT, and phospho- 
(Thr202/Tyr204) and total ERK in HCC1954-par and HCC1954-L cells treated with 1 
µM lapatinib for 24 hours. α-tubulin was used as a loading control on each gel. Images 
are representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** 
denotes p ≤ 0.001. 
 
3.5.2 Examination of previously published mechanisms of acquired lapatinib resistance 
The overexpression and/or upregulation of the following proteins have been shown in 
previously published cell line models of acquired lapatinib resistance; ER, MCL-1, SRC 
and XIAP. ER and phospho-SRC were undetectable in HCC1954-par and HCC1954-L 
cells. Controls for ER (BT474 cells) and phospho-SRC (MCF-7) were positive (not 
shown). HCC1954-L cells had higher levels of SRC (p = 0.01), and lower levels of 
XIAP (p = 0.0005) and MCL-1 (p = 0.01) compared to HCC1954-par cells [Figure 3-
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16]. Treatment with 1 µM lapatinib resulted in a decrease in XIAP levels in HCC1954-
par cells (p = 0.01) and an increase in XIAP levels in HCC1954-L cells (p = 0.02). The 
treatment also resulted in a decrease in MCL-1 levels in HCC1954-par cells (p = 0.03) 
but not in HCC1954-L cells, nor did the treatment have an effect on the levels of SRC 
in either cell line.  
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Figure 3-16: Immunoblotting for XIAP, ER, phospho- (Tyr416) and total SRC, and 
MCL-1 in HCC1954-par and HCC1954-L cells treated with 1 µM lapatinib for 24 
hours. α-tubulin was used as a loading control on each gel. Images are representative of 
triplicate experiments. Densitometry analysis of triplicate immunoblots was performed 
using ImageQuant software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001 
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3.6 Summary 
A novel cell line model of acquired lapatinib resistance, HCC1954-L, was developed by 
continuously culturing HCC1954 cells in the presence of lapatinib for 6 months. The 
HCC1954-L cells were resistant to lapatinib and the resistant phenotype was stable 
following a freeze-thaw cycle and 3 months growth in the absence of lapatinib. Array 
CGH analysis of HCC1954-L cells revealed increased gene amplification of HER2 
compared to HCC1954-par cells. This increased amplification was confirmed using 
immunoblotting and FISH analysis. However, phospho-HER2 levels were not increased 
in the HCC1954-L cells, and phospho-HER2 levels were decreased in both the parental 
and resistant cells following treatment with lapatinib. Immunoblotting also revealed 
alterations in phospho-AKT, phospho-ERK, XIAP, MCL-1 and SRC in the resistant 
cells. 
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Chapter 4 
 
Senescence – a novel mechanism of acquired lapatinib resistance 
 101 
 
4.1 Introduction 
In addition to developing HCC1954-L, the model of acquired lapatinib resistance 
described in Chapter 3, HCC1419 cells were also conditioned with lapatinib. However, 
in contrast to the HCC1954-L cells which became resistant to lapatinib, HCC1419 cells 
did not continue to grow in the presence of lapatinib. Previous data generated in our lab 
has shown that HCC1419 cells treated with 250 nM lapatinib ceased proliferation and 
after 6 months of treatment, very few treated cells remained and these cells neither 
proliferated nor died in the presence of lapatinib. When lapatinib was removed from the 
media the cells slowly began proliferating again, after 3 months of growth the cells were 
tested and found to exhibit the same sensitivity to lapatinib as lapatinib-naïve cells. In 
this chapter, the effects of lapatinib treatment on HCC1419 cells are examined and the 
mechanism which enables the cells to survive long-term lapatinib treatment without 
active proliferation is investigated.  
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4.2 Lapatinib conditioning of HCC1419 cells 
HCC1419 cells overexpress HER2 and thus represent a cell line model of HER2 
positive breast cancer. HCC1419 cells are resistant to trastuzumab, but are sensitive to 
lapatinib with an IC50 of 0.08 ± 0.01 µM [Figure 4-1]. This cell line was chosen to be 
conditioned in lapatinib-containing media. A lapatinib dose response assay was 
performed in order to select the concentration of lapatinib which would result in 70 % 
growth inhibition over a 4 day treatment. Treatment of HCC1419 cells with 200 nM 
lapatinib inhibited the growth of the cells by 67.5 ± 1.1 % compared to untreated 
controls (p = 0.0001), while 300 nM lapatinib inhibited 79.0 ± 2.3 % compared to 
untreated controls (p = 0.0005) [Figure 4-2]. Therefore lapatinib conditioning of 
HCC1419 cells began with twice weekly treatments of 250 nM lapatinib, as this 
concentration should result in approximately 70 % inhibition of cell growth.  
  
 
Figure 4-1: Proliferation of HCC1419 cells following a 5-day treatment with lapatinib 
(0 – 1.5 µM). Growth is expressed relative to untreated control cells. Error bars 
represent the standard deviation of triplicate experiments.  
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Figure 4-2: HCC1419 cells treated with varying concentrations of lapatinib over a four 
day period. Cell counts were performed using ViaCount reagent and Guava Software 
and expressed relative to control untreated cells. Error bars denote the standard 
deviation of triplicate cell counts from triplicate experiments. Percentages shown on 
graph represent the percentage of growth inhibition compared to control cells across 
three independent experiments. Student’s t-test was performed to determine significant 
differences: * denotes p < 0.05; ** denotes p < 0.01 
 
4.3 The lapatinib conditioning process 
HCC1419 cells were seeded into 2 flasks; one flask was left untreated but was passaged 
alongside the treated cells for the duration of the treatment process. These are referred 
to as control untreated cells. The other flask was treated twice weekly with 250 nM 
lapatinib and these cells are referred to as lapatinib conditioned cells. During the 
conditioning process the morphology and sensitivity of the cell lines to lapatinib was 
monitored. In contrast to HCC1954-L cells, HCC1419 lapatinib conditioned cells 
ceased active proliferation in the presence of lapatinib during the conditioning process. 
The growth of HCC1419 lapatinib conditioned cells completely ceased within 3 months 
of treatment, and the remaining cells displayed a visibly altered morphology; the 
conditioned cells exhibited a flatter and enlarged cell shape compared to control cells 
[Figure 4-3].  
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Figure 4-3: Images of (A) HCC1419 control untreated and (B) HCC1419 lapatinib (250 
nM) conditioned cells after 3 months of lapatinib conditioning at 400X magnification.  
 
The cells were conditioned for a further 3 months, as this was the length of time taken 
for HCC1954-L cells to become fully resistant to lapatinib. At this stage HCC1419 
lapatinib conditioned cells still appeared growth arrested and displaying morphological 
alterations compared to the control cells. Whether this arrested growth and the 
associated morphological changes were the result of lapatinib-induced cellular 
senescence was then investigated. Senescence is characterised most typically by specific 
morphological alterations, to flattened and enlarged cell shape, and the induction of 
senescence markers such as senescence-associated β-galactosidase (β-gal). β-gal is the 
most widely accepted marker of senescence [281] and two weeks of treatment with 50 
µM bromodeoxyuridine (BrdU) has been shown to induce senescence in mammalian 
cells regardless of cell type or species [282]. Treatment of HCC1419 cells with 50 µM 
BrdU for 2 weeks induced β-gal activity [Figure 4-4] and was therefore used a positive 
control for the β-gal assay.  
A. B.
HCC1419 Control untreated HCC1419 Control untreated 
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Figure 4-4: Staining for senescence-associated β-galactosidase activity in (A) 
HCC1419 control untreated, and (B) HCC1419 cells treated for 2 weeks with BrdU (50 
µM) Images are at 200X magnification. 
 
4.4 Lapatinib-conditioning induces senescence in HCC1419 cells 
Following confirmation that the β-gal assay could detect BrdU-induced senescence in 
HCC1419 cells, β-gal activity was examined in HCC1419 cells which had been 
conditioned with lapatinib for 6 months. HCC1419 lapatinib conditioned cells exhibit a 
senescent-like phenotype, as indicated by an increase in β-gal activity compared to 
control untreated cells [Figure 4-5]. During the conditioning process the cells appeared 
to display arrested growth and showed morphological changes within 12 weeks of 
treatment. Therefore, the length of time required for lapatinib to induce β-gal activity in 
HCC1419 cells was investigated. Cells were conditioned with 250 nM lapatinib, and the 
cells were tested for β-gal activity compared to untreated controls, at weekly intervals 
for a period of 6 weeks. One week of treatment with 250 nM lapatinib was sufficient to 
induce a senescent-like phenotype in HCC1419 cells [Figure 4-6], and this phenotype 
remained stable throughout the 6 week treatment period.  
A. B.
HCC1419 Control untreated HCC1419 50 µM BrdU treated 
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Figure 4-5: Staining for senescence-associated β-galactosidase activity in (A, B and C) 
HCC1419 control untreated cells and (D, E and F) HCC1419 cells following 6 month 
treatment with 250 nM lapatinib. Images are represented at (A, B) 100X, (C, D) 200X 
and (E, F) 400X magnifications respectively. 
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Figure 4-6: Staining for senescence-induced β-galactosidase activity in (A, C, E, G, I 
and K) HCC1419 untreated control cells and (B, D, F, H, J and L) HCC1419 cells 
treated with lapatinib 250 nM for 1 – 6 weeks. All images taken at 400X magnification.  
 
4.6 Examining other putative markers of senescence 
To further investigate the senescent-like phenotype induced by lapatinib treatment in 
HCC1419 cells, the expression of other putative markers of senescence were examined. 
While 1 week of 250 nM lapatinib treatment induced a senescent-like phenotype in 
HCC1419 cells, it did not induce a senescent-like phenotype in SKBR3 cells [Figure 4-
7]. Thus, SKBR3 cells were used as a control for this experiment.  
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Figure 4-7: Staining for senescence-associated β-galactosidase activity in (A) 
HCC1419 control untreated cells, (B) HCC1419 250nM lapatinib treated cells, (C) 
SKBR3 control untreated cells and (D) SKBR3 250 nM lapatinib treated cells following 
1 week of lapatinib treatment. Images taken at 400X magnification.  
 
4.6.1 Expression of p15, p16, p21 and p27 by qRT-PCR 
Increased expression of specific cyclin-dependent kinase inhibitors (CDKIs), including 
p15 (CDKN), p16 
Ink4a
 (CDKN2A), p21
Waf1
 (CDKN1A), and p27
Kip1
 (CDKN1B) are 
associated with the induction of senescence [283]. The expression of these targets was 
examined using quantitative reverse-transcriptase PCR in HCC1419 and SKBR3 cells. 
HCC1419 have 3.7-fold higher levels of p15 (p = 0.04), 7.7-fold higher levels of p21 (p 
= 0.01) and 17.5-fold higher levels of p27 (p = 0.01) [Table 4-1], compared to SKBR3 
cells. Treatment of HCC1419 cells with 250 nM lapatinib for 1 week resulted in a 12.1-
fold increase in p15 expression (p = 0.01), and a 6.8-fold increase in p27 expression (p 
A. B.
C. D.
HCC1419 Control untreated HCC1419 250 nM lapatinib treated 
SKBR3 Control untreated SKBR3 250 nM lapatinib treated 
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= 0.01). Similarly, treatment of SKBR3 cells with 250 nM lapatinib for 1 week resulted 
in a 25.3-fold increase in p15 (p = 0.0005), and a 3.1-fold increase in p27 expression, 
which failed to reach statistical significance (p = 0.07). There was no change in the 
expression of p21 in either cell line. As lapatinib treatment had the same effect on the 
expression of p15, p21 and p27 in both SKBR3 and HCC1419 cells, this suggests that 
higher expression of p15, p21 and p27 in untreated cells may predict whether lapatinib 
treatment induces a senescent-like phenotype. p16 mRNA was not detected in any of 
the samples tested.  
 
Table 4-1: Expression of p15, p21 and p27 in HCC1419 and SKBR3 cells quantified 
using qRT-PCR. Data is representative of triplicate technical replicates of triplicate 
biological replicates and presented as averages ± the standard deviation of the triplicate 
∆∆Cts, where RQ is the fold change increase in mRNA levels in HCC1419 compared to 
SKBR3 cells. 
Assay ∆Ct HCC1419 
CTRL 
∆Ct  SKBR3 
CTRL 
∆∆Ct (HCC1419-
SKBR3) 
RQ 
p15 14.41343 16.1632 - 1.7497 ± 0.2262 3.7 
p21 7.932068 10.87824 - 2.9462 ± 0.6587 7.7 
p27 7.63037 11.75963 - 4.1292 ± 0.3266 17.5 
 
4.7 Lapatinib-induced senescence is reversible 
Previous data generated in our laboratory showed that HCC1419 cells conditioned with 
250 nM lapatinib for 6 months resumed active proliferation 3 months after lapatinib was 
removed from the media [255]. HCC1419 cells were treated with 250 nM lapatinib for 1 
week and then tested for β-gal activity. The cells were confirmed as positive for 
senescence. Lapatinib was then removed from the media and cells were cultured for a 
further week, after which time they were again tested for β-gal activity. Removing 
lapatinib from the media of senescent HCC1419 cells reverses the senescent phenotype 
as indicated by the conditioned cells exhibiting a similar level of β-gal activity 
compared to control untreated cells [Figure 4-8]. 
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Figure 4-8: Staining for senescence-induced β-galactosidase activity in (A) HCC1419 
control untreated cells and (B) HCC1419 250 nM lapatinib treated cells following 1 
week treated with lapatinib. Lapatinib was removed from the media for one week and 
cells were tested again, (C) HCC1419 control untreated cells and (D) HCC1419 cells 
from which lapatinib had been removed. Images taken at 400X magnification.  
 
4.8 AKT versus ERK-mediated senescence induction 
The MAPK and PI3K/AKT pathways are activated by HER signalling. Inhibition of 
HER2 signalling with lapatinib inhibits both MAPK and AKT signalling. It is therefore 
possible that lapatinib-induced senescence may be mediated either by inhibition of 
MAPK signalling or PI3K signalling or may require inhibition of both signalling 
pathways. HCC1419 cells were treated with an ERK inhibitor, U0126, (MAPK 
pathway) and an AKT inhibitor, LY294002, (PI3K/AKT pathway) as single agents and 
in combination at a range of concentrations [Figure 4-9]. Treatment of HCC1419 cells 
with 250 nM LY294002 did not result in strong β-gal activity compared to control 
A. B.
C. D.
HCC1419 Control untreated HCC1419 250 nM lapatinib treated 
HCC1419 Control untreated HCC1419 lapatinib withdrawal 
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untreated cells but treatment with 500 nM and 1 µM resulted in strong β-gal activity. 
Treatment of HCC1419 cells with 500 nM, 1 µM or 2 µM U0126 resulted in strong β-
gal activity in each case. All tested combinations of LY294002 and U0126 resulted in β-
gal activity indicating that inhibition of either MAPK and/or PI3K/AKT signalling 
pathways results in induction of senescence in HCC1419 cells.  
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Figure 4-9: Staining for senescence-associated β-galactosidase activity in (A) 
HCC1419 control untreated cells,  and  (B) HCC1419 treated with 250 nM lapatinib, 
(C) 250 nM  LY294002, (D) 500 nM LY294002, (E) 1 µM LY294002, (F) 500 nM 
U0126, (G) 1 µM U0126, (H) 2 µM U0126, (I) 250 nM  LY294002 and 500 nM U0126, 
(J) 500 nM LY294002 and 1 µM U0126,  and (K) 1 µM LY294002 and 2 µM U0126 
following 1 week of treatment. Images taken at 400X magnification. 
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4.9 Lapatinib and trastuzumab-induced senescence 
HCC1419 cells were treated with a range of lapatinib concentrations (0.05 – 1 µM), 15 
µg/ml trastuzumab and a combination of lapatinib and trastuzumab for 1 week and the 
activity of β-gal was examined. Concentrations of 50 – 500 nM lapatinib induced strong 
β-gal activity compared to control cells. Although concentrations of lapatinib in excess 
of 500 nM (750 nM and 1 µM) induced some β-gal activity it appeared to be at a much 
lower intensity than that induced by lower concentrations, suggesting that lower 
concentrations of lapatinib resulted in stronger induction of the senescent-like 
phenotype in HCC1419 cells. Treatment of HCC1419 cells with trastuzumab did not 
induce senescence whereas trastuzumab combined with 250 nM lapatinib induced 
senescence, although the intensity of β-gal staining appears lower than that induced by 
250 nM lapatinib alone [Figure 4-10].  
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Figure 4-10: Staining for senescence-associated β-galactosidase activity in (A) 
HCC1419 control untreated cells and (B) HCC1419 treated with 50 nM lapatinib, (C) 
100 nM lapatinib, (D) 250 nM lapatinib, (E) 500 nM lapatinib, (F) 750 nM lapatinib, 
(G) 1 µM lapatinib, (H) 15 µg/ml trastuzumab, and (I) a combination of 15 µg/ml 
trastuzumab and 250 nM lapatinib following 1 week of treatment. Images taken at 400X 
magnification. 
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4.10 Lapatinib induced senescence in a panel of HER2 positive cell lines 
The induction of senescence was tested in a panel of HER2 cell lines which are 
sensitive to lapatinib [194]. Cells were treated with 250 nM lapatinib for 1 week and β-
gal activity was compared to control untreated cells. HCC1419 cells treated with 
lapatinib were included as a positive control for induction of β-gal activity. Although 
UACC812 and HCC2218 cells exhibit β-gal activity, there is no increase in activity 
compared to control untreated cells. Also, HCC2218 cells are an anchorage-independent 
cell line and the β-gal assay is designed for anchorage-dependent cells, therefore it is 
possible that the assay conditions were not optimal for that cell line. No other cell lines 
showed an alteration in β-gal activity following lapatinib treatment [Figure 4-11]. This 
suggests that lapatinib induced senescence may be specific to HCC1419 cells.  
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Figure 4-11: Staining for senescence-induced β-galactosidase activity in EFM-192A, 
MD-MBA-361, SUM225, UACC812, SKBR3, HCC2218, HCC1954, BT474, HCC202 
and HCC1419 cells treated with 250 nM lapatinib for 1 week. Images are representative 
of duplicate experiments and are taken at 400X magnification.  
 
4.11 Summary 
HCC1419 cells did not proliferate in the presence of 250 nM lapatinib, instead the 
lapatinib treatment induced a senescent-like phenotype in the cells, determined using an 
assay which detects activity of β-galactosidase. Lapatinib induced this phenotype in 
HCC1419 cells following short-term (1 week) and long term (6 months) treatment. 
Treatment of HCC1419 cells with 250 nM lapatinib for one week resulted in an increase 
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in the expression of p15 and p27, two other putative markers of senescence. SKBR3 
cells when treated with 250 nM lapatinib for 1 week also exhibited an increase in the 
expression of p15 and p27 but did not display β-galactosidase activity. The lapatinib-
induced senescent-like phenotype in HCC1419 cells was reversed when lapatinib was 
removed from the media. Inhibition of MAPK and/or PI3K/AKT signalling induced a 
senescent-like phenotype in HCC1419 cells. Different concentrations of lapatinib 
induced β-galactosidase activity to varying degrees with a trend towards higher activity 
occurring at lower concentration of lapatinib treatment. Treatment of HCC1419 cells 
with trastuzumab did not result in a β-galactosidase activity. Combined treatment with 
trastuzumab and lapatinib resulted in β-galactosidase activity but at a lower level than 
treatment with lapatinib alone. A panel of HER2-amplified cell lines were treated with 
250 nM lapatinib for one week but lapatinib did not induce β-galactosidase activity in 
any cell line other than HCC1419 cells.  
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Chapter 5 
SKBR3-L – a cell line model of acquired lapatinib resistance 
  
 119 
 
5.1 Introduction 
Previous work in our laboratory resulted in the generation of SKBR3-L cells, a cell line 
model of lapatinib resistance [255]. Briefly, SKBR3-par cells were conditioned with 
250 nM lapatinib for 6 months after which time the resulting cell line was resistant to 
lapatinib. Two-dimensional differential in-gel electrophoresis analysis was used to 
examine alterations in the levels of phospho-proteins in SKBR3-L compared to SKBR3 
parental cells (SKBR3-par). Further characterisation of the SKBR3-L cell line and 
validation of one of the most interesting targets from the phospho-proteomic analysis 
are described in this chapter.  
5.2 Characterisation of SKBR3-L cells 
5.2.1 SKBR3-L cells are resistant to lapatinib 
Characterisation of SKBR3-L cells was performed. The IC50 for lapatinib in the 
conditioned cell line was 6.5 ± 0.4 µM lapatinib compared to 0.1 ± 0.01 µM lapatinib in 
parental SKBR3 (SKBR3-par) cells (p = 0.0014) [Figure 5-1], consistent with previous 
results [255].  
 
 
Figure 5-1: Proliferation of SKBR3-par and SKBR3-L cells following a 5 day 
treatment with lapatinib (0 – 10 µM). Growth is expressed relative to untreated control 
cells. Error bars represent the standard deviation of triplicate experiments.  
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5.2.2 Assessing the stability of lapatinib resistance 
In order to assess the long-term stability of the resistant phenotype, drug withdrawal 
assays were performed. Lapatinib was removed from the media of SKBR3-L cells and 
the cells were cultured without lapatinib for approx. 4 months. The sensitivity of 
SKBR3-L cells to lapatinib was tested at 1 month intervals and the sensitivity of the 
SKBR3-par cells was measured concurrently with the SKBR3-L cells to ensure that 
there was no adverse effect of long-term culture on lapatinib sensitivity. After 1 month 
of growth in the absence of lapatinib, the  lapatinib IC50  in SKBR3-L cells was  4.4 ± 
1.5 µM lapatinib compared to 0.1 ± 0.0 µM  in SKBR3-par cells (p = 0.0372) [Figure 5-
2]. After 2 months of growth in the absence of lapatinib, the lapatinib IC50 in SKBR3-L 
cells was 3.8 ± 1.1 µM compared to 0.09 ± 0.01 µM in SKBR3-par cells (p = 0.0130). 
Although the lapatinib IC50 in SKBR3-L cells remained above 1 µM after both 1 and 2 
months growth in the absence of lapatinib the IC50 values were lower than the initial 
lapatinib IC50 of 6.5 ± 0.4 µM and there was a high standard deviation between the 
replicates suggesting the lapatinib IC50 was varying over the course of the 3 replicates. 
This suggests that SKBR3-L cells are slower regaining sensitivity to lapatinib the longer 
they are grown in the absence of lapatinib.  
 
 
Figure 5-2: Lapatinib IC50 values for SKBR3-par and SKBR3-L cells following 1 and 2 
months growth in the absence of lapatinib. IC50 values were calculated following a 5 
day lapatinib treatment (0 – 2.5 µM). Error bars represent the standard deviation of 
triplicate experiments.   
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The sensitivity of both cell lines to lapatinib was tested again at the 3 month interval. 
However, it was not possible to get reproducible replicates at this time point as the IC50 
values in SKBR3-L cells varied significantly. Over 2 weeks, and 4 independent 
replicates the lapatinib IC50 in SKBR3-L cells decreased from 4.6 µM to 0.2 µM 
lapatinib [Figure 5-3]. As a result accurate IC50 values with standard deviations could 
not be calculated at this time point. This data combined with the IC50 data generated 
after 1 month and 2 months of lapatinib withdrawal suggests that SKBR3-L cells slowly 
regain sensitivity to lapatinib over a 3-4 month period [Table 5-1]. 
 
 
Figure 5-3: Lapatinib IC50 values for SKBR3-par and SKBR3-L cells following 12, 13, 
14 and 15 weeks growth in the absence of lapatinib. IC50 values were calculated 
following a 5 day lapatinib treatment (0 – 2.5 µM). Each replicate is an independent 
experiment. 
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Table 5-1: Lapatinib IC50 values for SKBR3-par and SKBR3-L cells over the course of 
the lapatinib withdrawal experiment. Where indicated standard deviations are expressed 
for triplicate replicates. 
IC50 (µM) SKBR3-par SKBR3-L 
Initial 0.100 ± 0.011 6.540 ± 0.427 
1 month 0.108 ± 0.015 4.392 ± 1.474 
2 months 0.093 ± 0.002 3.794 ± 1.093 
12 weeks (rep 1) 0.095 4.634 
13 weeks (rep 2) 0.108 1.814 
14 weeks (rep 3) 0.103 0.512 
15 weeks (rep 4) 0.098 0.205 
 
5.2.3 Analysis of HER2 signalling pathways 
As lapatinib is a specific HER2/EGFR tyrosine kinase inhibitor, alterations in the 
phosphorylation and expression of HER2, EGFR, HER3 and HER4 between SKBR3-
par and SKBR3-L were examined. The effect of lapatinib treatment on the 
phosphorylation and expression of these proteins was also examined.  
 
5.2.3.1 Expression of HER2 
There was no significant difference in the levels of HER2 between SKBR3-par and 
SKBR3-L cells (p = 0.55) [Figure 5-4]. However, SKBR3-L cells have significantly 
higher levels of phospho-HER2 compared to SKBR3-par cells (p = 0.016). Treatment of 
SKBR3-par cells with 1 µM lapatinib resulted in a decrease in phospho-HER2 levels (p 
= 0.004), but no change in total HER2 levels (p = 0.452). Treatment of SKBR3-L cells 
with 1 µM lapatinib also resulted in a significant decrease in phospho-HER2 levels (p = 
0.0007) with no alteration in total HER2 levels (p = 0.772).  
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Figure 5-4: Immunoblotting for phospho-HER2 (Tyr1221/1222) and total HER2 in 
SKBR3-par and SKBR3-L cells following 24 hours treatment with 1µM lapatinib. α-
tubulin was used as a loading control. Images are representative of triplicate 
experiments. Densitometry analysis of triplicate immunoblots was performed using 
ImageQuant software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001. 
 
5.2.3.2 Expression of EGFR 
SKBR3-L cells express higher levels of EGFR (p = 0.004) and have higher levels of 
phospho-EGFR (p = 0.024) compared to SKBR3-par cells. Treatment of SKBR3-par 
cells with 1 µM lapatinib for 24 hours results in a non-significant decrease in phospho-
EGFR (p = 0.83) and no change in total EGFR levels (p = 0.48) compared to untreated 
cells [Figure 5-5]. Treatment of SKBR3-L cells with 1 µM lapatinib for 24 hours results 
in a significant decrease in phospho-EGFR levels (p = 0.009) with no change in total 
EGFR levels (p = 0.303) compared to untreated cells. 
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Figure 5-5: Immunoblotting for phospho-EGFR (Thr1173) and total EGFR in SKBR3-
par and SKBR3-L cells following 24 hours treatment with 1µM lapatinib. α-tubulin was 
used as a loading control. Images are representative of triplicate experiments. 
Densitometry analysis of triplicate immunoblots was performed using ImageQuant 
software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001. 
 
5.2.3.3 Expression of HER3 
There was no significant difference in the levels of phospho-HER3 (p = 0.14) between 
SKBR3-par and SKBR3-L cells. SKBR3-L cells have higher levels of total HER3 
compared to SKBR3-par cells however, the difference failed to reached statistical 
significance (p = 0.09) [Figure 5-6]. Treatment of SKBR3-par cells with 1 µM lapatinib 
resulted in a significant decrease in phospho-HER3 levels (p = 0.02) and a significant 
increase in total HER3 levels (p = 0.03). Treatment of SKBR3-L cells with 1 µM 
lapatinib resulted in a significant decrease in phospho-HER3 levels (p = 0.03). There 
was also a 2.7-fold increase in total HER3 levels in SKBR3-L cells following lapatinib 
treatment (p = 0.01).  
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Figure 5-6: Immunoblotting for phospho-HER3 (Tyr1289) and total HER3 in SKBR3-
par and SKBR3-L cells following 24 hours treatment with 1µM lapatinib. α-tubulin was 
used as a loading control. Images are representative of triplicate experiments. 
Densitometry analysis of triplicate immunoblots was performed using ImageQuant 
software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001. 
 
5.2.3.1 Expression of HER4 
SKBR3-par cells express significantly higher levels of HER4 compared to SKBR3-L 
cells (p = 0.04) [Figure 5-7]. Treatment with 1 µM lapatinib did not affect the levels of 
HER4 in either SKBR3-par (p = 0.93) or SKBR3-L cells (p = 0.21).  
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Figure 5-7: Immunoblotting for HER4 in SKBR3-par and SKBR3-L cells following 24 
hours treatment with 1µM lapatinib. α-tubulin was used as a loading control. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** 
denotes p ≤ 0.001. 
 
5.2.4 Alterations in MAPK and P13K/AKT signalling pathways 
SKBR3-L cells have significantly lower levels of phospho-AKT compared to SKBR3-
par cells (p = 0.0009), in fact levels of phospho-AKT are barely detectable in SKBR3-L 
cells [Figure 5-8]. Levels of phospho-ERK are also decreased in SKBR3-L cells 
compared to SKBR3-par (p = 0.009), while there are no significant differences in the 
expression of total AKT (p = 0.18) or total ERK (p = 0.21) between the 2 cell lines. 
Treatment of SKBR3-par cells with 1 µM lapatinib for 24 hours resulted in a significant 
decrease in phospho-AKT (p =0.0008) and phospho-ERK (p = 0.003) without any 
changes in the levels of total AKT (p = 0.39) or total ERK (p = 0.93). Treatment of 
SKBR3-L cells with 1 µM lapatinib for 24 hours resulted in no significant changes in 
the levels of phospho-AKT (p = 0.45), AKT (p = 0.22), phospho-ERK (p = 0.39) or 
ERK (p = 0.93). 
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Figure 5-8: Immunoblotting for phospho- (Ser473) and total AKT, and phospho- 
(Thr202/Tyr204) and total ERK in SKBR3-par and SKBR3-L cells treated with 1 µM 
lapatinib for 24 hours. α-tubulin was used as a loading control on each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** 
denotes p ≤ 0.001. 
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5.2.5 Sensitivity of SKBR3-L cells to EGFR inhibition 
As previously shown in Figure 5-5, SKBR3-L cells express higher levels of EGFR (p = 
0.004) and have higher levels of phospho-EGFR (p = 0.024) compared to SKBR3-par 
cells. Therefore, the sensitivity of both cell lines to the EGFR inhibitor gefitinib was 
examined. SKBR3-L cells are significantly less sensitive to gefitinib with an IC50 of 4.9 
± 1.1 µM compared to 0.8 ± 0.2 µM in SKBR3-par cells (p = 0.02) [Figure 5-9]. This 
suggests that SKBR3-L cells are resistant to both HER2 and EGFR inhibition.  
 
 
Figure 5-9: Proliferation of SKBR3-par and SKBR3-L cells following a 5 day 
treatment with gefitinib (0 – 5 µM). Growth is expressed relative to untreated control 
cells. Error bars represent the standard deviation of triplicate experiments.  
 
5.2.6 Sensitivity of SKBR3-L cells to IGF-IR inhibition  
Increased IGF-IR signalling has been associated with resistance to trastuzumab. 
Therefore, the expression of IGF-IR was examined in SKBR3-L cells to determine 
whether altered IGF-1R signalling is specific to trastuzumab resistance or more broadly 
relevant to resistance to HER2 inhibitors. SKBR3-L cells express significantly higher 
levels of IGF-IR (p = 0.02) and have higher levels of phospho-IGF-1R (p = 0.01) 
compared to SKBR3-par cells [Figure 5-10].  
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Figure 5-10: Immunoblotting for phospho-IGF-1R (Thr1131) and total IGF-1R in 
SKBR3-par and SKBR3-L cells. α-tubulin was used as a loading control. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05 
 
To examine whether the increased phosphorylation and expression of IGF-1R resulted 
in an alteration in sensitivity to IGF-1R inhibition, the cells were treated with two anti-
IGF-IR TKIs; NVP-AEW541 and BMS-536924. The  NVP-AEW541 IC50  in SKBR3- 
L cells was 8.4 ± 0.6 µM compared to 6.3 ± 0.1 µM in SKBR3-par cells, making 
SKBR3-L cells slightly less sensitive to NVP-AEW541 than SKBR3-par (p = 0.03) 
[Figure 5-11]. The BMS-536924 IC50 in SKBR3-L cells was 6.4 ± 0.3 µM compared to 
7.6 ± 0.3 µM in SKBR3-par cells. In contrast to the NVP-AEW541 results SKBR3-L 
cells were slightly more sensitive to BMS-536924 than SKBR3-par cells (p = 0.01) 
[Figure 5-12].  
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Figure 5-11: Proliferation of SKBR3-par and SKBR3-L cells following a 5 day 
treatment with NVP-AEW541 (0 – 10 µM). Growth is expressed relative to untreated 
control cells. Error bars represent the standard deviation of triplicate experiments. 
 
 
Figure 5-12: Proliferation of SKBR3-par and SKBR3-L cells following a 5 day 
treatment with BMS-536924 (0 – 10 µM). Growth is expressed relative to untreated 
control cells. Error bars represent the standard deviation of triplicate experiments. 
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5.2.7 Examination of previously published mechanisms of acquired lapatinib resistance  
The overexpression and/or upregulation of the following proteins have been shown in 
previously published cell line models of acquired lapatinib resistance; ER, MCL-1, 
SRC, and XIAP. Levels of ER were undetectable in SKBR3-par and SKBR3-L cells 
[Figure 5-13] (a positive control for ER (BT474 cells) was included on each replicate 
blot and was detected (not shown)). There were no significant changes in the levels of 
XIAP or phospho-SRC between SKBR3-par and SKBR3-L cells, and treatment of 
either cell line with 1 µM lapatinib for 24 hours did not affect the levels of these 
proteins in either cell line. Expression of MCL-1 was increased in SKBR3-L cells 
compared to SKBR3-par (p = 0.04), while treatment with lapatinib did not affect the 
expression of MCL-1 in either cell line.  
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Figure 5-13: Immunoblotting for XIAP, ER, phospho- (Tyr416) and total SRC, and 
MCL-1 in SKBR3-par and SKBR3-L cells treated with 1 µM lapatinib for 24 hours. α-
tubulin was used as a loading control on each gel. Images are representative of triplicate 
experiments. Densitometry analysis of triplicate immunoblots was performed using 
ImageQuant software. * denotes p ≤ 0.05 
XIAP
SKBR3-par SKBR3-L
C CL L
ER
tubulin
60 kD
55 kD
60 kD
p-SRC
SRC
MCL-1
60 kD
60 kD
37 kD
*
0
0.5
1
1.5
Control Lap Control Lap
P
ro
te
in
 a
b
u
n
d
a
n
ce
XIAP
0.0
2.5
5.0
7.5
10.0
Control Lap Control Lap
P
ro
te
in
 a
b
u
n
d
a
n
ce
MCL-1
0
0.05
0.1
0.15
Control Lap Control Lap
P
ro
te
in
 a
b
u
n
d
a
n
ce
phos-SRC
0
0.5
1
1.5
Control Lap Control Lap
P
ro
te
in
 a
b
u
n
d
a
n
ce
SRC
SKBR3-LSKBR3-par
 133 
 
5.3 Validation of eEF2, a phospho-protein down-regulated in SKBR3-L cells 
A phospho-proteomic comparison of the SKBR3-par and SKBR3-L cell lines was 
previously performed using 2D-DIGE and MALDI-ToF/ToF MS [255]. Protein lysates 
were prepared, enriched for phospho-proteins, separated by 2D-gel electrophoresis and 
identified using MS analysis. Forty-one differentially regulated phospho-proteins were 
identified, 20 were significantly higher and 21 were significantly lower in abundance in 
SKBR3-L compared to SKBR3-par. Proteins identified included heat shock proteins, 
translation, degradation and metabolism-related proteins. Several phosphorylated forms 
of eukaryotic elongation factor 2 (eEF2) were identified. One form of phospho-eEF2 
was up-regulated and 6 forms were down-regulated in SKBR3-L compared to SKBR3-
par. 
 
5.3.1 Decrease in phospho-eEF2 in SKBR3-L cells 
Phosphorylation of eEF2 at Thr56 inhibits the activity of eEF2 which in turn causes a 
decrease in protein synthesis. In order to confirm the 2D-DIGE results, immunoblotting 
for phospho-eEF2 was performed on SKBR3-par and SKBR3-L cells. SKBR3-L cells 
have significantly lower levels of phospho-eEF2 compared to SKBR3-par cells (p = 
0.0001). There is no significant difference in the levels of total eEF2 between the 2 cell 
lines (p = 0.55) [Figure 5-14]. 
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Figure 5-14: Immunoblotting for phospho-eEF2 (Thr56) and total eEF2 in SKBR3-par 
and SKBR3-L cells. α-tubulin was used as a loading control on each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** 
denotes p ≤ 0.001. 
 
5.3.2 Effect of lapatinib treatment on levels of phospho-eEF2 
Treatment of SKBR3-par cells with 1 µM lapatinib for 24 hours results in a significant 
increase in the levels of phospho-eEF2 compared to untreated cells (p = 0.0008) [Figure 
5-15]. Treatment of SKBR3-L cells with 1 µM lapatinib for 24 hours has no effect on 
the levels of phospho-eEF2 compared to untreated cells (p = 0.373).  
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Figure 5-15: Immunoblotting for phospho-eEF2 (Thr56) and total eEF2 in SKBR3-par 
and SKBR3-L cells treated with 1 µM lapatinib for 24 hours. α-tubulin was used as a 
loading control on each gel. Images are representative of triplicate experiments. 
Densitometry analysis of triplicate immunoblots was performed using ImageQuant 
software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001. 
 
5.3.3 Role of eEF2k in regulation of eEF2 phosphorylation 
eEF2k phosphorylates eEF2 at Thr56 leading to its inactivation. The activity of eEF2k 
is also negatively regulated by phosphorylation. Thus, we examined the expression and 
phosphorylation of eEF2k in SKBR3-par and SKBR3-L cells. SKBR3-L cells have 
higher levels of total eEF2k compared to SKBR3-par cells (p = 0.017), and treatment of 
either cell line with 1 µM lapatinib had no effect on the expression of eEF2k [Figure 5-
16]. eEF2k is phosphorylated at Ser366 via mTOR signalling, thus, we examined the 
mTOR-mediated phosphorylation of eEF2k. SKBR3-L cells have higher levels of 
Ser366 phosphorylation of eEF2k compared to SKBR3-par cells (p = 0.042). However, 
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lapatinib treatment of SKBR3-par cells caused a significant increase in eEF2k 
phosphorylation at Ser366 (p = 0.033), which would suggest decreased activity of 
eEF2k leading to decreased phosphorylation of eEF2, however, as previously seen in 
Figure 5-15 treatment of SKBR3-par cells with lapatinib results increased 
phosphorylation of eEF2. This result suggests that the phosphorylation of eEF2 is not 
regulated by mTOR signalling in SKBR3-par cells. The phosphorylation of eEF2k at 
another site, Ser359 was then examined. SKBR3-L cells have higher levels of Ser359 
phosphorylation of eEF2k compared to SKBR3-par cells (p = 0.003) [Figure 5-16]. 
Importantly, treatment of SKBR3-par cells with 1 µM lapatinib results in decreased 
phosphorylation of Ser359 of eEF2k (p = 0.047) which correlates with the increased 
phosphorylation of eEF2 following lapatinib treatment. While there was a small 
decrease in phosphorylation eEF2k at Ser359 in SKBR3-par cells following lapatinib 
treatment, the decrease was not significant (p = 0.239). Taken together these results 
suggest that the phosphorylation of eEF2 is regulated by phosphorylation of Ser359 of 
eEF2k in SKBR3 cells.  
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Figure 5-16: Immunoblotting for phospho-eEF2k (Ser366 and Ser359), and total eEF2k in SKBR3-par and SKBR3-L cells treated with 1 µM lapatinib 
for 24 hours. α-tubulin was used as a loading control on each gel. Images are representative of triplicate experiments. Densitometry analysis of 
triplicate immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001. 
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5.3.4 mTOR and phosphorylation of eEF2  
The above results have indicated that phosphorylation of Ser366 of eEF2k does not 
regulate the phosphorylation of eEF2, suggesting that eEF2 phosphorylation is mTOR-
independent. To determine whether or not mTOR signalling plays a role in eEF2 
regulation, the expression and phosphorylation of mTOR in SKBR3-par and SKBR3-L 
cells was examined. There was no significant difference in the expression of mTOR 
between the two cell lines and treatment of either cell line with lapatinib had no effect 
on the expression of mTOR [Figure 5-17]. The levels of phosphorylated mTOR 
(Ser2448) were significantly lower in SKBR3-L cells compared to SKBR3-par cells (p 
= 0.01) and interestingly, treatment of either cell line with 1 µM lapatinib significantly 
decreased the phosphorylation of mTOR ((SKBR3-par (p = 0.005), SKBR3-L (p = 
0.028)), indicating that lapatinib inhibits mTOR signalling in both cell lines. Examining 
whether inhibition of mTOR with rapamycin, lapatinib or a combination of lapatinib 
and rapamycin would affect the phosphorylation of eEF2 in SKBR3-par and SKBR3-L 
revealed that SKBR3-par cells exhibit a similar increase in phosphorylation of eEF2 in 
response to rapamycin, lapatinib or lapatinib and rapamycin combined. However, there 
was no change in the phosphorylation of eEF2 in SKBR3-L cells in response to any of 
the treatments. Taken together, these results suggest that the regulation of eEF2 in 
SKBR3-L cells is mTOR-independent. 
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Figure 5-17: (A) Immunoblotting for phospho-mTOR (Ser2448), and total mTOR in 
SKBR3-par and SKBR3-L cells treated with 1 µM lapatinib for 24 hours. α-tubulin was 
used as a loading control on each gel. Images are representative of triplicate 
experiments. Densitometry analysis of triplicate immunoblots was performed using 
ImageQuant software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001, (B) Immunoblotting for 
phospho-eEF2 (Thr56), and total eEF2 in SKBR3-par and SKBR3-L cells treated with 
100 nM lapatinib (L), 1 nM rapamycin (R), or a combination of 100 nM lapatinib and 1 
nM rapamycin (L+R) for 24 hours. α-tubulin was used as a loading control on each gel. 
Images are representative of duplicate experiments.  
 
5.3.5 Altered phosphorylation of p70S6k in acquired lapatinib resistance 
p70S6k lies downstream of mTOR and upstream of eEF2k. There was no difference in 
the levels of total p70S6k between SKBR3-par and SKBR3-L cells, nor was there a 
difference in the level of phosphorylation of p70S6k between SKBR3-par and SKBR3-
L cells [Figure 5-18]. However, when SKBR3-par cells were treated with lapatinib there 
was a significant decrease in phospho-p70S6k levels (p = 0.006). In contrast, there was 
no change in the phosphorylation of p70S6k in response to lapatinib treatment in 
SKBR3-L cells (p = 0.408).  
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Figure 5-18: Immunoblotting for phospho-p70S6k (Thr389), and total p70S6k in 
SKBR3-par and SKBR3-L cells treated with 1 µM lapatinib for 24 hours. α-tubulin was 
used as a loading control on each gel. Images are representative of triplicate 
experiments. Densitometry analysis of triplicate immunoblots was performed using 
ImageQuant software. * denotes p ≤ 0.05, ** denotes p ≤ 0.001. 
 
5.3.4 eEF2k in acquired lapatinib resistance 
There is increased phosphorylation and expression of eEF2k in SKBR3-L cells 
compared to SKBR3-par cells. In addition there is decreased phosphorylation of Ser359 
of eEF2k in SKBR3-par cells, resulting in increased activity, in response to lapatinib 
which correlates with increased phosphorylation of eEF2. These results suggest a role 
for altered eEF2k activity in lapatinib resistance. Thus, inhibition of eEF2k activity may 
result in decreased sensitivity to lapatinib in SKBR3-par cells. NH125 is a tyrosine 
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nM (p = 0.009), 250 nM (p = 0.025) or 500 nM (p = 0.019) significantly reduced the 
levels of phospho-eEF2 [Figure 5-19]. Treatment of SKBR3-par cells with the eEF2k 
inhibitor did not alter the levels of phospho-AKT or phospho-ERK at any of the 
concentrations tested suggesting specificity for eEF2k at the concentrations tested. 
 
 
Figure 5-19: Immunoblotting for phospho-eEF2 (Thr56), phospho-AKT (Ser473), 
phospho-ERK (Thr202/Tyr204) and total eEF2, AKT and ERK in SKBR3-par cells 
treated with lapatinib (1 µM) or eEF2k inhibitor NH125 at 100, 250 and 500 nM for 24 
hours. α-tubulin was used as a loading control. Images are representative of triplicate 
experiments. Densitometry analysis of triplicate immunoblots was performed using 
ImageQuant software.  * denotes p ≤ 0.05, ** denotes p ≤ 0.001. 
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After confirming that inhibition of eEF2k with NH125 reduced the phosphorylation of 
eEF2 in SKBR3-par cells, the effect of NH125 in combination with lapatinib on the 
growth of SKBR3-par cells was examined. SKBR3-par cells were pre-treated with 100 
nM NH125; a concentration that effectively inhibits the phosphorylation of eEF2 
without significantly affecting cell growth. After 24 hours, NH125 was removed from 
the media and the cells were treated with 250 nM lapatinib for 5 days. The combination 
of NH125 pre-treatment and lapatinib resulted in 70.8 % inhibition of growth compared 
to 77.4 % in cells treated with lapatinib alone (p = 0.03) [Figure 5-20]. This suggests the 
NH125 pre-treatment decreases the sensitivity of SKBR3-par cells to lapatinib.  
However, when 24 hour NH125 (100 nM) pre-treatment was performed prior to 
assessing the lapatinib IC50 in SKBR3-par cells, the NH125 pre-treatment did not 
decrease lapatinib sensitivity in SKBR3-par cells [Figure 5-21]. In fact, NH125 pre-
treatment resulted in a small increase the sensitivity of SKBR3-par cells to lapatinib; 0.1 
µM lapatinib alone compared to 0.08 µM in pre-treated cells. NH125 failed to decrease 
the sensitivity of SKBR3-par cells to lapatinib in a range of different concentrations and 
combinations [see appendix Figures 9-1 – 9-3]. These results suggest that inhibition of 
eEF2k with NH125 can decrease the sensitivity of SKBR3-par cells to lapatinib but 
only under very specific conditions. 
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Figure 5-20: Proliferation of SKBR3-par cells treated with NH125 and lapatinib. Cells 
were pre-treated with 100 nM NH125 for 24 hours, NH125 was removed from the 
media and the cells were treated with 250 nM lapatinib. NH125 100 nM alone and 
lapatinib 250 nM alone were used as comparative controls. Results are expressed as 
percentage growth relative to untreated control cells. Error bars represent the standard 
deviation of triplicate biological experiments. * denotes p ≤ 0.05, ** denotes p ≤ 0.01 
 
Figure 5-21: Proliferation of SKBR3-par cells following pre-treatment with 100 nM 
NH125 for 24 hours after which time NH125 was removed from the media and cells 
were treated with lapatinib (0 – 1 µM) for 5 days. Growth is expressed relative to 
untreated control cells. Represented here are the results of biological duplicate 
experiments. 
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5.4 Summary 
SKBR3-L is a cell line model of acquired lapatinib resistance. In the absence of 
lapatinib, the resistant phenotype is stable for 8 weeks; however, after this point the 
cells begin to regain sensitivity to lapatinib. Analysis of HER family members and other 
downstream pathways resulted in the detection of several significantly altered proteins 
in comparison with parental cells, including phospho-AKT and phospho-ERK and 
HER4, which were significantly lower in SKBR3-L cells, and phospho-HER2 which 
was higher in SKBR3-L cells compared to SKBR3-par. Both cell lines exhibit 
decreased levels of phospho-HER3, in response to lapatinib treatment, despite having 
increased expression of total HER3. Although SKBR3-L cells exhibited increased levels 
of phospho and total EGFR they were less sensitive to EGFR inhibition than SKBR3-
par cells. Increased levels of phospho- and total IGF-IR in SKBR3-L cells compared to 
SKBR3-par cells resulted in SKBR3-L cells being more sensitive to IGF-IR inhibition 
with BMS-536924, while being less sensitive to IGF-IR inhibition with NVP-AEW541.  
Phospho-proteomic analysis revealed decreased phosphorylation of eEF2 in SKBR3-L 
cells compared to SKBR3-par cells, which was confirmed using immunoblotting. The 
regulation of eEF2 phosphorylation in SKBR3-L cells was mTOR independent; i) 
phosphorylation of Ser359 rather than Ser366 correlated with alterations in eEF2 
phosphorylation in SKBR3-par cells,  ii) lapatinib treatment inhibited phospho-mTOR 
in both cell lines, iii) mTOR inhibition with rapamycin did not alter the phosphorylation 
of eEF2 in SKBR3-L cells. Inhibition of eEF2k with NH125 prevented the 
phosphorylation of SKBR3-par cells but had limited effects on the sensitivity of the 
cells to lapatinib. 
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Chapter 6 
SILAC proteomic comparison of SKBR3-par and SKBR3-L cells 
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6.1 Introduction 
To overcome some of the limitations of traditional 2D-DIGE and to gain a more 
comprehensive overview of the proteins and phosphorylated proteins which may play a 
role in acquired resistance to lapatinib a phospho-protein screen was performed on the 
SKBR3-par and SKBR3-L cells (with and without 24 hour treatment with 1 µM 
lapatinib), using stable-isotope labelling with amino acids in cell culture (SILAC). 
SILAC is one of the most effective methods for the simultaneous detection of diverse 
changes in protein expression. With SILAC, the entire proteome of a given cell 
population is metabolically labelled by heavy, non-radioactive isotopic variants of 
amino acids, thus making it distinguishable by mass spectrometry (MS) analysis. 
Thereafter, two or more distinctly SILAC-labelled cell populations can be mixed and 
analysed in one MS experiment which allows accurate quantitation of proteins from the 
different cellular states.  
 
6.2 Optimisation of purification procedure 
There are various methods that can be used to enrich for phospho-proteins. This study 
utilised the PhosphoScan ® Kit from Cell Signalling Technology which allows for the 
purification and identification of tyrosine phosphorylation sites in cellular proteins 
when coupled with liquid chromatography (LC) tandem mass spectroscopy. The assay 
is based on the specific enrichment of phospho-tyrosine-containing peptides using an 
antibody against phospho-tyrosine depicted in Figure 6-1. 
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Figure 6-1: Phospho-peptide purification procedure: protein lysate is digested with 
trypsin, cleared through a C18 column, lyophilized for 2 days, immunoaffinity purified 
using phospho-tyrosine beads, concentrated using Zip-tips and analysed using LC-
MS/MS. Image from PhosphoScan kit insert (Cell Signalling Technology #7900) 
 
6.2.1 Protein yield  
In order to assess and optimise the purification procedure an optimisation sample 
consisting of unlabelled SKBR3-par cells was prepared. A total of 1.5 x 10
8
 cells 
yielded a total of 32 mg of protein, which was the optimal quantity required for 
downstream purification.  
 
6.2.2 Protein digestion 
Following the protocol outlined in [section 2.15.2], the protein lysate was digested using 
trypsin overnight. The efficiency of the tryptic digestion was assessed by running 10 – 
50 µg of undigested and digested protein on a one dimensional gel and staining with 
Comassie Blue [Figure 6-2]. After 24 hours of digestion with trypsin the protein bands 
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were no longer visible suggesting that the proteins were successfully cleaved into 
peptides. 
 
 
Figure 6-2: Comassie-blue stained gel depicting undigested and digested SKBR3-par 
samples. 10 – 50 µg protein samples were run on a one dimensional gel and stained 
overnight with Comassie blue. Image was taken following de-staining procedure.  
 
6.2.3 Purification of control peptides 
The PhosphoScan ® kit supplies control peptides to act as a control for the 
immunoaffinity purification and LC-MS/MS analysis steps. The control sample consists 
of peptides purified from 2 x 10
8
 Jurkat cells, an immortalised line of T-lymphocytes, 
treated with pervandate and calculin A. A list of the top 40 phospho-tyrosine containing 
peptides identified in the Jurkat cells is supplied with the kit and acts as a reference. In 
optimisation experiments Jurkat peptides were included as a control for the 
immunoaffinity and LC-MS/MS stages. Thirty five of the top 40 phospho-peptides were 
identified which, according to the kit, is deemed to be a successful enrichment of 
phospho-tyrosine peptides. For example, analysis of the Jurkat cells is expected to 
reveal the phospho-peptide sequence ALGADDSY*Y*TAR for the protein ZAP70 
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(where the * indicates a phospho-tyrosine site at Y492 and Y493). When the Jurkat 
peptides were purfied, 22 peptides for ZAP70 were identified, including 6 identified 
copies of the phospho-peptide sequence ALGADDSY*Y*TAR, with phospho-tyrosine 
sites at Y492 and/or Y493 [Table 6-1]. Including this control in the experimental 
procedure indicated that the purification and LC-MS/MS was optimised.  
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Table 6-1: Phospho-tyrosine containing peptides for ZAP70 protein in Jurkat control 
cells. Peptide and protein identification performed using MASCOT software. The 
phosphotryosine-containing peptides are indicated by a Phospho (Y) after the peptide 
sequence. Highlighted in red is the phospho-peptide sequence ALGADDSY*Y*TAR; 
identification of which serves as a control for phospho-tyrosine enrichment. Score refers 
to the ion score where ≥ 42 indicates identity or extensive homology (p < 0.05). If there 
are duplicate matches to the same peptide, then only the highest scoring match is 
counted, lower scoring matches are shown in brackets, peptides are ranked 1-10 with 1 
being the best possible match. 
Query 
Mol. 
Weight 
Score Rank Peptide sequence 
103 465.2946 15 9  K.FLLRPRK.E 
176 566.7582 (21) 1  K.ADGLIYCLK.E + Phospho (Y) 
177 566.7596 (25) 1  K.ADGLIYCLK.E + Phospho (Y) 
178 566.7596 35 1  K.ADGLIYCLK.E + Phospho (Y) 
179 566.7596 (20) 2  K.ADGLIYCLK.E + Phospho (Y) 
318 458.5683 (24) 1  K.LKADGLIYCLK.E + Phospho (Y) 
319 687.3493 (35) 1  K.LKADGLIYCLK.E + Phospho (Y) 
320 687.3495 45 1  K.LKADGLIYCLK.E + Phospho (Y) 
321 687.3495 (44) 1  K.LKADGLIYCLK.E + Phospho (Y) 
322 687.3495 (43) 1  K.LKADGLIYCLK.E + Phospho (Y) 
326 691.7857 (61) 1  K.ALGADDSYYTAR.S + Phospho (Y) 
327 691.7859 (64) 1  K.ALGADDSYYTAR.S + Phospho (Y) 
328 691.7862 69 1  K.ALGADDSYYTAR.S + Phospho (Y) 
343 731.7691 (56) 1  K.ALGADDSYYTAR.S + 2 Phospho (Y) 
344 731.7695 (56) 1  K.ALGADDSYYTAR.S + 2 Phospho (Y) 
345 731.7696 (57) 1  K.ALGADDSYYTAR.S + 2 Phospho (Y) 
408 864.8789 (54) 1  R.IDTLNSDGYTPEPAR.I + Phospho (Y) 
409 864.8789 (57) 1  R.IDTLNSDGYTPEPAR.I + Phospho (Y) 
410 864.8800 58 1  R.IDTLNSDGYTPEPAR.I + Phospho (Y) 
475 628.9551 (36) 1  R.RIDTLNSDGYTPEPAR.I + Phospho (Y) 
476 628.9553 (42) 1  R.RIDTLNSDGYTPEPAR.I + Phospho (Y) 
477 942.9301 45 1  R.RIDTLNSDGYTPEPAR.I + Phospho (Y) 
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6.2.4 Purification of SKBR3-par peptides 
The Jurkat control peptides indicated that the purification procedure was optimised 
therefore the peptides obtained from SKBR3-par cells were purfied using the same 
procedure. Purification of SKBR3-par cells resulted in the identification of proteins 
containing multiple phospho-tyrosine containing peptide sequences. One such 
identification was tyrosine-phosphorylated HER2. HER2 has many phospho-tyrosine 
sites including those which regulate its kinase activity at Y1221 and Y1222. Nine 
copies of a sequence containing 1 phospho-tyrosine and 1 copy of a different sequence 
containing a phospho-tyrosine [Table 6-2] were identified. Based on these results the 
purification procedure was considered to be optimised. 
 
Table 6-2: Phospho-tyrosine containing peptides for HER2 protein in SKBR3-par 
control cells. Peptide and protein identification performed using MASCOT software. 
The phospho-tryosine-containing peptides are indicated by a Phospho (Y) after the 
peptide sequence. Score refers to the ion score where ≥ 42 indicates identity or 
extensive homology (p < 0.05). If there are duplicate matches to the same peptide, then 
only the highest scoring match is counted, lower scoring matches are shown in brackets, 
peptides are ranked 1-10 with 1 being the best possible match. 
Query   Mol. 
weight   
Score  Rank   Peptide 
12   378.2060   13   5    R.ENTSPK.A + Phospho (ST) 
440   926.4242   (45)  1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
441   926.4242   (45)  1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
442   926.4246   85   1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
443   926.4247   (60)  1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
444   926.4247   (71)  1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
445   926.4253   (37)  1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
446   926.4253   (70)  1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
447   926.4256   (50)  1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
448   926.4259   (34)  1    K.GTPTAENPEYLGLDVPV.- + Phospho (Y) 
519   816.7215   36   1    R.FVVIQNEDLGPASPLDSTFYR.S + 
Phospho (Y) 
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6.3 Optimisation of labelling procedure 
Optimisation experiments, as described below, were performed in order to ascertain the 
following:  
- the length of time required to obtain 95% incorporation of the heavy lysine 
- the growth rate of the cells in the media following incorporation 
- the viability of the cells in the media following incorporation 
- the lapatinib resistance status of SKBR3-L cells in the media following 
incorporation. 
 
6.3.1 Incorporation of labelled amino acid 
An amino-acid incorporation experiment was performed over the course of 15 days. 
SKBR3-par and SKBR3-L cells were cultured in SILAC media containing with [U-
13
C
6
]-L-Lysine, known as heavy SILAC media. Incorporation of [U-
13
C
6
]-L-Lysine is 
reported to take approximately 6 cell doublings, and SKBR3-par cells complete 6 
doublings in approximately 9 days and SKBR3-L cells in approximately 11 days [255], 
therefore the incorporation experiment was performed over 15 days with  protein 
samples taken at day 6, 9, 12 and 15. The percentage of incorporation of heavy lysine 
was estimated using the top 5 protein hits from each cell line at each time point. 
Optimal incorporation of heavy lysine, defined as > 95 % incorporation, was achieved 
after 9 days for SKBR3-par cells [Table 6-3], and after 12 days for SKBR3-L cells 
[Table 6-4]. Therefore prior to all further experiments, SKBR3-par cells were treated 
with heavy SILAC media for 9 days to ensure full incorporation and SKBR3-L cells 
were treated for 12 days to ensure full incorporation. 
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Table 6-3: Incorporation of [U-
13
C
6
]-L-Lysine in glyceraldehyde-3-phosphate 
dehydrogenase, one of the top 5 proteins identified in SKBR3-par cells, following 9 
days growth in heavy SILAC media. [U-
13
C
6
]-L-Lysine is indicated by a red # symbol 
within the peptides below. * indicates carboxymethylation 
Scan Peptide 
Glyceraldehyde-3-phosphate dehydrogenase [MASS=36053] 
446 K.AGAHLQGGAK#.R 
1407 R.VVDLM*AHM*ASK#E.- 
1549 R.LEK#PAK#YDDIK#.K 
2253 K.VGVNGFGR.I 
3450 R.VVDLMAHMASK#.E 
3533 R.VVDLMAHMASK#E.- 
3555 R.VVDLMAHMASKE.- 
3609 R.GALQNIIPASTGAAK.A 
3648 R.GALQNIIPASTGAAK#.A 
3731 R.VPTANVSVVDLTCR.L 
3926 K.RVIISAPSADAPMFVM*GVNHEK#.Y 
3926 K.RVIISAPSADAPM*FVMGVNHEK#.Y 
4668 K.RVIISAPSADAPMFVMGVNHEK#.Y 
4749 K.RVIISAPSADAPMFVMGVNHEK#YDNSLK#.I 
5038 R.VIISAPSADAPMFVMGVNHEK#.Y 
5179 K.LVINGNPITIFQERDPSK#.I 
5197 K.GILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVK#.L 
5207 K.LVINGNPITIFQERDPSK.I 
5362 K.LISWYDNEFGYSNR.V 
6115 K.IK#WGDAGAEYVVESTGVFTTMEK#.A 
6155 K.WGDAGAEYVVESTGVFTTMEK#.A 
6185 K.WGDAGAEYVVESTGVFTTMEK.A 
6389 K.VIHDNFGIVEGLM*TTVHAITATQK#.T 
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Table 6-4: Incorporation of [U-
13
C
6
]-L-Lysine in glyceraldehyde-3-phosphate 
dehydrogenase, one of the top 5 proteins identified in SKBR3-L cells, following 12 
days growth in heavy SILAC media. [U-
13
C
6
]-L-Lysine is indicated by a red # symbol 
within the peptides below. * indicates carboxymethylation 
Scan Peptide 
Glyceraldehyde-3-phosphate dehydrogenase [MASS=36053] 
478 K.AGAHLQGGAK#R.V 
532 K.AGAHLQGGAK#.R 
1553 R.LEK#PAK#YDDIK#.K 
2272 K.VGVNGFGR.I 
3495 R.VVDLMAHMASK#.E 
3607 R.VVDLMAHMASK#E.- 
3608 R.VVDLMAHMASKE.- 
3659 R.GALQNIIPASTGAAK.A 
3662 R.GALQNIIPASTGAAK#.A 
4690 K.RVIISAPSADAPMFVMGVNHEK#.Y 
4727 K.RVIISAPSADAPMFVMGVNHEK#YDNSLK#.I 
5060 R.VIISAPSADAPMFVMGVNHEK#.Y 
5074 R.VIISAPSADAPMFVMGVNHEK#YDNSLK#.I 
5182 K.GILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVK#.L 
5185 K.LVINGNPITIFQERDPSK#.I 
5369 K.LISWYDNEFGYSNR.V 
5873 K.LVINGNPITIFQER.D 
6153 K.IK#WGDAGAEYVVESTGVFTTMEK#.A 
6164 K.WGDAGAEYVVESTGVFTTMEK#.A 
6391 K.VIHDNFGIVEGLM*TTVHAITATQK#.T 
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6.3.2 Effect of heavy lysine incorporation on cell viability and growth rate 
To ensure that incorporation of the heavy amino acid had no impact on the growth rate 
of SKBR3-par and SKBR3-L cells, the growth rate of both cell lines was monitored. 
Both cell lines were cultured in SILAC media containing either heavy lysine or light 
lysine and the incorporation of the heavy amino acid had no apparent effect on the 
viability of either cell line [Figure 6-3].  
 
Figure 6-3: The viability of (A) SKBR3-par and (B) SKBR3-L cells was measured 
following 9, 12 and 15 days growth in heavy and light SILAC media. The percentage 
viability was measured and calculated using ViaCount reagent and Guava Software. 
These are the results of a single biological experiment. 
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There was an increase in the estimated doubling time () of both cell lines cultured in 
the heavy media. To minimise the effects on cell growth SKBR3-par cells were cultured 
in the heavy media, as these cells exhibited a smaller change in estimated doubling time 
compared to the SBKR3-L cells [Table 6-5].  
 
Table 6-5: Cell counts and estimated doubling time of SKBR3-par and SKBR3-L cells 
cultured for 15 days in heavy and light SILAC media. These results are from a single 
biological experiment.  
Cell line Condition 
Cell count Day 
12 
Cell count Day 
15 
Doubling time 
(hours) 
SKBR3-par Light 2.06E+06 6.27E+06 44.9 
 Heavy 1.72E+06 5.18E+06 49.2 
SKBR3-L Light 1.43E+06 3.83E+06 50.6  
 Heavy 1.63E+06 3.83E+06 58.3 
 
6.3.4 Effect of heavy lysine incorporation on lapatinib sensitivity 
In order to assess whether incorporation of heavy lysine into SKBR3-par and SKBR3-L 
cells affected the sensitivity of the cells to lapatinib, sensitivity was measured both prior 
to and following heavy amino acid incorporation. There was no significant change in 
the sensitivity of SKBR3-par cells or SKBR3-L cells to lapatinib following 
incorporation [Figure 6-4]. This experiment was only performed once as the results 
were consistent with our previous experiments measuring lapatinib sensitivity in these 
cells lines [Chapter 5].  
 
                                                 

  Cells were split on days 9, 12 and 15 and one third of the cells reseeded at each passage. The doubling 
time is estimated between days 12 and 15. This experiment was performed once. 
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Figure 6-4: Proliferation of (A) SKBR3-par and (B) SKBR3-L cells prior to and 
following incorporation with heavy amino acid, following a 5-day treatment with 
lapatinib (0 – 10 µM). Growth is expressed relative to untreated control cells. 
 
6.4 Outline of SILAC protocol 
Based on the results of the optimisation experiments, which showed that it took 9 days 
for SKBR3-par cells to incorporate the SILAC label compared to 12 days in SKBR3-L 
cells, SKBR3-par cells were chosen as the cell line to be labelled with the heavy amino 
acid for the full experimental protocol. The SILAC experiment consists of 2 separate 
comparisons performed in triplicate; SKBR3-par control untreated versus SKBR3-L 
control untreated and the second comparison of SKBR3-par 1 µM lapatinib treated 
0
20
40
60
80
100
120
0 0.2 0.4 0.6 0.8 1
%
 G
ro
w
th
 
Lapatinib conc. (µM) 
SKBR3-par Pre-
incorporation
Post-
incorporation
A. 
0
20
40
60
80
100
120
0 2 4 6 8 10
%
 G
ro
w
th
 
Lapatinib conc. (µM) 
SKBR3-L Pre-
incorporation
Post-
incorporation
B. 
 158 
 
versus SKBR3-L 1 µM lapatinib treated. The experimental flowchart for the SILAC 
experiment is depicted in [Figure 6-5]. 
 
 
Figure 6-5: Schematic depiction of SILAC experiment. The two populations of cells 
were grown, one in light SILAC media and the other in heavy SILAC media. All 
peptides and/or proteins in the heavy population are 6 Daltons heavier than the 
corresponding peptide/protein in the light population. This enables the samples to be 
mixed and a direct comparison to be made of altered peptides/proteins between the two 
populations. 
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The experiment was set-up as depicted in [Figure 6-5], with SKBR3-par cells cultured 
in heavy SILAC media and SKBR3-L cells cultured in light SILAC media. Three 
biologically different passages of SKBR3-par and SKBR3-L cells were grown 
independently of each other and termed replicates 1, 2 and 3. Each biological replicate 
for each cell line consisted of twelve T175 cm
2
 flasks of cells, which was calculated to 
give an approx. total cell number per replicate of 2 x 10
8
 cells. The cells were grown for 
approx. 15 days in the SILAC media which allowed for optimal labelled amino acid 
incorporation and enabled the cells to reach 80% confluent. At this stage each of the 3 
replicates for each cell line was split in two; 6 of the flasks were fed with the 
appropriate SILAC media while the other 6 flasks were treated with SILAC media 
containing 1 µM lapatinib. After exactly 24 hours the cells in 60 of the flasks were lysed 
and the Phospho-Scan procedure was followed as described in [sections 2.15.1 and 
2.15.2]. The remaining 12 flasks, corresponding to one flask per replicate per cell line 
was lysed using RIPA buffer and stored to use for protein validation purposes. The 
protein yield of each biological replicate is listed in [Table 6-6]. The samples were 
combined at a 1:1 ratio based on protein concentration to compare SKBR3-par untreated 
with SKBR3-L untreated and both cell lines treated with lapatinib. Following phospho-
purification the samples were analysed by LC-MS/MS by Dr. Julian Whitelegge and 
Mr. Punett Souda in UCLA. 
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Table 6-6: Total protein yield from each sample following growth in SILAC media and 
protein extraction. 
Cell line  Treatment Rep mg/ml total protein (mg) 
SKBR3-par Control 1 5.8 29.2 
  2 7.3 36.7 
  3 7.3 36.6 
SKBR3-par Lap 1 µM  1 5.0 25.1 
  2 5.8 29.0 
  3 6.0 30.0 
SKBR3-L Control 1 4.5 22.3 
  2 3.7 18.3 
  3 3.6 18.1 
SKBR3-L Lap 1 µM  1 3.6 17.8 
  2 4.8 24.2 
  3 4.2 21.0 
 
6.5 Results of SILAC phospho-proteomic analysis 
The purified, phospho-tyrosine enriched peptides were analysed using LC-MS/MS. The 
first analysis consisted of SKBR3-par untreated cells compared to SKBR3-L untreated 
cells in triplicate followed by a second analysis of SKBR3-par cells treated with 1 µM 
lapatinib compared to SKBR3-L cells treated with 1 µM lapatinib. The results of these 
two analyses are outlined below. 
 
6.5.1 Comparison of SKBR3-par and SKBR3-L control untreated samples. 
Proteins were identified for the SKBR3-par and SKBR3-L control untreated samples; 
33 in replicate 1, 67 in replicate 2 and 51 in replicate 3. Of the proteins identified, only 
5 proteins were phosphorylated and common to all 3 reps [Table 6-7]. However, only 
one of the phosphorylated proteins, cyclin-dependent kinase 1 (CDK1), had SILAC 
quantification data. The identification of phospho-Glycogen synthase kinase-3 alpha 
(GSK3A) is depicted in Figure 6-6, where a light peptide for phospho-GSK3A was 
detected, however, there was no matching heavy peptide identified. Thus, there is no 
quantification data available for GSK3A. The identification of phospho-CDK1 is 
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depicted in Figure 6-7, where both heavy and light peptides for phospho-CDK1 were 
identified. Levels of phosphorylated CDK1 were 6.4-fold higher in SKBR3-L cells 
compared to SKBR3-par cells. However, the SILAC ratios ranged from 1:1.66 to 
1:15.95, across the 3 replicates giving a deviation of 129 %, indicating very high 
variability between replicates.  
 
Table 6-7: Identified phospho-proteins in SKBR3-par compared to SKBR3-L control 
untreated cells.  
Protein Identification Phospho-Ty 
SILAC Ratio 
Heavy/Light % Dev 
Serine/threonine-protein kinase PRP4 
homolog  
Yes 
  
Mitogen-activated protein kinase 1  Yes   
Glycogen synthase kinase-3 alpha Yes   
Cyclin-dependent kinase 1  Yes 1:6.40 129.11 
Dual specificity tyrosine-
phosphorylation-regulated kinase 1A  
Yes 
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Figure 6-6:  Full-MS scan (Bioworks) depicting the identification of a light phospho-
peptide only for GSK3A. No matched heavy phospho-peptide was identified.  
ps_Slamon_Martina_110910_SILAC2 #760 RT: 15.029 NL: 9.23E3
F: FTMS + p NSI Full ms [300.00-1700.00]
675 676 677 678 679 680 681 682 683 684 685 686 687 688
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
681.78
682.29
684.25
681.30
684.17676.54
Peptide sequence - R.GEPNVSY*ICSR.Y
Light 
peptide
 163 
 
 
Figure 6-7: Identification of phospho-CDK1 using Bioworks. (A.) Full-MS scan 
depicting the light and heavy peptides of phospho-CDK1. (B) Identification of a light 
phospho-CDK1 peptide and (C) identification of a heavy phospho-CDK1 peptide. 
Phosphorylated tyrosine is highlighted with a red circle. 
 
6.5.2 Comparison of SKBR3-par and SKBR3-L cells treated with 1 µM lapatinib 
Proteins were identified for the SKBR3-par and SKBR3-L lapatinib treated samples; 43 
in replicate 1, 43 in replicate 2 and 25 in replicate 3. Of these identified proteins there 
were 3 phosphorylated proteins which were common to all 3 replicates; 
serine/threonine-protein kinase PRP4 homolog; glycogen synthase kinase-3 alpha; and 
dual specificity tyrosine-phosphorylation-regulated kinase 1A. However, matched 
peptides for these phospho-proteins were not detected thus SILAC quantification data is 
unavailable.  
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6.5.3 Analysis of phospho-proteomic results. 
The phospho-proteomic analysis was not as efficient as expected. Only 5 phospho-
tyrosine containing proteins were identified in the control untreated comparison 
experiment and of these 5 phospho-proteins, the SILAC H/L ratio could only be 
calculated for one protein, CDK1. For all other identified phospho-proteins the 
differences were not readily quantitated. The extremely low yield of protein 
identifications suggests that optimum purification of the phospho-tyrosine peptides was 
not achieved. However, the remaining labelled total protein (not phospho-enriched) was 
then used to examine alterations in total proteins between the two cell lines.  
 
6.6 Alterations in total protein levels 
6.6.1 Outline of SILAC proteomic experiment 
The experimental design comparing the levels of total protein between SKBR3-par and 
SKBR3-L cells is outlined in Figure 6-8. Comparisons between SKBR3-par and 
SKBR3-L control samples, and SKBR3-par and SKBR3-L 1 µM lapatinib treated were 
both performed in triplicate. Briefly, 10 µg of sample from each cell line was mixed and 
resolved on a 10 % gel. The gel was then stained with Comassie Blue to visualise 
protein bands. Each lane on the gel was cut into 32 pieces, known as gel plugs. These 
gel plugs were trypsinised and dehydrated to give digested peptides. The digested 
peptides were re-suspended in elution buffer and analysed using LC-MS/MS, this step 
was performed by Mr Michael Henry in DCU. The data was then analysed using 
Bioworks to assign protein identifications and SILAC ratio information. 
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Figure 6-8: Schematic representation of total protein SILAC experimental protocol. (A) 
Cells are metabolically labelled using SILAC media, (B) Cells are lysed, (C) Lysates 
are combined at a 1:1 ratio based on protein concentration and resolved on a 10 % gel, 
(D) Gel is stained with Comassie blue and each is split into 32 separate gel plugs, (E) 
Gel plugs are digested with trypsin and peptides are eluted from the plugs, (F) Peptides 
are quantified using nano-LC-MS/MS technology, (G) Proteins are identified and 
SILAC ratios calculated using Bioworks software, (H) A list of proteins which are 
altered between the two cell lines is established and then (I) target proteins are validated 
using western blotting.  
 
6.6.2 Comparison of SKBR3-par and SKBR3-L control untreated cells 
SKBR3-par control untreated cells were compared to SKBR3-L control untreated cells. 
Triplicate biological samples were prepared by combining replicate 1 of untreated 
parental lysate with an equal amount of replicate 1 of untreated SKBR3-L lysate, and so 
forth for the other 2 replicates [Table 6-8].   
A.
sp|P04406|G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 [MASS=36053]1:1.54
sp|P49748|ACADV_HUMAN Very long-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Homo sapiens GN=ACADVL PE=1 SV=1 [MASS=70390]1:1.78
sp|P11586|C1TC_HUMAN C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens GN=MTHFD1 PE=1 SV=3 [MASS=101559]1:1.97
sp|P08238|HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 [MASS=83264]1:1.95
sp|P15311|EZRI_HUMAN Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 [MASS=69412] 1:1.19
sp|P27797|CALR_HUMAN Calreticulin OS=Homo sapiens GN=CALR PE=1 SV=1 [MASS=48141] 1:1.26
sp|Q09666|AHNK_HUMAN Neuroblast differentiation-associated protein AHNAK OS=Homo sapiens GN=AHNAK PE=1 SV=2 [MASS=629097]1:1.29
sp|Q9UQ80|PA2G4_HUMAN Proliferation-associated protein 2G4 OS=Homo sapiens GN=PA2G4 PE=1 SV=3 [MASS=43787]1:1.34
sp|Q9Y4L1|HYOU1_HUMAN Hypoxia up-regulated protein 1 OS=Homo sapiens GN=HYOU1 PE=1 SV=1 [MASS=111335]1:1.34
sp|O43390|HNRPR_HUMAN Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens GN=HNRNPR PE=1 SV=1 [MASS=70943]1:1.23
sp|P13798|ACPH_HUMAN Acylamino-acid-releasing enzyme OS=Homo sapiens GN=APEH PE=1 SV=4 [MASS=81224]1:1.68
sp|Q13435|SF3B2_HUMAN Splicing factor 3B subunit 2 OS=Homo sapiens GN=SF3B2 PE=1 SV=2 [MASS=100227] 1:2.16
sp|P14314|GLU2B_HUMAN Glucosidase 2 subunit beta OS=Homo sapiens GN=PRKCSH PE=1 SV=2 [MASS=59425] 1:2.02
sp|Q58FG1|HS904_HUMAN Putative heat shock protein HSP 90-alpha A4 OS=Homo sapiens GN=HSP90AA4P PE=5 SV=1 [MASS=47712]1:1.97
sp|P50995|ANX11_HUMAN Annexin A11 OS=Homo sapiens GN=ANXA11 PE=1 SV=1 [MASS=54389] 1:1.52
sp|Q15075|EEA1_HUMAN Early endosome antigen 1 OS=Homo sapiens GN=EEA1 PE=1 SV=2 [MASS=162465] 1:2.39
sp|Q9NYF8|BCLF1_HUMAN Bcl-2-associated transcription factor 1 OS=Homo sapiens GN=BCLAF1 PE=1 SV=2 [MASS=106121]1: .17
sp|Q13510|ASAH1_HUMAN Acid ceramidase OS=Homo sapiens GN=ASAH1 PE=1 SV=5 [MASS=44659] 1:2.36
sp|Q9P2E9|RRBP1_HUMAN Ribosome-binding protein 1 OS=Homo sapiens GN=RRBP1 PE=1 SV=4 [MASS=152471] 1:2.13
B. C.
D.
E.F.G.
I.
SILAC labelling
H.
Protein lysate
Protein 
combined and 
resolved by 
GE
Gel stained 
and bands 
excised
Bands 
digested and 
peptides 
eluted
Peptides analysed by 
nano LC-MS/MS
Protein identification 
and SILAC calculation
List of alterations 
between  cell lines
Validation of 
target proteins by 
Western Blotting
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Table 6-8: Combining biological replicates of SKBR3-par and SKBR3-L control 
untreated samples to yield the 3 comparative samples analysed by LC-MS/MS. 
Replicate Sample 1 Sample 2 Combined sample  
1 SKBR3-par CTRL 1 SKBR3-L CTRL 1 CTRL V CTRL 1  
2 SKBR3-par CTRL 2 SKBR3-L CTRL 2 CTRL V CTRL 2  
3 SKBR3-par CTRL 3 SKBR3-L CTRL 3 CTRL V CTRL 3  
 
6.6.2.1 Protein identification and global protein profiling 
There were 306 proteins identified in replicate 1, 359 proteins in replicate 2 and 335 
proteins in replicate 3. There were 236 proteins common to replicates 1 and 2, 262 
proteins common to replicates 2 and 3, and 239 proteins common to replicates 1 and 3. 
Of these proteins, 208 were identified in all 3 biological comparisons of SKBR3-par 
untreated control cells and SKBR3-L untreated control cells [Figure 6-9]. Panther 
software was used to analyse the list of common proteins for molecular function, 
biological processes, cellular component, pathways and protein class [Figure 6-10]. This 
analysis indicates that the identified proteins encompass a vast range of different 
processes, functions and pathways. The SILAC ratios for these 208 common proteins 
were then calculated. 
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Figure 6-9: Venn diagram illustrating the overlap of identified proteins between the 
different biological replicates of SKBR3-par and SKBR3-L control untreated samples. 
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Figure 6-10: Analysis of Pathways, Molecular function, Biological Processes, Protein 
Class and Cellular Component on the 208 proteins that were common to all 3 reps of 
control SKBR3-par versus control SKBR3-L using Panther software. Pie-charts were 
constructed in Excel using percentages with the only the 10 largest percentages forming 
the legend for each pie chart to aid visibility. 
 
6.6.2.2 Generation of list of  significantly altered proteins 
SILAC ratios were calculated for the 208 proteins which were common to all 3 
replicates of the SKBR3-par compared to SKBR3-L. Each of the 208 proteins had 
SILAC ratios calculated for each biological replicate. Of these 208 proteins, 39 showed 
the same trend in SILAC ratios across the 3 reps, (e.g., some proteins had SILAC ratios 
which showed an increase in one cell line in 2 reps but a decrease in the same cell line 
in the third rep – these proteins were omitted from further study). The SILAC ratios of 
the remaining 39 proteins were averaged and standard deviations were calculated. 
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Proteins with a standard deviation 20 % or less and a fold change greater than or equal 
to 1.2-fold were considered significant. Of the 39 proteins, 26 proteins had a standard 
deviation of 20 % or less, and 20 of those had a fold change greater than or equal to 1.2-
fold and were considered to be the significantly altered proteins between SKBR3-par 
and SKBR3-L control untreated cells. The expression of 8 proteins was higher in 
SKBR3-par compared to SKBR3-L cells [Table 6-9], while the expression of 12 
proteins was higher in SKBR3-L cells compared to SKBR3-par cells [Table 6-10].  
 
Table 6-9: List of identified proteins whose expression was ≥ 1.2-fold higher in 
SKBR3-par cells compared to SKBR3-L cells. SILAC heavy/light (H/L) ratios are 
represented as the average ratio of triplicate biological experiments where the 
percentage standard deviation between replicate ratios is ≤ 20 %. The deviations of the 
proteins in red suggest further validation is required to confirm a significant alteration in 
expression. 
Protein Identification 
SILAC Ratio 
H/L 
St. 
Dev % Dev 
Glucose-6-phosphate 1-dehydrogenase 2.0:1 0.4 20.3 
Heterogeneous nuclear ribonucleoprotein Q 1.9:1 0.3 16.2 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex 
1.3:1 0.2 16.2 
Heterogeneous nuclear ribonucleoprotein F 1.3:1 0.2 16.3 
Heterogeneous nuclear ribonucleoprotein K 1.3:1 0.2 12.0 
Polyadenylate-binding protein 1 1.2:1 0.1 10.8 
Heterogeneous nuclear ribonucleoprotein A3 1.2:1 0.1 8.3 
Heterogeneous nuclear ribonucleoprotein D0 1.2:1 0.2 14.3 
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Table 6-10: List of identified proteins whose expression was ≥ 1.2-fold higher in 
SKBR3-L cells compared to SKBR3-par cells. SILAC heavy/light (H/L) ratios are 
represented as the average ratio of triplicate biological experiments where the 
percentage standard deviation between replicate ratios is ≤ 20 %. The deviations of the 
proteins in red suggest further validation is required to confirm a significant alteration in 
expression. 
Protein Identification 
SILAC Ratio 
H/L 
St. 
Dev % Dev 
Early endosome antigen 1 1:2.4 0.2 9.2 
Acid ceramidase 1:2.4 0.3 10.7 
Ribosome-binding protein 1 1:2.1 0.4 16.7 
C-1-tetrahydrofolate synthase 1:2.0 0.3 16.5 
Very long-chain specific acyl-CoA dehydrogenase 1:1.8 0.3 15.9 
Acylamino-acid-releasing enzyme 1:1.7 0.1 4.4 
Glyceraldehyde-3-phosphate dehydrogenase 1:1.5 0.2 14.3 
Annexin A11 1:1.5 0.2 13.5 
PDZ and LIM domain protein 5 1:1.4 0.3 20.3 
Neuroblast differentiation-associated protein 
AHNAK 1:1.3 0.1 6.8 
Calreticulin 1:1.3 0.1 1.8 
Heterogeneous nuclear ribonucleoprotein R 1:1.2 0.2 16.9 
 
6.6.2.3 Pathway Analysis of altered proteins 
The 20 proteins showing altered expression between SKBR3-par and SKBR3-L were 
analysed using Pathway Studio 8.0. Nine of the 20 proteins had direct interactions with 
each other; either by direct protein binding (purple lines) or direct regulation of 
expression (blue arrows) [Figure 6-11]. Analysis of the common regulators of 
expression of the differentially expressed proteins suggests that insulin, IGF1, EGF and 
TGFβ1, among others, may play a role in regulating the expression of the differentially 
expressed proteins [Figure 6-12]. Analysis of the common targets of the differentially 
expressed proteins revealed a huge array of different proteins involved in multiple 
processes and signalling pathways, in particular several proteins were implicated in 
AKT signalling including glucose-6-phosphate 1-dehydrogenase and calreticulin 
[Figure 6-13].  
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Figure 6-11: Analysis of direct protein interactions using Pathway Studio 8.0. Direct 
protein binding is shown by purple lines and direct regulation of protein expression is 
shown by blue arrows.  
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Figure 6-12: Analysis of common regulators of expression of the 20 proteins 
differentially expressed in SKBR3-par and SKBR3-L cells. Analysis performed using 
Pathway Studio 8.0. Proteins highlighted in blue are from the list of altered proteins.  
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Figure 6-13: Analysis of common targets for the 20 differentially expressed proteins. 
Analysis performed using Pathway Studio 8.0. Proteins highlighted in blue are from the 
list of altered proteins. 
 
6.6.3 Comparison of SKBR3-par and SKBR3-L cells treated with 1 µM lapatinib 
In addition to examining alterations in the levels of total protein between SKBR3-par 
control untreated cells and SKBR3-L control untreated cells; the effect of 24 hour 
treatment with 1 µM lapatinib on each cell line was compared.  Samples were combined 
as per [Table 6-11].  
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Table 6-11: Combining biological replicates of SKBR3-par and SKBR3-L 1 µM 
lapatinib treated samples to yield the 3 comparative samples analysed by LC-MS/MS. 
Replicate Sample 1 Sample 2 Combined sample  
1 SKBR3-par LAP 1 SKBR3-L LAP 1 LAP V LAP 1  
2 SKBR3-par LAP 2 SKBR3-L LAP 2 LAP V LAP 2  
3 SKBR3-par LAP 3 SKBR3-L LAP 3 LAP V LAP 3  
 
6.6.3.1 Protein identification and global protein profiling 
There were 215 proteins identified in replicate 1, 335 proteins in replicate 2 and 352 
proteins in replicate 3. There were 175 proteins common to replicates 1 and 2, 263 
proteins common to replicates 2 and 3, and 184 proteins common to replicates 1 and 3. 
Of these proteins, 163 were identified in all 3 biological comparisons of SKBR3-par 1 
µM lapatinib treated cells compared to SKBR3-L 1 µM lapatinib treated cells [Figure 6-
14]. Panther analysis again showed that the identified proteins encompass a vast range 
of different processes, functions and pathways [Figure 6-15], similar to the results of the 
analysis for the proteins identified in the untreated cells. This again indicates that there 
is no bias in the type of proteins detected by this identification method.  
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Figure 6-14: Venn diagram illustrating the overlap of identified proteins between the 
different biological replicates of SKBR3-par and SKBR3-L lapatinib treated samples. 
 
Rep 1 = 215
Rep 3 = 352Rep 2 = 335
163
12 21
100
19
60 68
 176 
 
 
Figure 6-15: Analysis of Pathways, Molecular function, Biological Processes, Protein 
Class and Cellular Component on the 163 proteins that were common to all 3 reps of  
SKBR3-par lapatinib treated versus  SKBR3-L lapatinib treated cells using Panther 
software. Pie-charts were constructed in Excel using percentages with the only the 10 
largest percentages forming the legend for each pie chart to aid visibility. 
 
6.6.3.2 Generation of list of  significantly altered proteins 
SILAC ratios were calculated for the 163 proteins which were common to all 3 
replicates of the SKBR3-par 1 µM lapatinib treated compared to SKBR3-L 1 µM 
lapatinib treated. Of the 163 common proteins, 157 proteins had SILAC ratios 
calculated for each biological replicate. Of these 157 proteins, 50 showed the same 
trend in SILAC ratios across the 3 reps. The SILAC ratios of the 50 proteins were 
averaged and standard deviations were calculated. Of the 50 proteins, 18 had a standard 
deviation of 20 % or less and 15 proteins of those showed a fold change greater than or 
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equal to 1.2-fold and were considered to be the significantly altered proteins between 
SKBR3-par and SKBR3- L lapatinib treated cells. The expression of 13 proteins was 
higher in SKBR3-par compared to SKBR3-L cells while the expression of 2 proteins 
was higher in SKBR3-L cells compared to SKBR3-par cells [Table 6-12].  
 
Table 6-12: List of identified proteins whose expression was ≥ 1.2-fold higher or ≥ 1.2-
fold lower in SKBR3-par cells compared to SKBR3-L cells following 24 hour treatment 
with 1 µM lapatinib. SILAC heavy/light (H/L) ratios are represented as the average 
ratio of triplicate biological experiments where the percentage standard deviation 
between replicate ratios is ≤ 20 %. The deviations of the proteins in red suggest further 
validation is required to confirm a significant alteration in expression. 
Protein Identification 
SILAC Ratio 
H/L 
St. 
Dev % Dev 
Protein SET 1.9:1 0.3 14.2 
Receptor tyrosine-protein kinase erbB-2  1.6:1 0.2 14.5 
Putative pre-mRNA-splicing factor ATP-
dependent- RNA helicase DHX15  
1.5:1 0.2 13.0 
Elongation factor 1-gamma  1.5:1 0.1 8.9 
Selenium-binding protein 1  1.5:1 0.3 16.7 
Programmed cell death 6-interacting protein  1.4:1 0.3 20.4 
Splicing factor, proline- and glutamine-rich  1.3:1 0.2 16.1 
Heterogeneous nuclear ribonucleoprotein D0  1.3:1 0.2 13.5 
Transaldolase  1.3:1 0.1 10.9 
Heterogeneous nuclear ribonucleoprotein C-like 1  1.3:1 0.1 7.7 
Desmin  1.3:1 0.1 9.9 
Transformer-2 protein homolog beta  1.2:1 0.2 12.7 
Neutral alpha-glucosidase AB  1.2:1 0.1 3.9 
 Proliferation-associated protein 2G4  1:1.6 0.3 18.6 
 Elongation factor 1-delta  1:1.2 0.2 12.9 
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6.6.3.3 Pathway analysis of altered proteins 
The 15 proteins which showed altered expression between SKBR3-par and SKBR3-L 
were analysed using Pathway Studio 8.0. Five of the 15 proteins had direct interactions 
with each other; either by direct protein binding (purple lines) or direct regulation of 
expression (blue lines and arrows) [Figure 6-16]. This analysis suggests a link between 
PA2G4 (also known as EBP1) and HER2. Analysis of common regulators of expression 
suggests the androgen receptor, FAS, TGF1β and IGF1 as possible regulators of interest 
for this data set [Figure 6-17]. Analysis of the common targets for the 15 proteins 
identified, revealed a huge array of different proteins involved in multiple processes and 
signalling pathways [Figure 6-18], however of particular note, the targets appear to 
centralise around HER2 and protein SET.  
 
 
Figure 6-16: Analysis of direct protein interactions using Pathway Studio 8.0. Direct 
protein binding is shown by purple lines and direct regulation of protein expression is 
shown by blue arrows or lines.   
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Figure 6-17: Analysis of common regulators of expression of the 15 proteins 
differentially expressed in SKBR3-par and SKBR3-L cells. Analysis performed using 
Pathway Studio 8.0. Proteins highlighted in blue are from the list of altered proteins. 
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Figure 6-18: Analysis of common targets for the 15 differentially expressed proteins. 
Analysis performed using Pathway Studio 8.0. Proteins highlighted in blue are from the 
list of altered proteins. 
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6.7 Validation of altered proteins 
Six of the differentially expressed proteins were selected for validation by 
immunoblotting [Table 6-13]. These proteins were selected after literature mining 
suggested an association between these proteins and signalling pathways downstream of 
HER2.  
 
Table 6-13: Proteins selected for validation by immunoblotting 
Protein ID. SILAC Ratio (H/L) % Dev 
Phospho – Cyclin dependent kinase 1 1:6.40 129.11 
Glyceraldehyde-3-phosphate dehydrogenase 1:1.5 14.3 
Selenium-binding protein 1  1.5:1 16.7 
Receptor tyrosine-protein kinase erbB-2  1.6:1 14.5 
Protein SET 1.9:1 14.2 
Proliferation-associated protein 2G4 1:1.6 12.9 
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6.7.1 Validation of phospho-CDK1 
Cyclin-dependent kinase 1 (CDK1) is a protein that function as a serine/threonine 
kinase and plays a key role in the regulation of cell cycle progression. SILAC phospho-
proteomic profiling of SKBR3-par and SKBR3-L cells revealed a 6.4-fold increase in 
the levels of phospho-CDK1 in SKBR3-L cells compared to SKBR3-par cells. 
Immunoblotting confirmed the increased phosphorylation of CDK1 in SKBR3-L cells 
compared to SKBR3-par cells (p = 0.006) [Figure 6-19]. In addition lapatinib treatment 
resulted in decreased levels of phosphorylation in both cell lines, and also decreased the 
expression of total CDK1 in both cell lines.  
 
 
Figure 6-19: Immunoblotting for phospho- (Tyr15) and total CDK1 in SKBR3-par and 
SKBR3-L cells. α-tubulin was used as a loading control on each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** 
denotes p ≤ 0.001. 
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6.7.2 Validation of Glyceraldehyde-3-phosphate dehydrogenase 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an enzyme which catalyses 
the conversion of glyceraldehyde-3-phosphate to D-glycerate 1,3-bisphosphate, a key 
step required in the breakdown on glucose to supply energy to cells. Total proteomic 
analysis revealed that SKBR3-L cells have higher levels of GAPDH compared to 
SKBR3-par cells. Immunoblotting confirmed a small, yet significant difference in the 
levels of GAPDH between the two cell lines. SKBR3-L cells have 1.3-fold higher levels 
of GAPDH protein compared to SKBR3-par cells (p = 0.013) [Figure 6-20].  
 
 
Figure 6-20: A) Full-MS revealing an alteration in matched heavy and light peptide 
sequence (-.VVDLM’AHM’ASK#.-) which corresponds to GAPDH protein, where # 
indicates labeled lysine and M’ indicates methylation B) Immunoblotting for GAPDH 
protein in SKBR3-par and SKBR3-L cells. α-tubulin was used as a loading control on 
each gel. Images are representative of triplicate experiments. Densitometry analysis of 
triplicate immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, 
** denotes p ≤ 0.001. 
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6.7.3 Validation of HER2 
Total proteomic analysis revealed decreased expression of HER2 in SKBR3-L cells 
following lapatinib treatment compared to SKBR3-par cells. SKBR3-L cells have 
higher levels of HER2 following lapatinib treatment compared to SKBR3-par cells 
following lapatinib treatment (p = 0.06), however, the altered expression of HER2 did 
not achieve significance [Figure 6-21]. 
 
 
Figure 6-21: A) Full-MS revealing an alteration in matched heavy and light peptide 
sequence (R.LLDIDETEYHADGGK#.) which corresponds to HER2 protein, where # 
indicates labeled lysine, B) Immunoblotting for HER2 protein in SKBR3-par and 
SKBR3-L cells using 5 µg of protein. α-tubulin was used as a loading control on each 
gel. Images are representative of triplicate experiments. Densitometry analysis of 
triplicate immunoblots was performed using ImageQuant software.  
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6.7.4 Validation of Selenium-binding protein 1 
Total proteomic analysis revealed that following lapatinib treatment the levels of 
selenium-binding protein 1 (SELENBP1) were higher in SKBR3-par cells compared to 
SKBR3-L cells. Selenium is an essential trace element which has been proposed to have 
an anti-cancer effect. A link between insufficient selenium and increased risk of cancer 
has been suggested [284, 285]. Immunoblotting confirmed that the expression of 
SELENBP1 was unaltered between untreated SKBR3-par and SKBR3-L cells, however 
following lapatinib treatment there was no significant change in the expression of 
SELENBP1 in SKBR3-par cells, while the expression of SELENBP1 was decreased in 
SKBR3-L cells following lapatinib treatment (p = 0.017) [Figure 6-22]. Thus, the levels 
of SELENBP1 were higher in SKBR3-L cells compared to SKBR3-par cells following 
lapatinib treatment (p = 0.002).  
 
 
Figure 6-22: A) Full-MS revealing an alteration in matched heavy and light peptide 
sequence (R.LTGQLFLGGSIVK#.G) which corresponds to SELENBP1 protein, where 
# indicates labeled lysine, B) Immunoblotting for SELENBP1 protein in SKBR3-par 
and SKBR3-L cells. α-tubulin was used as a loading control on each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** 
denotes p ≤ 0.001. 
c2 #1306 RT: 24.133 NL: 1.45E6
F: FTMS + p NSI Full ms [300.00-2000.00]
666.0 666.5 667.0 667.5 668.0 668.5 669.0 669.5 670.0 670.5 671.0 671.5
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
669.9
666.9 670.4
667.4
670.9
670.0
670.3
667.9
671.3
671.4
671.3668.8666.7666.8 667.7 669.4
671.0
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
Control Lap Control Lap
P
ro
te
in
 A
b
u
n
d
a
n
ce
SELENBP1
C L C L
SELENBP1 52 kD
SKBR3-par SKBR3-L
tubulin 55 kD
*
*
**
B.A.
Light 
peptide
heavy 
peptide
Peptide sequence - R.LTGQLFLGGSIVK#.G
SKBR3-LSKBR3-par
 186 
 
6.7.5 Validation of Protein SET 
SET, more commonly known as I
2
PP2A, is an oncoprotein with diverse cellular 
functions including cell cycle control, apoptosis and cell migration. SET was 
differentially expressed in SKBR3-par and SKBR3-L cells following treatment with 
lapatinib and this result was confirmed using immunoblotting. SKBR3-L cells treated 
with 1 µM lapatinib have 1.5-fold lower levels of I
2
PP2A compared to SKBR3-par cells 
treated with lapatinib (p = 0.03) [Figure 6-23]. Lapatinib treatment had no effect on 
I
2
PP2A expression in SKBR3-par cells, but resulted in decreased expression of I
2
PP2A 
in SKBR3-L cells (p = 0.02). There was no significant difference in the expression of 
I
2
PP2A between the untreated controls of each cell line. 
 
 
Figure 6-23: A) Full-MS revealing an alteration in matched heavy and light peptide 
sequence (R.IDFYFDENPYFENK#.V) which corresponds to SET/I
2
PP2A protein, 
where # indicates labeled lysine, B) Immunoblotting for SET/I
2
PP2A protein in 
SKBR3-par and SKBR3-L cells. α-tubulin was used as a loading control on each gel. 
Images are representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** 
denotes p ≤ 0.001. 
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6.7.6 Validation of Proliferation-associated protein 2G4 
SILAC analysis revealed a 1.6-fold increase in the levels of Proliferation-associated 
protein 2G4, also known as EBP1, in SKBR3-L cells compared to SKBR3-par cells 
following treatment with lapatinib. EBP1 can interact with the cytoplasmic domain of 
HER3 and may contribute to transducing growth regulatory signals. EBP1 has been 
implicated in growth inhibition and the induction of differentiation of human cancer 
cells. Where there was no difference in the expression of EBP1 between SKBR3-par 
and SKBR3-L control untreated samples (p = 0.94) [Figure 6-24], treatment of the cells 
with lapatinib resulted in a significant decrease in EBP1 expression in SKBR3-par cells 
(p = 0.03), but no significant change in EBP1 expression in SKBR3-L cells. This 
resulted in SKBR3-L lapatinib treated cells having 2.5-fold higher expression of EBP1 
compared to SKBR3-par lapatinib treated cells (p = 0.01).   
 
 
Figure 6-24: A) Full-MS revealing an alteration in matched heavy and light peptide 
sequence (K.TIIQNPTDQQK#.K) which corresponds to EBP1 protein, where # 
indicates labeled lysine, B) Immunoblotting for EBP1 protein in SKBR3-par and 
SKBR3-L cells. α-tubulin was used as a loading control on each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageQuant software. * denotes p ≤ 0.05, ** 
denotes p ≤ 0.001. 
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6.7 Summary  
Metabolic labelling of cells using [U-
13
C
6
]-L-Lysine in SILAC media was achieved in 
SKBR3-par cells. The phospho-proteome of SKBR3-par cells was compared to 
SKBR3-L cells, both as untreated controls and in response to 1 µM lapatinib treatment. 
While the phospho-protein enrichment experiment was inefficient, CDK1 was identifed 
as a protein with increased phosphorylation in SKBR3-L cells compared to SKBR3-par 
cells. Lapatinib treatment resulted in decreased expression and phosphorylation of 
CDK1 in both cell lines. In addition to comparing the phospho-proteome of SKBR3-par 
and SKBR3-L cells, total proteomic analysis was also performed with the SILAC 
labelled protein extracts. A total of 20 proteins  were detected that were altered between 
SKBR3-par and SKBR3-L cells, of these 20, the expression of 8 proteins were higher in 
SKBR3-par cells and the expression of 12 proteins was higher in SKBR3-L cells. The 
detected proteins encompass a range of different biological processes, functions and 
pathways. By comparing both cell lines following 24 hours treatment with 1 µM 
lapatinib a total of 15 proteins were detected that were altered between SKBR3-par and 
SKBR3-L cells (the expression of 13 proteins were higher in SKBR3-par cells and the 
expression of 2 proteins was higher in SKBR3-L cells). Significant alterations in the 
expression of GAPDH, HER2, SELENBP1 SET/I
2
PP2A and EBP1 between SKBR3-
par and SKBR3-L cells were confirmed using immunoblotting.  
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Chapter 7 
Role of P13K, MAPK, mTOR and HER family signalling in innate 
lapatinib resistance 
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7.1 Introduction 
Through collaboration with Dr Neil O’Brien in UCLA this study utilised a panel of 15 
HER2-amplified cell lines which have under-gone extensive characterisation in their 
laboratory. The sensitivity of these cells lines to lapatinib has been published previously 
[194]. Ten of the cell lines are sensitive to lapatinib with IC50s of less than 1 µM while 5 
of the cell lines are resistant to lapatinib with IC50s greater than 1 µM. Key signalling 
pathways which may contribute to innate lapatinib resistance were examined using this 
cell line panel. The key pathways involved in HER2 signalling and lapatinib response 
and resistance are the HER family members themselves, the downstream signalling 
pathways MAPK and P13K/AKT, and as demonstrated in SKBR3-L cells, the mTOR 
pathway. The basal levels of phospho-HER2, phospho-HER3 and phospho-EGFR have 
been shown to correlate with response to lapatinib [194]. Therefore in addition to 
examining the basal levels of proteins, the effect of lapatinib treatment on key members 
of these signalling pathways was examined and alterations of these proteins were 
correlated with response to lapatinib based on the IC50 data described in Table 7-1.  
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Table 7-1: The panel of HER2-amplified cell lines with lapatinib IC50 values ± the 
standard deviation of triplicate experiments. The responsiveness of each cell line to 
lapatinib is also described where S indicates sensitive while R indicates resistant. The 
lapatinib-resistant cell lines are highlighted in red. The assays in this table were 
performed by Dr Neil O’Brien and the data is reproduced from [194] with his 
permission.  
 Cell Line                    Lapatinib 
  IC
50
 ± SD (μM) Response 
BT-474 0.016 ± 0.011 S 
SUM-190 0.038 ± 0.003 S 
HCC-1419 0.050 ± 0.021 S 
SKBR3 0.054 ± 0.008 S 
EFM192A  0.075 ± 0.002 S 
HCC-202 0.074 ± 0.026 S 
SUM-225 0.089 ± 0.052 S 
ZR75-30 0.271 ± 0.136 S 
MDA-361 0.295 ± 0.064 S 
HCC-1954 0.358 ± 0.064 S 
UACC-893 1.211 ± 0.251 R 
JIMT-1 2.374  ± 0.246  R 
UACC-732 2.629 ± 0.480 R 
HCC-1569 3.550 ± 0.715 R 
MDA-453 5.997 ± 1.103 R 
 
7.2 Alterations in HER family members and lapatinib response 
Lapatinib is a dual inhibitor of HER2 and EGFR; therefore the effect of lapatinib 
treatment on the phosphorylation of these proteins was examined. HER3 and HER2 
heterodimers lead to activation of downstream signalling cascades. Thus the levels of 
phospho-HER3 following lapatinib treatment was also examined.  
 
7.2.1 Expression and phosphorylation of HER2 and innate lapatinib sensitivity 
The basal expression and phosphorylation of HER2 was examined in a panel of HER2-
amplified cell lines. In addition, each cell line was treated with 1 µM lapatinib for 24 
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hours and examined alterations in phospho- and total HER2 levels [Figure 7-1]. 
Phospho-HER2 was detected in all cell lines, with the exception of JIMT-1 cells which 
had undetectable phospho-HER2 and UACC732 cells which had extremely low levels. 
An association was found between basal levels of phospho-HER2 and lapatinib 
response (p = 0.094), with higher levels of phospho-HER2 in lapatinib sensitive cells 
[Figure 7-2]. An association was also found between loss of phospho-HER2 following 
lapatinib treatment and lapatinib response (p = 0.054), with lapatinib sensitive cells 
exhibiting a greater decrease in phospho-HER2 levels following lapatinib treatment. 
Total HER2 was detected in all 15 cell lines. The basal expression of HER2 
significantly correlates with lapatinib response (p = 0.03), with lapatinib sensitive cell 
lines expressing higher levels of HER2 compared to lapatinib-resistant cells, however 
there was no relationship between increased levels of HER2 following lapatinib 
treatment and lapatinib response (p = 0.267).  
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Figure 7-1: Immunoblotting for phospho-HER2 (Tyr1221/1222) and total HER2 in 
BT474, SUM225, SUM190, EFM192A, ZR7530, SKBR3, HCC202, HCC1419, MDA-
MB-361, HCC1954, JIMT-1, MD-MBA-453, UACC893, HCC1569 and UACC732 
cells treated with 1 µM lapatinib for 24 hours. α-tubulin was used as a loading control 
on each gel (not shown). Images are representative of triplicate experiments. 
Densitometry analysis of triplicate immunoblots was performed using ImageQuant 
software. Cell lines in red indicate innate lapatinib resistance. 
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Figure 7-2: Bi-variant scattergraphs of lapatinib IC50 values compared to A) basal 
expression of phospho-HER2, B) percentage loss of phospho-HER2 following 24 hour 
1 µM lapatinib treatment, C) basal expression of HER2 and D) percentage gain of 
HER2 following 24 hour 1 µM lapatinib treatment in a panel of HER2-amplified breast 
cancer cell lines.. Correlations performed using Speatman rank correlation (Statview). 
 
7.2.2 Expression and phosphorylation of HER3 and innate lapatinib sensitivity 
The basal expression and phosphorylation of HER3 was examined in the panel of 
HER2-amplified cell lines, and in response to 1 µM lapatinib (24 hours) [Figure 7-3]. 
Several cell lines had very low expression of phospho-HER3. A correlation between 
basal levels of phospho-HER3 and lapatinib response (p = 0.049) was found, with 
lapatinib sensitive cell lines exhibiting higher levels of phospho-HER3 compared to 
lapatinib-resistant cells [Figure 7-4]. There was no correlation between loss of phospho-
HER3 following lapatinib treatment and lapatinib response (p = 0.921). Total HER3 
was detected in all 15 cell lines; however, several cell lines had very low expression 
levels. There was no correlation between the basal expression of HER3 and lapatinib 
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response (p = 0.721). There was also no correlation between increased expression of 
HER3 following lapatinib treatment and lapatinib response (p = 0.401).  
 
Figure 7-3: Immunoblotting for phospho-HER3 (Tyr1289) and total HER3 in BT474, 
SUM225, SUM190, EFM192A, ZR7530, SKBR3, HCC202, HCC1419, MDA-MB-361, 
HCC1954, JIMT-1, MD-MBA-453, UACC893, HCC1569 and UACC732 cells treated 
with 1 µM lapatinib for 24 hours. α-tubulin was used as a loading control on each gel 
(not shown). Images are representative of triplicate experiments. Densitometry analysis 
of triplicate immunoblots was performed using ImageQuant software. Cell lines in red 
indicate innate lapatinib resistance. 
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Figure 7-4: Bi-variant scattergraphs of lapatinib IC50 values compared to A) basal 
expression of phospho-HER3, B) percentage loss of phospho-HER3 following 24 hour 
1 µM lapatinib treatment, C) basal expression of HER3 and D) percentage gain of 
HER3 following 24 hour 1 µM lapatinib treatment in a panel of HER2-amplified breast 
cancer cell lines. Correlations performed using Speatman rank correlation (Statview). 
 
7.2.3. Expression and phosphorylation of EGFR and innate lapatinib sensitivity 
Levels of phospho-EGFR were either very low or undetectable in the panel of cell lines, 
thus correlations between phospho-EGFR and lapatinib response were not performed 
[Figure 7-5]. EGFR was not detected in 3 of the cell lines tested. There was no 
correlation between basal expression of EGFR and lapatinib response (p = 0.299), nor 
was there a correlation between decreased EGFR expression following lapatinib 
treatment and lapatinib response (p = 0.420) [Figure 7-6]. 
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Figure 7-5: Immunoblotting for phospho-EGFR (Tyr1173) and total EGFR in BT474, 
SUM225, SUM190, EFM192A, ZR7530, SKBR3, HCC202, HCC1419, MDA-MB-361, 
HCC1954, JIMT-1, MD-MBA-453, UACC893, HCC1569 and UACC732 cells treated 
with 1 µM lapatinib for 24 hours. α-tubulin was used as a loading control on each gel 
(not shown). Images are representative of triplicate experiments. Densitometry analysis 
of triplicate immunoblots was performed using ImageQuant software. Cell lines in red 
indicate innate lapatinib resistance. 
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Figure 7-6: Bi-variant scattergraphs of lapatinib IC50 values compared to A) basal 
expression of EGFR, and B) percentage loss of EGFR following 24 hour 1 µM lapatinib 
treatment in a panel of HER2-amplified breast cancer cell lines. Correlations performed 
using Speatman rank correlation (Statview). 
 
7.3 Alterations in signalling pathways downstream of HER2 and lapatinib 
response 
The key signalling pathways activated by HER2 signalling are the P13K/AKT, MAPK 
and mTOR pathways, thus the expression and phosphorylation of key members of the 
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7.3.1 Expression and phosphorylation of AKT and innate lapatinib sensitivity 
Phospho-AKT was detected in all cell lines with the exception of UACC732 cells 
[Figure 7-7]. No correlation was found between basal levels of phospho-AKT and 
lapatinib response (p = 0.595) [Figure 7-8]. There was a correlation between loss of 
phospho-AKT following lapatinib treatment and lapatinib response (p = 0.035), with 
lapatinib sensitive cells exhibiting a greater reduction in phospho-AKT levels compared 
to lapatinib-resistant cells following lapatinib treatment. Total AKT was detected in all 
cell lines and there was no association between basal AKT expression and lapatinib 
response (p = 0.628). There were no statistically significant alterations in the expression 
of AKT following lapatinib treatment. 
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Figure 7-7: Immunoblotting for phospho-AKT (Ser473) and total AKT in BT474, 
SUM225, SUM190, EFM192A, ZR7530, SKBR3, HCC202, HCC1419, MDA-MB-361, 
HCC1954, JIMT-1, MD-MBA-453, UACC893, HCC1569 and UACC732 cells treated 
with 1 µM lapatinib for 24 hours. α-tubulin was used as a loading control on each gel 
(not shown). Images are representative of triplicate experiments. Densitometry analysis 
of triplicate immunoblots was performed using ImageQuant software. Cell lines in red 
indicate innate lapatinib resistance. 
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Figure 7-8: A) Percentage loss of phospho-AKT (± standard deviation) in the panel of 
HER2-amplified cells followed 24 hour treatment with 1 µM lapatinib, ordered from 
lowest to highest lapatinib IC50 value (left to right). Bi-variant scattergraphs of lapatinib 
IC50 values compared to B) percentage loss of phospho-AKT following lapatinib 
treatment, C) basal expression of phospho-AKT and D) basal expression of AKT in a 
panel of HER2-amplifed cell lines. Correlations performed using Spearman rank 
correlation (Statview). 
 
7.3.2 Expression and phosphorylation of ERK and innate lapatinib sensitivity 
Phospho-ERK was detected in all cell lines at differing levels [Figure 7-9]. No 
correlation was found between basal levels of phospho-ERK and lapatinib response (p = 
0.986) however there was a correlation between loss of phospho-ERK following 
lapatinib treatment and lapatinib response (p = 0.014) with the more sensitive cell lines 
showing a greater decrease in phospho-ERK levels following lapatinib treatment 
[Figure 7-10]. Total ERK was detected in all cell lines and there was a weak correlation 
between basal ERK expression and lapatinib response (p = 0.093), with a trend towards 
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higher expression of ERK in lapatinib-resistant cell lines. There were no statistically 
significant alterations in the expression of ERK following lapatinib treatment. 
 
 
Figure 7-9: Immunoblotting for phospho-ERK (Thr202/204) and total ERK in BT474, 
SUM225, SUM190, EFM192A, ZR7530, SKBR3, HCC202, HCC1419, MDA-MB-361, 
HCC1954, JIMT-1, MD-MBA-453, UACC893, HCC1569 and UACC732 cells treated 
with 1 µM lapatinib for 24 hours. α-tubulin was used as a loading control on each gel 
(not shown). Images are representative of triplicate experiments. Densitometry analysis 
of triplicate immunoblots was performed using ImageQuant software. Cell lines in red 
indicate innate lapatinib resistance. 
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Figure 7-10: A) Percentage loss of phospho-ERK (± standard deviation) in the panel of 
HER2-amplified cells followed 24 hour treatment with 1 µM lapatinib, ordered from 
lowest to highest lapatinib IC50 value (left to right). Bi-variant scattergraphs of lapatinib 
IC50 values compared to B) percentage loss of phospho-ERK following lapatinib 
treatment, C) basal expression of phospho-ERK and D) basal expression of ERK in a 
panel of HER2-amplifed cell lines. Correlations performed using Spearman rank 
correlation (Statview). 
 
7.3.3 Expression and phosphorylation of p70S6k and innate lapatinib sensitivity 
Experiments described in Chapter 5 show that alterations in the mTOR pathway, 
specifically alterations in phospho-p70S6k and phospho-eEF2 correlate with lapatinib 
resistance in a model of acquired lapatinib resistance. The effect of lapatinib treatment 
was examined in the panel of HER2-amplified cell lines to see if alterations in these 
proteins would correlate with innate lapatinib resistance also. 
 
Phospho-p70S6k was detected in all of the cell lines at varying levels [Figure 7-11]. The 
basal levels of phospho-p70S6k did not correlate with lapatinib response (p = 0.997), 
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however, loss of phospho-70S6k following lapatinib treatment correlated significantly 
(p = 0.046), with the more sensitive cell lines showing a greater decrease in phospho-
p70S6k levels following lapatinib treatment [Figure 7-12]. Total p70S6k was expressed 
in all of the cell lines and the basal expression of p70S6k, was higher in lapatinib 
sensitive cell lines, however, this result failed to reach statistical significance (p = 
0.057). There were no statistically significant alterations in the expression of p70S6k 
following lapatinib treatment. 
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Figure 7-11: Immunoblotting for phospho- p70S6k (Thr389) and total p70S6k in 
BT474, SUM225, SUM190, EFM192A, ZR7530, SKBR3, HCC202, HCC1419, MDA-
MB-361, HCC1954, JIMT-1, MD-MBA-453, UACC893, HCC1569 and UACC732 
cells treated with 1 µM lapatinib for 24 hours. α-tubulin was used as a loading control 
on each gel (not shown). Images are representative of triplicate experiments. 
Densitometry analysis of triplicate immunoblots was performed using ImageQuant 
software. Cell lines in red indicate innate lapatinib resistance. 
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Figure 7-12: A) Percentage loss of phospho-p70S6k (± standard deviation) in the panel 
of HER2-amplified cells followed 24 hour treatment with 1 µM lapatinib, ordered from 
lowest to highest lapatinib IC50 value (left to right). Bi-variant scattergraphs of lapatinib 
IC50 values compared to B) percentage loss of phospho- p70S6k following lapatinib 
treatment, C) basal expression of phospho- p70S6k and D) basal expression of p70S6k 
in a panel of HER2-amplifed cell lines. Correlations performed using Spearman rank 
correlation (Statview). 
 
7.3.4 Expression and phosphorylation of eEF2 and innate lapatinib sensitivity 
Phospho-eEF2 was detected in all of the cell lines, with the exception of UACC732 
cells [Figure 7-13]. The basal levels of phospho-eEF2 did not correlate with lapatinib 
response (p = 0.513), however, gain of phospho-eEF2 following lapatinib treatment 
correlated significantly with lapatinib response (p = 0.011), with the more sensitive cell 
lines showing a greater increase in phospho-eEF2 levels following lapatinib treatment [ 
Figure 7-14]. Total eEF2 was expressed in all of the cell lines however, there was no 
correlation between the basal expression of eEF2 and lapatinib response (p = 0.912). 
There were no statistically significant alterations in the expression of eEF2 following 
lapatinib treatment. 
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Figure 7-13: Immunoblotting for phospho-eEF2 (Thr56) and total eEF2 in BT474, 
SUM225, SUM190, EFM192A, ZR7530, SKBR3, HCC202, HCC1419, MDA-MB-361, 
HCC1954, JIMT-1, MD-MBA-453, UACC893, HCC1569 and UACC732 cells treated 
with 1 µM lapatinib for 24 hours. α-tubulin was used as a loading control on each gel 
(not shown). Images are representative of triplicate experiments. Densitometry analysis 
of triplicate immunoblots was performed using ImageQuant software. Cell lines in red 
indicate innate lapatinib resistance. 
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 Figure 7-14: A) Percentage loss of phospho-eEF2 (± standard deviation) in the panel of 
HER2-amplified cells followed 24 hour treatment with 1 µM lapatinib, ordered from 
lowest to highest lapatinib IC50 value (left to right). Bi-variant scattergraphs of lapatinib 
IC50 values compared to B) percentage loss of phospho-eEF2 following lapatinib 
treatment, C) basal expression of phospho-eEF2 and D) basal expression of eEF2 in a 
panel of HER2-amplifed cell lines. Correlations performed using Spearman rank 
correlation (Statview). 
 
Lapatinib treatment resulted in significant alterations in the phosphorylation of AKT, 
ERK, p70S6k and eEF2 [summarised in Table 7-2]. These results suggest that although 
the majority of cell lines exhibit uniform alterations dependent on their classification as 
a lapatinib sensitive or lapatinib-resistant cell line, there are several cell lines which do 
not respond as expected. For example, SUM190 and MDA-MB-361 cells exhibit 
alterations in the phosphorylation of the above proteins which are more characteristic of 
lapatinib-resistant cells rather than lapatinib sensitive cells, in addition MDA-MB-453 
cells exhibit a small increase in peEF2 levels following lapatinib treatment in contrast to 
the other lapatinib-resistant cell lines which all exhibit either decreased levels or not 
change. Thus, these results suggest that when studying innate lapatinib resistance 
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SUM190, MDA-MB and MDA-MB-453 cell lines should not be studied in isolation, 
but rather only as part of a larger panel of cell lines. 
 
Table 7-2: Summary of alterations in phosphorylation of AKT, ERK, p70S6k and eEF2 
in lapatinib treated HER2-amplified breast cancer cell lines. Results are represented as 
either greater than or less than the average decrease in levels of phosphorylated protein 
for AKT, ERK and p70S6k, and as an increase or decrease in the phosphorylation of 
eEF2. Innate lapatinib-resistant cell lines are depicted in red. Italics indicate atypical 
cell lines. 
 
7.4 Summary 
The basal phosphorylation and expression of members of the HER family and several 
key members of signalling pathways downstream of HER2 were examined in a panel of 
HER2-amplified breast cancer cell lines. In addition the effects of lapatinib treatment on 
the expression and phosphorylation of these proteins was examined and correlations 
with the lapatinib IC50 value of each cell line were performed. High basal levels of 
Cell line loss of p-AKT loss of p-p70S6k loss of p-ERK p-eEF2 levels 
BT474 ≥ 70 % ≥ 35 % ≥ 65 % increase 
SUM190 ≤ 70 % ≤ 35 % ≤ 65 % increase 
HCC1419 ≥ 70 % ≥ 35 % ≥ 65 % increase 
SKBR3 ≥ 70 % ≥ 35 % ≥ 65 % increase 
EFM192A ≥ 70 % ≥ 35 % ≥ 65 % increase 
HCC202 ≥ 70 % ≥ 35 % ≥ 65 % increase 
SUM225 ≥ 70 % ≥ 35 % ≥ 65 % increase 
ZR7530 ≥ 70 % ≥ 35 % ≥ 65 % increase 
M361 ≤ 70 % ≤ 35 % ≤ 65 % decrease 
HCC1954 ≤ 70 % ≥ 35 % ≥ 65 % increase 
UACC893 ≤ 70 % ≤ 35 % ≤ 65 % decrease 
JIMT1 ≤ 70 % ≤ 35 % ≤ 65 % decrease 
UACC732 ≤ 70 % ≤ 35 % ≤ 65 % decrease 
HCC-1569 ≤ 70 % ≤ 35 % ≤ 65 % decrease 
MDA453 ≤ 70 % ≤ 35 % ≤ 65 % increase 
 210 
 
phospho-HER3 significantly correlated with sensitivity to lapatinib and there was a 
weak association between higher levels of phospho-HER2, HER2, and p70S6k and 
lapatinib sensitivity. Lower basal levels of ERK weakly associated with lapatinib 
sensitivity also. In contrast, there was no correlation between the levels of HER3, 
EGFR, phospho- or total AKT, phospho-ERK, phospho-p70S6k, phospho-or total eEF2 
and sensitivity to lapatinib in the panel of HER2-amplifed cell lines. Each cell line was 
treated with 1 µM lapatinib for 24 hours and alterations in the expression and 
phosphorylation of the proteins were correlated with lapatinib IC50 values. There were 
no significant alterations in the expression of AKT, ERK, p70S6k or eEF2, and 
alterations on the levels of HER2, phospho-HER3, HER3 or EGFR did not correlate 
with response to lapatinib. However, there were significant correlations between 
lapatinib sensitivity and decreased levels of phospho-HER2, phospho-AKT, phospho-
ERK and phospho-p70S6k. In addition, lapatinib sensitivity also correlated with 
increased levels of phospho-eEF2.  
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Chapter 8 
 
Discussion 
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8.1 Introduction 
Lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor, in combination with 
capecitabine is approved for the treatment of HER2-positive trastuzumab refractory 
metastatic breast cancer. However, lapatinib has limited response as a single agent and 
many patients treated with lapatinib fail to respond to therapy, de novo (innate) 
resistance, or after a period of response develop resistance to lapatinib, acquired 
resistance [131]. A major stumbling block in the study and treatment of acquired 
lapatinib resistance is the limited number of published and characterised cell line 
models of resistance. This study sought to address this by developing new cell line 
models of acquired lapatinib resistance and characterising the resistance phenotype, 
with a view to identifying mechanisms of acquired lapatinib resistance. The use of in 
vitro cell line models of cancer, derived from patient tumour samples has long been the 
primary method used for the preclinical study of cancer. Promising in vitro data is 
frequently examined using in vivo cancer models, prior to evaluation using patient 
samples – successful hypotheses are then subject to analysis in clinical cancer trials. 
However, a recent study has suggested that in vitro models of cancer are not reflective 
of the heterogeneity seen in cancer patients, and those in vitro models more closely 
resemble each other rather than the cancer they are modelling [286]. The authors advise 
that investigators exercise caution when interpreting results derived from established 
cell lines used for the study of drug resistance, and call for use of primary tumour 
models to more closely mimic in vivo tumour environments and avoid cell culture 
mediated changes in gene expression. While this represents the ideal scenario for 
modelling cancer, established cell line models of cancer remain the standard method 
used to examine mechanisms of resistance, particularly resistance to inhibitors for 
which the supply of primary patient tumour is limited (e.g. lapatinib).  
8.2 Comparison of newly developed cell line models to the published models of 
acquired lapatinib resistance 
SKBR3, HCC1419 and HCC1954 cells are HER2-amplified, lapatinib-sensitive cell 
lines which were conditioned with lapatinib containing media for 6 months. SKBR3 
lapatinib-resistant cells (SKBR3-L) were established by Dr. Brigid Browne [255]. 
HCC1954 lapatinib conditioned cells (HCC1954-L) and SKBR3-L cells began active 
proliferation in the presence of lapatinib. In contrast, HCC1419 cells did not actively 
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proliferate in lapatinib and thus may represent an alternative model of acquired lapatinib 
resistance (further discussed in section 8.3.1). 
8.2.1 Methods of lapatinib conditioning 
Of the published models of acquired lapatinib resistance there is very little commonality 
in the procedures used to condition the cells, in either the concentrations of lapatinib 
used or in the determination of resistance status [see Chapter 1, Table 1-3]. For instance, 
the procedures used to develop models of acquired lapatinib resistance included a single 
cell cloning technique [229, 232], fixed dose conditioning [233] and dose escalation 
conditioning [231, 235, 236]. There was significant variation in the concentrations of 
lapatinib used to condition the cells; many studies began with a low dose of lapatinib 
(e.g. 100 nM) which was dose-escalated to upwards of 2 µM. Fixed concentration 
conditioning was performed with concentrations of lapatinib ranging from 3 µM to 10 
µM. The length of conditioning required to achieve resistance varied from study to 
study with the majority of studies taking approximately 12 weeks to achieve resistance, 
whereas other studies took up to 1 year to achieve resistance. Another variation in 
different models of lapatinib resistance was the definition of lapatinib resistance. Most 
of the studies defined their conditioned cell lines as resistant based on their ability to 
grow in the presence of the concentration of lapatinib used to condition the cells, only 
one study used an IC50 method while a number of studies did not quantify the level of 
resistance. In contrast to the previously published models of acquired lapatinib 
resistance, the resistant models described in this study were developed using a relatively 
low dose of lapatinib relative to the IC50 of the resulting cell line. To our knowledge our 
models of acquired lapatinib resistance, HCC1954-L and SKBR3-L are the first to show 
that extended exposure to low dose lapatinib results in significant lapatinib resistance, 
with resulting lapatinib IC50 values significantly higher than the concentration used for 
conditioning.  
8.2.2 Stability of lapatinib-resistant phenotype 
The stability of the resistance phenotype was examined by performing freeze-thaw 
cycles and drug-withdrawal assays to ensure that the cells did not revert back to a 
lapatinib sensitive phenotype following freezing, or while being cultured in the absence 
of lapatinib, as the cells were routinely cultured without lapatinib prior to all 
experiments. HCC1954-L and SKBR3-L cells exhibited stable resistance to lapatinib 
following a freeze-thaw cycle and drug-withdrawal experiments. HCC1954-L cells were 
stably-resistant in the absence of lapatinib for 3 months, while SKBR3-L cells were 
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stable for 2 months but then regained sensitivity to lapatinib after 4 months in the 
absence of drug. A recent study provided a model whereby a drug-tolerant phenotype 
was transiently acquired and relinquished by individual cells within a population. 
Treatment of a NSCLC-derived cell line (PC9) cells with gefitinib resulted in the 
outgrowth of “drug-tolerant expanded persistor” (DTEP) cells which were insensitive to 
the effects of gefitinib. Notably the authors found that the resistance of the cells was 
stable until passage 30 of the cells, after this point the sensitivity of the cells to gefitinib 
was restored. This suggests that the drug-tolerant (resistant) state was only stable for 90 
doublings of the cells [287]. For SKBR3-L cells, 90 doublings equated to approximately 
4 months [255] which would correlate with the results we have seen in the drug 
withdrawal experiments for the SKBR3-L cells. Only one other study reported data on 
the stability of the lapatinib resistant phenotype, and they noted that removal of 
lapatinib from HCT116 lapatinib-resistant cells did not cause a reversion of the resistant 
phenotype after 2 months drug absence [233].  
8.2.3 Alterations in HER/P13K/MAPK signalling pathways in lapatinib resistance 
An important question to address when characterising a model of acquired lapatinib 
resistance,  is whether or not a sub-population of HER2-negative lapatinib-resistant 
cells has been cloned out of the HER2 positive lapatinib sensitive total population or if 
there are any alterations in the expression or phosphorylation of HER2.  
Innate lapatinib sensitivity has been correlated with increased expression of HER2 
[194], however, our cell line models of acquired lapatinib resistance exhibited either no 
significant change in HER2 expression (SKBR3-L) or increased HER2 expression 
(HCC1954-L) compared to parental cells. This suggests that acquired lapatinib 
resistance is not associated with loss of expression of HER2. While HCC1954-L cells 
have higher levels of phospho-HER2 compared to parental cells, there was no 
difference in the levels of phospho-HER2 between SKBR3-par and SKBR3-L cells, and 
lapatinib treatment resulted in a decrease in phospho-HER2 levels in all four of the cell 
lines, suggesting that in contrast to previous studies of innate response/resistance to 
lapatinib [134, 194], phosphorylation of HER2 does not correlate with response to 
lapatinib in acquired lapatinib resistance models. These results also indicate that 
HCC1954-L and SKBR3-L cells have retained HER2 overexpression, and that the 
ability of lapatinib to inhibit the phosphorylation of HER2 is unaltered in these cells. 
Thus altered expression and/or phosphorylation of HER2 do not mediate lapatinib 
resistance in these cells.  
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Treatment of SKBR3-par, SKBR3-L and HCC1954-L cells with lapatinib resulted in 
increased expression of total HER3, while the expression of HER3 was unaffected by 
lapatinib treatment in HCC1954-par cells. In another study, BT474, SKBR3 and 
SUM225 cells treated with 1 µM lapatinib for 24 hours exhibited increased HER3 at the 
mRNA and protein level [288], and these authors proposed that up-regulated HER3 is 
phosphorylated by HER2, resulting in the maintenance of phospho-AKT, thus limiting 
the efficacy of lapatinib. Another study, examining the effects of gefitinib and erlotinib, 
two EGFR TKIs, found that the dephosphorylation of HER3 following TKI treatment 
was a transient event and was accompanied by increased expression of HER3 [289]. In 
contrast to the above studies, while 24 hour treatment with 1 µM lapatinib in SKBR3-L 
and HCC1954-L cells increased the expression of HER3, it did not result in a 
corresponding increase in the phosphorylation of HER3. This suggests that altered 
expression and/or phosphorylation of HER3 may not be key mediators of lapatinib 
resistance in these cells. However, examining the effect of lapatinib treatment at 
different time-points on the expression and phosphorylation of HER3 may shed more 
light on the role of HER3 in acquired lapatinib resistance.  
SKBR3-L cells have significantly less HER4 than SKBR3-par cells. HER4 expression 
has been correlated with favourable prognostic factors and improved survival in breast 
cancer patients [290]. The reintroduction of HER4 into HER4-negative cell lines 
resulted in apoptosis in breast cancer cell lines [291]. HER4 is thought to have a tumour 
suppressor function in breast cancer and epigenetic silencing of HER4 is mediated by 
promoter hypermethylation. Reactivation of epigenetically silenced HER4 using a DNA 
demethylating agent resulted in apoptosis [292], as did reintroduction of HER4 
expression in several breast cancer cell lines [291]. Interestingly, expression of HER4 
has been correlated with response to trastuzumab in breast cancer patients [293] and the 
loss of HER4 expression has been associated with tamoxifen resistance both in vitro and 
in vivo [294]. To date alterations in HER4 expression have not been associated with 
lapatinib sensitivity or resistance. It is possible that the loss of HER4 may potentially be 
an important mechanism of lapatinib resistance in our SKBR3-L cells. Examining the 
effect of HER4 knockdown on lapatinib response in HER2-amplified lapatinib sensitive 
cells and re-introducing HER4 into SKBR3-L cells would help determine whether or 
not altered HER4 expression plays a causative role in acquired lapatinib resistance.  
As lapatinib is a dual inhibitor of HER2 and EGFR, it is important to determine if cells 
with acquired resistance to lapatinib are resistant to EGFR inhibition also. SKBR3-L 
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cells displayed a marked decrease in sensitivity to gefitinib, an anti-EGFR targeted 
agent, compared to SKBR3-par cells. Cross-resistance to lapatinib and another HER2-
targeted agent, trastuzumab, has been shown in innate lapatinib-resistant cells [194]. 
However, to our knowledge SKBR3-L cells are the first model of acquired lapatinib 
resistance which has been shown to have cross-resistance to an EGFR targeted therapy 
as cross-resistance to EGFR inhibition has been tested in reported in published models 
of acquired lapatinib resistance. SKBR3-L cells also have increased levels of phospho- 
and total EGFR compared to SKBR3-par cells. Several mechanisms for resistance to 
EGFR targeted therapy have already been proposed including mutations in EGFR, MET 
amplification and an escape mechanism mediated by HER3 phosphorylation [289, 295-
297]. Alterations in EGFR have also been implicated in resistance to trastuzumab [214]. 
However, in this study lapatinib treatment inhibits phosphorylation of EGFR in both the 
parental and resistant cells. As previously mentioned, the lapatinib resistance cells did 
not exhibit increased phosphorylation of HER3, suggesting that lapatinib and gefitinib 
resistance is not mediated by a HER3-dependent escape mechanism. These results 
suggest that, rather than alterations in the expression and/or phosphorylation of EGFR, 
HER2 and HER3, the mechanism(s) of resistance to lapatinib and gefitinib are likely to 
be either downstream of the HER family, or through activation of alternative signalling 
pathways. A recent study has shown that activating MET, using HGF, results in 
lapatinib resistance in a panel of HER2-postive gastric cancer cell lines [298], and MET 
amplification is associated with gefitinib resistance [296], suggesting the potential for 
an overlapping mechanism of resistance. Examining the role of MET in SKBR3-par and 
SKBR3-L cells, either by stimulating activity using HGF, or inhibiting activity using a 
specific MET inhibitor would determine if MET plays a role in acquired lapatinib and 
gefitinib resistance. 
The key signalling pathways which are activated by HER2 are the P13K/AKT pathway 
and MAPK pathway leading to cell proliferation and survival. Treatment of lapatinib 
sensitive cells has been shown to decrease the levels of phospho-AKT and phospho-
ERK, indicating inhibition of signalling through both the P13K/AKT and the MAPK 
pathway [134]. Treatment of both HCC1954-par and HCC1954-L cells with lapatinib 
resulted in a decrease in the levels of phospho-AKT and phospho-ERK, however the 
steady state levels of these two phospho-proteins were significantly higher in 
HCC1954-L cells compared to HCC1954-par cells. However, inhibition of phospho-
AKT and phospho-ERK following lapatinib treatment was also seen in SUM190 [231] 
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and BT474 [229] lapatinib-resistant cells. In contrast to HCC1954-L cells, in which 
phospho-AKT and phospho-ERK are inhibited by lapatinib, using a different BT474 
model of acquired lapatinib resistance, lapatinib treatment did not affect the levels of 
phospho-AKT or phospho-ERK [232]. This maintenance of phospho-AKT and 
phospho-ERK in response to lapatinib treatment is also shown in several other models 
of acquired lapatinib resistance [235].  
In contrast to HCC1954-L cells, SKBR3-L cells had lower levels of both phospho-AKT 
and phospho-ERK; in fact the levels of phospho-AKT were barely detectable by 
immunoblotting. This suggests that the lapatinib-resistant cells are no longer dependent 
on AKT signalling for survival. Alterations in the PI3K/AKT pathway are frequent in 
human cancer, either due to amplification of the genes encoding either PI3K or AKT, 
PI3K mutations or loss of PTEN all of which result in increased activation of AKT 
[reviewed in [50]]. While alterations in the PI3K pathway have been implicated in 
resistance to trastuzumab [82, 299], the role of P13K mutations and pathway alteration 
in lapatinib resistance is still controversial. It has been reported that loss of PTEN 
expression and/or P13K mutations conferred resistance to lapatinib and trastuzumab, 
using BT474 breast cancer cell line [224]. However another study, using a panel of 
HER2 positive breast cancer cell lines, reported that loss of PTEN and/or P13K 
mutations is associated with innate resistance to trastuzumab but not lapatinib [194]. 
While mutations in PI3K are commonly thought to result in downstream activation of 
AKT, there is also evidence to suggest that P13K mutation may result in diminished 
AKT signalling [300]. Therefore, examination of the mutation status of PI3K, and the 
levels of PTEN, in the SKBR3-L cells may help to elucidate the mechanism of the 
decreased phospho-AKT in these cells.  
 
8.2.4 Previously reported mechanisms of lapatinib resistance 
8.2.4.1 Upregulation of ER signalling  
Gene expression profiling comparing a BT474 model of acquired lapatinib resistance to 
its parent cell line revealed increased dependence on ER signalling for survival, and 
combining lapatinib with anti-ER therapy prevented the emergence of lapatinib-resistant 
cells [229]. Importantly, this study also showed that lapatinib treatment of HER2 
positive breast tumours resulted in increased ER expression. Upregulation of ER 
signalling has also been shown in several other models of acquired lapatinib resistance. 
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In another BT474 model of acquired lapatinib resistance, in addition to showing 
upregulation of AXL as a novel mechanism of acquired lapatinib resistance, the 
lapatinib resistance cells had higher levels of ER and were sensitive to lapatinib when 
combined with fulvestrant or estrogen deprivation [232]. A recent study using BT474 
and UACC812 models of lapatinib resistance also showed upregulated ER signalling 
and sensitivity to fulvestrant following acquisition of lapatinib resistance [236]. The 
above studies suggest that when HER2 signalling is inhibited by long-term lapatinib 
treatment in ER positive cells, ER becomes the dominant driver of growth in these cells. 
The expression of ER was measured in HCC1954-L and SKBR3-L cell lines and the 
levels of ER were found to be undetectable in both parental and resistant cell lines, 
indicating that upregulation of ER signalling was not a mechanism of lapatinib 
resistance in these cell lines. Thus, upregulation of ER signalling in lapatinib-resistant 
cells appears to be limited to HER2/ER positive cell lines and a switch from HER2 to 
ER signalling does not function as an escape mechanism for ER negative cell lines [231, 
236, 301].  
8.2.4.2 Upregulation of SRC family kinases 
Phospho-proteomic profiling of lapatinib-resistant cells suggested that SRC (or a SRC 
family kinase) activity was upregulated in lapatinib-resistant cells compared to parental 
cells. BT474 resistant cells exhibited increased activity of YES while HCC1954 
resistant cells exhibited increased activity of LYN and SRC was more ubiquitously 
expressed in all lapatinib-resistant cell lines tested [235]. Their study also showed that 
treatment of lapatinib-resistant cells with SRC inhibitors resulted in growth inhibition, 
and more importantly they showed that mRNA expression of several SRC family 
members was upregulated in a small cohort of primary HER2 positive tumours 
following lapatinib treatment. The levels of total and phosphorylated SRC were 
examined in HCC1954-L and SKBR3-L cells. While there was no change in the 
expression of SRC in SKBR3-L cells compared to SKBR3-par cells, HCC1954-L cells 
exhibited a small yet significant increase in SRC compared to HCC1954-par cells. The 
levels of phospho-SRC were practically undetectable in all four cell lines. The increased 
expression of SRC in HCC1954-L cells may indicate an alteration in sensitivity to SRC 
inhibition and further work to investigate the role altered SRC may play in acquired 
lapatinib resistance is warranted.  
8.2.4.3 Upregulation of XIAP 
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XIAP, an inhibitor of apoptosis protein, has been linked to therapeutic resistance in 
multiple cancer types [245], and it has been reported to be expressed in breast tumour 
samples [302]. The expression of XIAP correlates with shorter overall survival and may 
act as an independent prognostic biomarker for invasive ductal carcinoma [246].  
Trastuzumab treatment results in increased XIAP expression [303], and using IAP 
inhibitors in combination with either trastuzumab or lapatinib, increased apoptosis 
compared to either agent alone [304]. Notably, upregulation of XIAP has been seen in a 
SUM190 cell line model of lapatinib-resistant inflammatory breast cancer [231]. These 
studies suggested a strong interaction between HER2 signalling, resistance to anti-
HER2 targeted therapy and expression of XIAP. The expression of XIAP was measured 
in HCC1954-L and SKBR3-L cells and found no change in expression between 
SKBR3-L and SKBR3-par cells. Interestingly, the steady state levels of XIAP were 
slightly lower in HCC1954-L cells compared to HCC1954-par, but when treated with 
lapatinib HCC1954-L cells exhibited a significant increase in XIAP expression, while 
the parental cells exhibited a decrease in XIAP. Decreased XIAP following lapatinib 
treatment has been reported previously in SUM190 lapatinib sensitive cells [303], 
however other studies have noted that lapatinib treatment did not affect the expression 
of XIAP in a panel breast cancer cell lines  [144, 150]. In addition, XIAP expression 
was unaltered in HCT116 lapatinib-resistant cells [233]. The study identifying up-
regulated XIAP in lapatinib resistance stated that the lapatinib-resistant cells were 
routinely cultured in lapatinib-containing medium; therefore it is unclear whether the 
change in XIAP expression represents a change in the steady-state expression levels or a 
change in expression in response to lapatinib, as seen in the case of HCC1954-L cells. 
Also of note, Aird et al., use GW583340, a lab grade analogue of lapatinib, rather than 
GW572016. These results suggest that at present XIAP may not represent a common 
mechanism of acquired lapatinib resistance.  
8.2.4.4 Upregulation of MCL-1 
HCT116 cells, a colon cancer cell line conditioned with lapatinib, over-expresses MCL-
1, an anti-apoptotic member of the BCL-2 family. Knockdown of MCL-1 in lapatinib-
resistant cells enhanced lapatinib activity [233, 244]. The interaction between lapatinib 
treatment and altered MCL-1 expression is not limited to colon cancer. Treatment of 
HER2 positive breast cancer cell lines with lapatinib in combination with CDK 
inhibitors resulted in inhibition of MCL-1 expression, and combining lapatinib with an 
inhibitor of MCL-1 (obatoclax) enhanced the activity of lapatinib both in vitro and in 
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vivo [145]. Treatment of cell lines with trastuzumab has also been shown to alter MCL-
1 expression levels [305]. The expression of MCL-1 was examined in HCC1954-L and 
SKBR3-L cells; SKBR3-L cells exhibit higher levels of MCL-1 compared to SKBR3-
par cells. In contrast, HCC1954-L cells exhibit a decrease in steady-state MCL-1 levels 
compared to parental cells. The altered expression of MCL-1 in both resistant cells lines 
suggests that alterations in MCL-1 and possibly other members of the BCL-2 family 
may play a role in lapatinib resistance in these cell lines, and inhibition of MCL-1 has 
the potential to restore sensitivity to SKBR3-L cells. In fact, recent work from our 
laboratory has shown that in addition to increased expression of MCL-1, SKBR3-L cells 
exhibit decreased expression of BAX and are sensitive to combined inhibition with 
lapatinib and obatoclax [306].  
8.2.4.5 Additional mechanisms of acquired lapatinib resistance 
There are a number of other reported mechanisms of acquired lapatinib resistance 
including; up regulation of AXL [232], up regulation of β1 integrin [234], increased 
autophagy [252], RelA regulation [230], and increased expression of truncated HER2 
[307]. Future work examining the possible role that these mechanisms may play in 
SKBR3-L and HCC1954-L cells would help elucidate mechanisms of lapatinib 
resistance.  
In summary, this study reports the development and characterisation of two newly 
established cell line models of acquired lapatinib resistance; HCC1954-L cells and 
SKBR3-L cells. The lapatinib-resistant phenotype was stable in both cell lines 
following freeze-thaw cycles and for up to 2 months in the absence of lapatinib (3 
months for HCC1954-L cells). Both cell lines retained their HER2 overexpression 
status following lapatinib conditioning and treatment of the cells with lapatinib inhibited 
the phosphorylation of HER2. SKBR3-L cells expressed significantly less HER4 
compared to SKBR3-par cells, and thus, lack of HER4 expression may be mechanism 
of acquired lapatinib resistance in SKBR3-L cells. SKBR3-L cells also exhibited cross-
resistance to EGFR targeted therapy, and have increased expression and 
phosphorylation of EGFR. Interestingly, the phosphorylation status of AKT and ERK 
were not associated with lapatinib response in HCC1954-L cells, however, SKBR3-L 
cells exhibited a lack of phospho-AKT in untreated cells. Future work will be required 
to determine the effect of lack of phospho-AKT and its relationship to lapatinib 
resistance in these cells. Published mechanisms of acquired lapatinib resistance were 
examined in HCC1954-L and SKBR3-L cells. Neither cell line exhibited increased 
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expression of ER suggesting that while ER upregulation has been shown as a 
mechanism of lapatinib resistance in HER2 positive cell lines which co-express ER, it is 
not a mechanism of lapatinib resistance in HER2 positive ER negative breast cancer. 
Upregulation of SRC was found in HCC1954-L cells only, upregulation of MCL-1 was 
found in SKBR3-L cells only and increased expression of XIAP was found in 
HCC1954-L cells following treatment with lapatinib. These results suggest that the 
published mechanisms of lapatinib resistance may contribute to lapatinib resistance in 
HCC1954-L and SKBR3-L cells and further investigation of these alterations would 
increase our understanding of acquired lapatinib resistance.  
 
8.3 Novel mechanisms of acquired lapatinib resistance 
8.3.1 Senescence – a novel effect of lapatinib conditioning 
HCC1954-L and SKBR3-L cells, two cell line models of acquired resistance to lapatinib 
were developed. In contrast, HCC1419 cells conditioned with lapatinib did not result in 
the development of an actively proliferating cell line model of acquired lapatinib 
resistance. HCC1419 cells conditioned with lapatinib ceased proliferation and cells 
remaining after 6 months of conditioning displayed an altered morphology and arrested 
growth rate which lead us to hypothesise that lapatinib induced a senescent-like 
phenotype in HCC1419 cells.  Senescence is a state of permanent cell cycle arrest 
characterised by a distinct and recognisable flattened and enlarged cellular morphology 
with a prominent nucleus and increased cytoplasmic granularity. Senescent cells remain 
viable and metabolically active but are permanently growth arrested in either the G1 or 
G2/M stage of the cell cycle [281]. A study showing that senescent cells had β-
galactosidase activity, detectable at pH 6.0, that was not detectable in quiescent cells 
[308], led to the development of senescence-associated β-galactosidase activity as the 
most widely used biomarker in studies of cellular senescence in vitro and in vivo [309]. 
Lapatinib conditioning of HCC1419 cells, either short term (1 week), or long term (6 
months), resulted in increased activity of senescence-associated β-galactosidase, 
suggesting that lapatinib induces a senescent-like phenotype in HCC1419 cells.  This is 
the first to report of induction of senescence-associated β-galactosidase activity 
following lapatinib treatment. 
Replicative or cellular senescence is a mechanism whereby aging cells exhaust their 
replicative potential and remain viable but become permanently growth arrested [310]. 
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Human cells cultured in vitro displayed limited proliferation over an extended period 
[311], and the mechanism which controls the limited proliferative potential of cells was 
discovered to be the shortening of telomeres [312].  One of the hallmarks of cancer is 
increased and dysregulated proliferation [74], thus replicative senescence has a tumour 
suppressor function in normal cells [reviewed in [313, 314]]. Cells can also undergo 
senescence in response to stress which is independent of telomerase shortening, 
commonly referred to as therapy-induced senescence, or accelerated cellular senescence 
(ACS) [281].  Chemotherapeutic agents and several antibiotic compounds induced ACS 
in response to DNA damage, in multiple types of cancer both in vitro and in vivo [315-
317]. Hydroxyurea, pyrithione and resveratrol induced reactive oxygen species (ROS)-
mediated ACS in colon cancer and neuroblastoma cell lines [318-320]. Inhibition of 
PTEN, with a specific PTEN inhibitor (VO-OHpic) induced ACS in prostate cancer 
cells [321], and inhibition of aurora kinase A with MLN8054 induced ACS in multiple 
cancer cell lines in vitro and in vivo [322]. These studies show that in addition to 
playing a role in controlling the replicative potential of cells, induction of senescence 
may be a mode of action of several therapeutic interventions, including lapatinib. 
The mechanism of how lapatinib induces a senescent-like phenotype in HCC1419 cells 
is not fully understood, however, specific inhibitors of both ERK and AKT show that 
inhibition of either pathway was sufficient to induce a senescent-like-phenotype in these 
cells. This suggests that the induction of a senescent-like-phenotype is not dependent on 
combined inhibition of P13K and MAPK signalling in HCC1419 cells. There is 
evidence to suggest that induction of ACS is dependent on the concentration of the 
inducing agent. Lower concentrations of the agent may trigger a senescence response 
without activating the cascade of caspase activity that commits the cell to apoptosis 
[315]. High dose doxorubicin induces apoptosis in cardiomyocytes, whereas low dose 
doxorubicin induces ACS [323]. Consistent with this result HCC1419 cells treated with 
low dose lapatinib (50 – 500 nM) induced stronger senescence-associated β-
galactosidase activity compared to concentrations of lapatinib in excess of 500 nM. 
Interestingly, senescence-associated β-galactosidase activity was induced following 
combined treatment with trastuzumab and lapatinib in HCC1419 cells but not following 
treatment with trastuzumab alone. This result suggests lapatinib-induced senescence 
may be mediated by direct inhibition of the HER2 kinase domain. 
The tumour suppressor p53 plays a key role in promoting senescence [reviewed in 
[324]], and has been reported to be critical for the establishment of senescence in human 
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cells [325, 326]. However, other studies have shown that transformed cells that lack p53 
retain the capacity to develop senescence in response to anti-cancer agents [327, 328]. 
Intriguingly, our study reports lapatinib-induced senescent-like phenotype in HCC1419 
cells which are p53 negative [329]. In contrast SKBR3 cells which have mutant p53 
(p53R175H), which has a gain of function effect on p53 [330], do not undergo lapatinib 
induced senescence.  
p16 
Ink4A
 (CDKN2A) is a cyclin-dependent kinase (CDK) inhibitor whose expression is 
often increased in senescent cells [331], along with increased expression of p15
Ink4B 
(CDKN2B) [332], p21
Waf1
 (CDKN1A) [333] and p27
Kip1
 (CDKN1B) [334] [reviewed in 
[281, 283, 335]]. Treatment of SKBR3 and HCC1419 cells with lapatinib had a similar 
effect on the expression of these CDKs; the levels of p21 were unchanged in both cell 
lines, and the levels of p15 and p27 increased in both cell lines. However, only 
HCC1419 cells exhibited increased β-galactosidase activity. This may be due to 
HCC1419 cells having much higher levels of p15, p21 and p27 than SKBR3 cells when 
the cells were treatment naive, therefore following lapatinib treatment the levels of p15, 
p21 and p27 were significantly higher in HCC1419 cells compared to SKBR3. 
Interestingly p16 levels were undetectable in both SKBR3 and HCC1419 cells; this is 
consistent with reports that loss of p16 expression is a frequent occurrence in tumour-
derived cell lines [336-338]. Thus, lapatinib induced a senescent-like phenotype in 
HCC1419 cells characterised by increased β-galactosidase activity and high levels of 
p15, p21 and p27.  
Based on these results we propose the induction of a senescent-like phenotype as a 
novel mechanism of action of lapatinib. Recently there has been increasing interest in 
senescence-induction as a mechanism for inhibiting the growth of cancer cells. This 
type of strategy would result in tumour cytostatis rather than tumour regression or 
ablation. Senescence can be induced in tumour models that have inactivated apoptotic 
pathways leading to improved survival following chemotherapy [339]. In addition, 
evidence suggesting that senescence is induced with lower doses of drugs than that 
required for apoptosis induction suggests reduced toxicity related side effects for 
patients [320, 323]. Taken together these results suggest senescence induction may play 
an increasing role in cancer-therapy and the ability of lapatinib to induce senescence 
warrants further investigation as a mechanism of lapatinib action. 
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In addition to the discovery that lapatinib induces a senescent-like phenotype in 
HCC1419 cells, there is evidence suggesting that the senescent-like phenotype induced 
by lapatinib is reversible. The senescent-like phenotype was reversed when lapatinib 
was removed from the media; the previously senescent cells began to actively 
proliferate and retained their initial sensitivity to lapatinib. Senescence is defined as a 
being the permanent and irreversible loss of proliferative potential, given that growth 
factors cannot stimulate senescent cells to divide [313, 340]. However, several other 
studies have suggested that senescence can be reversed [317, 341, 342]. A model of 
reversible senescence has been proposed where the reversibility of senescence is 
dependent on the expression of p16 and p53 [341]. Senescence induced in cells which 
expressed low levels of p16 was reversible when p53 was inactivated or when 
oncogenic RAS was expressed in the cells. In contrast, inactivation of p53 and/or 
expression of RAS were incapable of reversing senescence induced in cells expressing 
high levels of p16 [341]. Studies show that p21 plays an important role in arresting cell 
growth in the early stages of senescence whereas p16 is the key effector in the 
maintaining long-term growth arrest, known as terminal senescence [316, 343]. In 
another model, senescence induced in response to a variety of chemotherapeutic agents 
was reversible in the p53-null, p16-deficient lung cancer cell line [317]. The cells that 
“escaped” senescence were found to overexpress CDK1 and targeting these cells with a 
CDK1 inhibitor prevented the cells from escaping senescence. A subsequent study with 
the same cells found that survivin is phosphorylated by CDK1, and that phosphorylated 
survivin is necessary for the reversibility of senescence and for viability of the cells 
following senescence escape [342]. Thus, suggesting that combining senescence-
induction with inhibition of survivin, is a means of preventing reversible senescence. 
Taken together these studies suggest a mechanism for the reversibility of the senescence 
phenotype induced in HCC1419 cells following lapatinib treatment [Figure 8-1]. The 
lack of detectable p16 expression coupled with p53 negativity suggests that the 
senescence induced by lapatinib in HCC1419 cells is reversed when the repression of 
oncogenic HER2 signalling by lapatinib is removed. Restoration of HER2 signalling 
provides a mechanism for senescent HCC1419 cells to escape senescence and re-
establish active proliferation in response to growth factor signalling. As the cells are 
once again dependent on HER2 for proliferation and survival, treating the cells with 
lapatinib inhibits their growth. Lapatinib-induced expression was examined in several 
additional models of HER2 positive lapatinib sensitive breast cancer but to date another 
cell line has not yet been identified which undergoes senescence in response to lapatinib 
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treatment. Future work examining the induction of senescence in response to lapatinib 
in HER2 positive cells should be focused on p53 and p16 negative cell lines. 
 
Figure 8-1: Proposed model of induction of reversible and/or irreversible senescence 
following lapatinib treatment. (A) HER2 positive cells expressing p53, but lacking p16 
expression do not undergo senescence following lapatinib treatment (e.g. SKBR3 cells). 
(B) Senescence can be induced by lapatinib in HER2 positive cells with high levels of 
p16 and/or p53 expression; however, due to the expression of p16 the induced 
senescence is irreversible, despite reactivation of HER2 signalling. (C) HER2 positive 
cells lacking p53 and p16 expression undergo senescence in response to lapatinib 
treatment (e.g. HCC1419 cells). Without expression of p16 to maintain the senescence 
phenotype, reactivation of HER2 signalling reverses the senescence.  
The induction of senescence in cancer cells following lapatinib treatment may represent 
a clinically relevant model of lapatinib resistance. Senescence has been identified in 41 
% of patient breast tumours following treatment with cyclophosphamide, doxorubicin, 
and 5-fluorouracil [316]. The staining was confined to tumour cells with no detection in 
normal tissues. Senescent markers have also been observed in lung tumours after 
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treatment with carboplatin and docetaxel [317]. These studies suggest that senescence 
may be a more prevalent tumour response to current anti-cancer therapy than previously 
thought.  
In summary, lapatinib induces senescence in HCC1419 cells following either short or 
long term treatment with lapatinib. HCC1419 cells are p53 negative, do not express 
p16, and express higher levels of p15, p21 and p27 compared to p53 positive SKBR3 
cells, which do not exhibit senescence-associated β-galactosidase activity following 
lapatinib treatment. Lapatinib, but not trastuzumab, induced senescence in a dose-
dependent manner, an effect which is simulated inhibition of AKT or ERK. 
Interestingly, lapatinib induced senescence in HCC1419 cells is reversible; following 
removal of lapatinib from the media HCC1419 cells began active proliferation and 
retain their initial sensitivity to lapatinib. Thus, the induction of senescence is being 
proposed as a novel mechanism of lapatinib action. In addition, p53 negativity coupled 
with lack of p16 expression may prevent induction of terminal senescence. Therefore 
the escape from lapatinib-induced senescence may be a novel mechanism of resistance 
to lapatinib in HCC1419 cells. Furthermore, loss of p53 and p16 may be potential 
biomarkers to identify tumours likely to undergo this reversible senescence in response 
to lapatinib treatment.  
 
8.3.2 Chromosomal alterations  
Alterations at the genetic level are quite common in cancer cells and reflect changes in 
biological process and signalling pathways that lead to cancer development and 
progression. Array Comparative Genomic Hybridisation (aCGH) is a technique that 
detects genome–wide copy number alterations which allows for the detection of cancer-
associated genes [reviewed in [257]]. aCGH technology was used to interrogate 
HCC1954-L cells for gene copy number alterations compared to the parental cell line. 
The alterations that found span several different chromosomes. Array CGH has 
previously been used to identify changes and characterise newly derived trastuzumab-
resistant cells [266], [267]. To our knowledge, aCGH has not yet been used to 
characterise a model of acquired lapatinib resistance.  
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Amplification of chr17q12 
HCC1954-L cells have increased amplification of chr17q12 compared to HCC1954-par 
cells. This region corresponds to multiple genes, the most instantly recognisable of 
which is HER2. The amplification of HER2 in HCC1954-L cells detectable at the 
genomic level, was also detectable at the protein level. A small but significant increase 
in HER2 levels was found in HCC1954-L cells compared to the parental cells which 
already have high levels of HER2. This increased amplification of HER2 was also 
detectable by FISH. However, given that the phosphorylation of HER2 is inhibited by 
lapatinib in HCC1954-L cells, it is unlikely that the increased expression and 
amplification of HER2 is playing a causative role in lapatinib resistance in these cells. 
Chromosome 17q12-21 contains the HER2 gene which is frequently amplified in breast 
cancer, however, the other genes from this region which are often co-amplified with 
HER2 have recently come under scrutiny. The genes associated with the HER2 
amplicon are depicted in Figure 8-2. TOP2A has aroused particular interest as it is 
frequently co-amplified with HER2 and has been associated with response to 
anthracycline-based chemotherapy in breast cancer [344, 345]. There was no increase in 
TOP2A amplification in HCC1954-L compared to HCC1954-par cells, however there 
was an increase in other genes from the chr17q12-21 region, including STARD3, GRB7 
and GSDMA. GSDMA, also known as GSDM1 and Gasdermin, is frequently 
suppressed in gastric cancer and associates with TGF-β in apoptotic regulation [346]. 
Upregulation of GRB7, growth factor receptor-bound protein 7, has been implicated in 
response to lapatinib therapy using in vitro and in vivo models [254]. Knockdown of 
GRB7 in HER2-amplified cells results in decreased cell proliferation [347]. Validating 
whether or not amplification of these genes corresponds to increased expression at the 
protein level will be important in determining the significance of these alterations. 
Intriguingly, using immunoblotting, the increased amplification of STARD3 (StAR-
related lipid transfer (START) domain containing 3) was also associated with a 
dramatic increase in STARD3 protein expression. STARD3, often referred to as 
MLN64 (metastatic lymph node 64), was initially identified from a breast-cancer-
derived metastatic lymph node cDNA library as a gene that was overexpressed and 
amplified in breast cancer [280].  STARD3 is frequently co-amplified with HER2 and 
over-expressed in breast cancer [348-350]. Studies also show its over-expression in 
prostate cancer [351]. HER2 and STARD3 share common transcriptional control 
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mechanisms [348]. In addition, overexpression of STARD3 in breast cancer correlates 
with poorer prognosis and survival [350]. Knockdown of STARD3 resulted in 
decreased cell proliferation and decreased cell-cycle progression in HER2 positive 
breast cancer cell lines which co-express STARD3 [347, 350]. Taken together these 
studies suggest that amplification and over-expression of STARD3 in HCC1954-L cells 
may contribute to lapatinib-resistant phenotype and also suggest that STARD3 could be 
promoting proliferation in HCC1954-L cells.  
Interestingly, while the co-amplification of GRB7, STARD3 and GSDMA with HER2 
has been reported previously [253, 347, 350], increased amplification of these genes has 
not previously been reported in lapatinib resistance. 
 
 
Figure 8-2: The HER2 amplicon on chromosome 17. LASP1, LIM and SH3 protein 1; 
RPL19, ribosomal protein L19; STARD3, StAR-related lipid transfer (START) domain 
containing 3; GRB7, growth factor receptor-bound protein 7; NR1D1, nuclear receptor 
subfamily 1, group D, member 1; RARA, retinoic acid receptor alpha; TOP2A, 
Topoisomerase 2-alpha; SMARCE1, SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily e, member 1. This figure and legend were 
reproduced from [352]. 
 
Amplification of chr12p12.1-12.2 
There were several other amplifications and deletions in the HCC1954-L cell line 
compared to HCC1954-par cells which warrant further investigation. HCC1954-L cells 
have an amplification in the region of chr12p12.1-12.2 compared to HCC1954-par cells. 
This region encodes multiple genes including all four members of the OATP1 (organic 
anion transporting polypeptide 1) family. OATPs belong to the superfamily of solute 
carrier anion transporters (SLCO), and HCCC1954-L cells have amplification of 
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OAPT1C1 (SLCO1C1), OATP1B3, (SLCO1B3), OATP1B1 (SLCO1B1) and 
OATP1A2 (SLCO1A2), [for review see [353]]. Altered expression of these OATPs has 
been reported in several cancer types including breast cancer [354]. OATPs transport a 
wide range of compounds into cells, OATP substrates include substrates include 
antibiotics, anti-diabetic drugs, anti-inflammatory drugs, antifungals, antivirals, 
antihistamines, anti-hypertensives, fibrates, statins, cardiac glycosides, 
immunosuppressants, and anti-cancer drugs [353, 355]. While the transport of lapatinib 
by OATPs has not been reported, OATP1B1 can transport CP724-714, a potent HER2 
tyrosine kinase inhibitor [356]. The OATP1 family amplified in HCC1954-L cells 
transport several anti-cancer drugs into the cell, including imatinib, methotrexate, SN-
38, docetaxel, paclitaxel and rapamycin [353]. This suggests that treating the lapatinib-
resistant cells with any of the above agents may be an effective treatment strategy as 
more of the drug would be transported into the cells, however, the increased 
amplification of the OATP1 family would need to confirmed at the protein level and the 
increased activity of the transporters validated.  
 
In summary, aCGH analysis of HCC1954-L cells compared to HCC1954-par cells 
revealed increased amplification of chr17q12, corresponding to several genes including 
HER2 and STARD3. The amplification of HER2 and STARD3 at the genomic level 
also translated into increased expression at the protein level. Of particular interest is the 
amplification and increased expression of STARD3 as several studies have highlighted 
the potential of STARD3 knockdown as a means of inhibiting the growth of cancer 
cells. Future work investigating the role of STARD3 amplification and protein 
expression in lapatinib resistance is warranted.  
 
8.3.3 Decreased phosphorylation of eEF2 
Previous work in our laboratory included the development of the SKBR3-L model of 
acquired lapatinib resistance, and phospho-proteomic profiling of SKBR3-L cells and 
their parent cell line, SKBR3-par [255]. The results of the phospho-proteomic analysis 
revealed alterations in the levels of phospho-eEF2, showing down regulation of 6 forms 
of phospho-eEF2 in SKBR3-L cells compared to SKBR3-par.  
Eukaryotic elongation factor 2 (eEF2) is a monomeric GTPase that plays an essential 
role in protein synthesis, whereby it catalyses the coordinated movement of two tRNA 
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molecules and the mRNA, and catalyses conformational changes in the ribosome. The 
activity of eEF2 regulates protein synthesis and the activity of eEF2 is inhibited upon 
phosphorylation. Phosphorylation of eEF2 at Thr56 inhibits its activity by preventing 
eEF2 binding to the ribosome [reviewed in [60, 256]]. Phospho-proteomic analysis 
revealed that SKBR3-L cells have significantly lower levels of phospho-eEF2 compared 
to SKBR3-par cells and this result was confirmed using immunoblotting with an 
antibody specific to the Thr56 phosphorylation site of eEF2. In addition, treatment of 
SKBR3-par cells with lapatinib resulted in a significant increase in phospho-eEF2 
levels, suggesting inhibition of protein synthesis. In contrast, there was no change in the 
levels of phospho-eEF2 in SKBR3-L cells following lapatinib treatment, suggesting that 
lapatinib does not inhibit protein synthesis in SKBR3-L cells. These results suggest that 
alterations in the levels of phospho-eEF2 may play a role in acquired lapatinib 
resistance. eEF2 was found to be highly expressed in lung adenocarcinoma where its 
expression was associated with an increased incidence of tumour recurrence and a 
significantly worse prognosis [357]. eEF2 is also expressed in gastrointestinal and 
colorectal cancer, where eEF2 promoted G2/M progression and enhanced cell growth 
[358]. Although the expression of eEF2 has previously been associated with cancer, it 
has not previously been studied in acquired lapatinib resistance. We therefore sought to 
determine the mechanism responsible for the altered phosphorylation of eEF2 in 
SKBR3-L cells. 
eEF2 kinase (eEF2k), also known as calmodulin-dependent protein kinase III, is a 
calcium/calmodulin-dependent enzyme that inhibits protein synthesis by 
phosphorylating and inactivating eEF2 [359]. The expression of eEF2k was increased in 
SKBR3-L cells compared to SKBR3-par cells, which correlates with the decreased 
phosphorylation of eEF2 in SBR3-L cells. A previous study has shown that eEF2k 
expression and activity was increased in breast tumours compared to normal adjacent 
breast tissue [360]. eEF2k is a substrate for p70S6k, a kinase which is activated in an 
mTOR-dependent manner. p70S6k phosphorylates eEF2k at Ser366 resulting in the 
inactivation of eEF2k, thus preventing the phosphorylation of eEF2 [361]. SKBR3-L 
cells have higher levels of Ser366 phosphorylation of eEF2k compared to SKBR3-par 
cells. Based on this result, it was hypothesised that phosphorylation of eEF2k at Ser366 
may regulate the phosphorylation of eEF2, and that the increased Ser366 
phosphorylation of eEF2k in SKBR3-L cells may be responsible for decreased phospho-
eEF2 levels in SKBR3-L cells compared to SKBR3-par cells.  However, while 
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treatment of SKBR3-L cells with lapatinib had no effect on the levels of Ser366 
phosphorylation of eEF2k, treatment of SKBR3-par cells with lapatinib resulted in a 
small, yet significant increase in Ser366 phosphorylation of eEF2k. Increased 
phosphorylation of Ser366 should decrease the activity of eEF2k, however, in SKBR3-
par cells phospho-eEF2 is significantly increased following lapatinib treatment. These 
results suggest that phosphorylation of eEF2k at Ser366 does not regulate the activity of 
eEF2k on the phosphorylation of eEF2 in these cells. 
The activity of eEF2k is also regulated by phosphorylation of Ser359 by 
SAPK4/p38MAPKδ (SAPK4), whereby phosphorylation of eEF2k at Ser359 results in 
the inactivation of eEF2k leading to reduced phosphorylation of eEF2 (activation) 
[362]. In addition, cdc2, also known as CDK1, phosphorylates eEF2k at Ser359 [363]. 
Phosphorylation of eEF2k at Ser359 was significantly increased in SKBR3-L cells 
compared to SKBR3-par cells. Treatment of SKBR3-par cells with lapatinib resulted in 
decreased levels of phospho-eEF2k at Ser359. This suggests that phosphorylation of 
Ser359, rather than Ser366, regulates the activity of eEF2k in SKBR3-par cells. While 
there was a small decrease in phospho-eEF2k (Ser359) in SKBR3-L cells following 
lapatinib treatment, the decrease was not significant. To summarise, we propose that 
increased phosphorylation of Ser359 of eEF2k contributes to the decrease in eEF2 
phosphorylation observed in SKBR3-L cells [Figure 8-3].  
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Figure 8-3: Regulation of eEF2 phosphorylation: (A) lapatinib-induced 
dephosphorylation of eEF2k at Ser359 results in the activation of eEF2k and the 
subsequent phosphorylation and inactivation of eEF2 in SKBR3-par cells. (B) 
Maintained phosphorylation at Ser359 of eEF2k prevents lapatinib-induced activation 
of eEF2k and thus, eEF2 remains un-phosphorylated and active in SKBR3-L cells.  
By showing that the activity of eEF2k is not regulated via phosphorylation of Ser366, a 
mechanism is proposed whereby the phosphorylation of eEF2 is regulated in an mTOR-
independent manner. However, it has been reported that insulin-like growth factor 1 
(IGF-1) can phosphorylate eEF2k at Ser359 and treatment with the mTOR inhibitor 
rapamycin prevents this effect [362]. SAPK4 is not activated by IGF-1, nor thought to 
be regulated by mTOR, suggesting that the phosphorylation of Ser359 may occur via 
both mTOR dependent and independent mechanisms. To determine whether or not 
mTOR signalling plays a role in the regulation of eEF2 signalling, SKBR3-par and 
SKBR3-L cells were treated with lapatinib and examined the phosphorylation and 
expression of mTOR. The phosphorylation of mTOR at Ser2448 was lower in SKBR3-
L cells compared to SKBR3-par cells; however, lapatinib treatment of both cell lines 
resulted in the inhibition of Ser2448 phosphorylation. This indicates that lapatinib 
inhibits mTOR signalling in both cell lines and thus the alteration in eEF2 
phosphorylation is not likely to be mediated by mTOR. This result was further 
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confirmed by treating SKBR3-par and SKBR3-L cells with rapamycin; rapamycin 
treatment increased the phosphorylation of eEF2 in SKBR3-par but had no effect on 
eEF2 phosphorylation in SKBR3-L cells. Thus, inhibition of mTOR signalling by either 
lapatinib or rapamycin leads to increased phospho-eEF2 in the SKBR3-par cells but not 
in the SKBR3-L cells. Although lapatinib inhibits mTOR signalling in SKBR3-L cells, 
our results suggest alterations in other pathways that regulate eEF2k phosphorylation 
are responsible for the dephosphorylation and activation of eEF2 in SKBR3-L cells.  
After identifying a mechanism whereby the phosphorylation of eEF2k at Ser359 
regulates the phosphorylation of eEF2, the effect of inhibition of eEF2k activity on 
phosphorylation of eEF2 and on the sensitivity of SKBR3-par cells to lapatinib was 
examined. NH125 is a potent and selective inhibitor of eEF2k activity, with an IC50 of 
60 nM for eEF2k in vitro [364]. Treatment of SKBR3-par cells with concentrations of 
NH125 ranging from 100 to 500 nM, resulted in the inhibition of eEF2k activity, 
measured as the dephosphorylation of eEF2 at Thr56. NH125 treatment 
dephosphorylated eEF2 without affecting signalling through AKT or ERK. Following 
confirmation that NH125 treatment resulted in the inactivity of eEF2k, and 
dephosphorylation of eEF2, the combined treatment of SKBR3-par cells with NH125 
and lapatinib was examined to test whether it would decrease the sensitivity of SKBR3-
par cells to lapatinib, suggesting the development of lapatinib resistance. Under very 
specific conditions, (ie. 100 nM NH125 pre-treatment, followed by 250 nM lapatinib 
treatment for 5 days), combining NH125 with lapatinib resulted in a small, yet 
significant decrease in sensitivity of SKBR3-par cells to lapatinib. However, the same 
effect was not seen using different concentrations of either NH125 or lapatinib. In 
addition, pre-treatment of SKBR3-par cells with 100 nM NH125 resulted in a decrease 
in lapatinib IC50 in SKBR3-par cells. Therefore it seems that NH125 can affect the 
sensitivity of SKBR3-par cells to lapatinib but its effects on lapatinib sensitivity are 
concentration dependent. Interestingly, although NH125 is a potent inhibitor of eEF2k, 
thus activating eEF2 (dephosphorylating) and enhancing protein synthesis, it has also 
been reported have anti-proliferative and pro-apoptotic effects in cancer cell lines [364-
366]. There are also conflicting reports on the effects of NH125 on the phosphorylation 
of eEF2, our study and others have shown that treatment with NH125 results in the 
dephosphorylation of eEF2 [364, 366]. This is in contrast to a recent study which 
reports that the anti-cancer activity of NH125 is correlated with induction of phospho-
eEF2 rather than inhibition of eEF2k [365]. For this reason the authors of the study 
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warn against the use of NH125 as an eEF2k inhibitor, although it should be noted that 
the concentration of NH125 used in the study were significantly higher (1 – 10 µM) 
than the concentrations used here (100 nM) to successfully dephosphorylate eEF2 and 
decrease lapatinib sensitivity in SKBR3-par cells. Inhibition of eEF2k activity, via 
NH125 treatment may not represent the most effective means of altering eEF2 
phosphorylation in SKBR3-par cells, or indeed give the most accurate representation of 
the effects of reduced eEF2k activity and phospho-eEF2 on the efficacy of lapatinib. 
Further work utilising eEF2k shRNA, to give sustained knockdown eEF2k expression 
and activity, or alternatively using a different inhibitor of eEF2k, such as the small 
molecule inhibitor A-484954, would be required to confirm the effect of eEF2k 
inhibition on lapatinib sensitivity.  
Inhibition of eEF2k activity via NH125 resulted in the dephosphorylation of eEF2 but 
was not sufficient to reliably alter the sensitivity of SKBR3-par cells to lapatinib. 
Indirectly targeting the activity of eEF2k, via inhibition of the protein/pathway 
regulating its phosphorylation at Ser359, could provide a more effective means of 
altering lapatinib sensitivity. We have proposed that phosphorylation of eEF2k at 
Ser359, possibly mediated by SAPK4 [362], or CDK1 [363], may be responsible for the 
regulation of eEF2 phosphorylation. Immunoblotting revealed that SKBR3-L cells have 
increased phosphorylation of CDK1 at Tyr15 (which is associated with decreased 
CDK1 activity), despite having decreased expression of CDK1 compared to SKBR3-par 
cells. This result suggests that CDK1 activity may play a role in eEF2 phosphorylation, 
as CDK1 phosphorylates eEF2k at Ser359. However, treatment of the cell lines with 
lapatinib revealed decreased expression and phosphorylation of CDK1 in both cells, 
suggesting that lapatinib treatment has a similar effect on CDK1 activity in both cell 
lines. Thus, the role that CDK1 may play in the regulation of eEF2 phosphorylation is 
unclear and future work examining the effect of CDK1 activation and suppression on 
eEF2 signalling is warranted.  
SAPK4 signalling may also play a role in the regulation of eEF2 phosphorylation. If 
SAPK4 is the kinase regulating the phosphorylation of eEF2k at Ser359, then 
pharmacological inhibition of SAPK4 would result in the phosphorylation and 
inactivation of eEF2 in SKBR3-L cells. SAPK4 is a member of the 38MAPK family, of 
which there are four member (p38α, p38β, p38γ and p38δ (SAPK4)). In additional to its 
role in the phosphorylation of eEF2k, SAPK4 is thought to play a role in cytoskeletal 
regulation [367, 368]. The chemical inhibitors SB203580 and SB202190 inhibit p38α 
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and p38β but do not inhibit p38γ and SAPK4 [369], and although BIRB0796 can inhibit 
SAPK4, it also inhibits the other members of the p38MAPk family [370]. Therefore, at 
present specific pharmacological inhibition of SAPK4 is not feasible. A possible 
method of examining the role SAPK4 plays in regulating eEF2 phosphorylation would 
be to knockdown SAPK4 expression using siRNA in SKBR3-L cells and examine the 
phosphorylation of eEF2 and activity of lapatinib in the cells.  
Described above is a mechanism whereby eEF2 phosphorylation is mediated by 
increased eEF2k (Ser359) phosphorylation, however, future work will be required to 
determine the alteration(s) upstream of eEF2k causing its inactivation in SKBR3-L 
cells. In addition it is important to note that several other proteins/pathway can directly 
or indirectly regulate the phosphorylation of eEF2, as depicted in Figure 8-4. These 
include MEK, AMPK, PKC and PP2A. An activated form of MEK has been shown to 
dephosphorylate eEF2 via PI3K/mTOR dependent [371] and independent mechanisms 
[372]. Interestingly, SKBR3 cells overexpressing Ras develop resistance to lapatinib 
which can be overcome via MEK inhibition [373]. SKBR3-L cells exhibit lower levels 
of phospho-ERK compared to SKBR3-par cells and ERK is the only known substrate 
for MEK [374], thus, it is unlikely that decreased phosphorylation of eEF2 in SKBR3-L 
cells is mediated by activated MEK. AMP-activated protein kinase (AMPK) plays a key 
role in cellular energy homeostasis; depletion of ATP leads to a rise in the levels of 
AMP which activates AMPK [375]. AMPK phosphorylates eEF2k at Ser398, resulting 
in phosphorylation and inactivation of eEF2 via a non-mTOR mediated mechanism 
[376], and a generic HER1/2 inhibitor (GW-2974) activated AMPK in cancer cells 
[138]. It was not possible to examine phosphorylation at this site as there is currently no 
Ser398 phospho-eEF2k antibody commercially available. Oxytocin can induce 
dephosphorylation of eEF2 via the protein kinase C (PKC) pathway and Ser359 of 
eEF2k has been suggested to be a putative PKC phosphorylation site [377]. There is 
also evidence that PKC activation leads to increased PP2A activity [378, 379]. PP2A is 
a ubiquitously expressed protein phosphatase that functions to reverse the action of 
kinases in most major signalling cascades. Transgenic mice overexpressing PP2A 
exhibit increased eEF2 dephosphorylation [380] and inhibitors of PP2A attenuate the 
effects of angiotensin II on eEF2 dephosphorylation [371]. Tyrosine phosphorylation of 
PP2A results in inactivation of its phosphatase activity and loss of function as a tumour 
suppressor. Treatment of BT474 cells with heregulin resulted in increased 
phosphorylation of PP2A on Thr307 and treatment with a HER2 kinase inhibitor 
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(AG825) resulted in a decrease in PP2A phosphorylation thus increasing its activity. In 
breast tumour specimens, phosphorylated PP2A was high in HER2 positive breast 
tumours and significantly correlated with tumour progression [381]. This indicates that 
in HER2 positive cancer cells, signalling through HER2 is associated with 
phosphorylated PP2A and thus phosphorylated eEF2 and when signalling through 
HER2 is inhibited then PP2A is activated resulting in a dephosphorylation of eEF2. 
PP2A can also inactivate SAPK4 [382]. It is tempting to speculate that there could 
potentially be an alteration in PP2A activity leading to the constitutive 
dephosphorylation of eEF2 in SKBR3-L cells as a result of lapatinib conditioning. 
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Figure 8-4: mTOR-independent signalling pathways which interact with eEF2k or 
eEF2 to regulate the phosphorylation of eEF2. 
 
Acquired lapatinib resistance in SKBR3-L cells is associated with decreased 
phosphorylation of eEF2. The phosphorylation of eEF2 is regulated by phosphorylation 
of Ser359 of eEF2k and the activity of eEF2k is independent of mTOR signalling in 
these cells. Although inhibition of eEF2k activity, with NH125, did not reliably affect 
the sensitivity of lapatinib, it did result in the dephosphorylation of eEF2. Thus we 
propose that the alterations in the activity of eEF2k and eEF2 represent potential, novel, 
biomarkers of acquired lapatinib resistance. Validation in additional models of acquired 
lapatinib resistance would be required prior to pursuing this in tumour samples. 
Although a role for mTOR in the regulation of eEF2 phosphorylation in SKBR3-L cells 
has been ruled out, an interesting alteration was uncovered in the phosphorylation of 
p70S6k, a kinase directly phosphorylated by mTOR. The levels of phosphorylated 
p70S6k (Thr389) are unaltered between SKBR3-par and SKBR3-L cells, however, 
while treatment of SKBR3-par cells with lapatinib inhibits the phosphorylation of 
eEF2k
eEF2
phos
AMPK
Ser 398 P
SAPK4
Ser 359P
MEK
phos
PP2A
CDK1
active
inactive
CDK1
 238 
 
p70S6k, there was no effect on the levels of phospho-p70S6k in SKBR3-L cells. 
Phosphorylated p70S6k regulates the activity of eEF2k via phosphorylation at Ser366, 
however, the phosphorylation of eEF2k at Ser366 does not affect the activity of eEF2k 
towards eEF2. Thus suggesting that the alteration in the phosphorylation of p70S6k is 
independent of the alteration in eEF2 phosphorylation. The phosphorylation of p70S6k 
at Thr389 has been shown to be dependent on mTORC1 signalling, as rapamycin 
treatment results in the inhibition of p70S6k phosphorylation [383]. The 
phosphorylation of mTOR at Ser2448 has been reported to correlate with the activity of 
mTORC1 whereas phosphorylation at Ser2148 correlates with the activity of mTORC2 
[384]. Interestingly, although mTOR signalling is inhibited in SKBR3-L cells following 
lapatinib treatment, the phosphorylation of p70S6k was unaffected. This result suggests 
that the phosphorylation of p70S6k in SKBR3-L cells is maintained independently of 
mTORC1. mTORC1 was thought to be the sole kinase which phosphorylated p70S6k at 
Thr389 until experiments using cells with mutant p70S6k, revealed continued 
phosphorylation of p70S6k following mTORC1 inhibition with rapamycin [385]. The 
discovery that mTORC2, which is insensitive to acute rapamycin, can phosphorylate 
p70S6k in an mTORC1-independent manner, suggests a mechanism whereby the 
phosphorylation of p70S6k is maintained despite inhibition of mTORC1 signalling 
[386]. This suggests that mTORC2 may be responsible for maintaining the 
phosphorylation of p70S6k in SKBR3-L cells. 
Although alterations in p70S6k phosphorylation are not responsible for the 
dephosphorylation and activation of eEF2 via Ser359 phosphorylation and inactivation 
of eEF2k, maintenance of p70S6k phosphorylation in SKBR3-L cells may be an 
independent marker of acquired lapatinib resistance in SKBR3-L cells. Overexpression 
and/or amplification of p70S6k is associated with a worse prognosis, decreased overall 
survival and increased risk or recurrence in breast cancer patients [387, 388], and the 
expression of p70S6k has been correlated with HER2 overexpression [389]. A recent 
study has reported that sensitivity to lapatinib is associated with its ability to inhibit the 
phosphorylation of p70S6k in breast cancer cell lines [390], and an association between 
hyper-phosphorylation of p70S6k and lapatinib resistance in an MCF-7-HER2 
transfected model of acquired lapatinib resistance [391]. These studies support the 
hypothesis that altered phosphorylation of p70S6k may be a marker of acquired 
lapatinib resistance, and the mechanism maintaining phosphorylation of p70S6k in 
SKBR3-L cells warrants further investigation.  
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In summary, SKBR3-L cells have lower levels of phospho-eEF2 compared to SKBR3-
par cells. Treatment of SKBR3-par cells with lapatinib resulted in increased 
phosphorylation of eEF2 but it had no effect on the phosphorylation of eEF2 in SKBR3-
L cells. Phosphorylation of eEF2k at Ser359 but not the mTOR dependent Ser366 site, 
correlated with eEF2k activity. Lapatinib treatment inhibited mTOR activity in both cell 
lines, as indicated by inhibition of Ser2448 phosphorylation, and rapamycin treatment 
was incapable of phosphorylating eEF2 in SKBR3-L cells. These results confirm that 
eEF2k regulation of eEF2 phosphorylation is independent of mTOR, and represent a 
novel association between alterations in the eEF2 phosphorylation and acquired 
lapatinib resistance. SKBR3-L cells also exhibited mTOR-independent maintenance of 
phospho-p70S6k which may be an eEF2-independent marker of acquired lapatinib 
resistance. 
  
8.3.4 SILAC phospho- and total proteomics  
SILAC labelling coupled with phospho-tyrosine enrichment was performed to compare 
the tyrosine phospho-proteome of SKBR3-par cells to SKBR3-L cells. The 
quantification and identification of alterations in tyrosine phosphorylation is hindered 
by the low abundance of phospho-proteins, particularly tyrosine-phosphorylated 
proteins in human cells. A major break-through in the study of altered phospho-tyrosine 
signalling came with the development of a phospho-peptide enrichment procedure 
utilising an immunoaffinity-based based method [272]. This enrichment procedure 
revealed more than 300 distinct tyrosine phosphorylation sites in protein extracts from 
three different human cancer cell lines. Since then, this enrichment procedure has been 
used to study tyrosine phosphorylation in multiple different settings including in the 
study of human cancer [273, 392-395], and also in the study of drosophila [396] and 
plants [397]. The technique has also been utilised to examine alterations in phospho-
tyrosine signalling in a BT474 cell lines model of acquired lapatinib resistance [235].  
Unfortunately, despite positive indications from optimisation experiments, the same 
tyrosine phosphorylation enrichment procedure was inefficient in the identification of 
alterations in tyrosine phosphorylation between SKBR3-par and SKBR3-L cells. In fact, 
only a single tyrosine-phosphorylated protein (CDK1) was identified which was present 
in all three biological replicates and had quantitative data associated with it. Why the 
tyrosine-enrichment procedure was inefficient in identifying alteration in phospho-
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tyrosine signalling between SKBR3-par and SKBR3-L cells remains unclear. However, 
it is possible that inefficient binding of phospho-tyrosine peptides to the antibody beads 
and/or loss of sample during the concentration and clean-up steps may be contributing 
factors. If this procedure was to be repeated analysis of a small quantity of the sample 
by LC-MS prior to and following the antibody-binding step and clean-up steps would be 
recommended.  
Although the volume of results generated from the phospho-tyrosine analysis were 
disappointing CDK1 was identified as a tyrosine phosphorylated protein whose level 
was significantly higher in untreated SKBR3-L cells compared to untreated SKBR3-par 
cells. Immunoblotting for phospho-CDK1 with an antibody which targets Tyr15 
confirmed increased levels of phospho-CDK1 in SKBR3-L cells. Cyclin dependent 
kinase 1(CDK1), also known as cdc2, is a protein which plays a key role in regulating 
the mammalian cell cycle [reviewed in [398]]. CDK1, forms a complex with cyclin-B 
but is held in an inactive state by phosphorylation of CDK1 at Tyr15 and Thr14 by the 
protein kinases Wee1 and Myt1. Dephosphorylation of the CDK1-cyclin B complex at 
Thr14, following by Tyr15 by Cdc25 phosphatases results in activation and cell cycle 
progression [399]. The phosphorylation of CDK1 at Tyr15 is higher in SKBR3-L cells 
compared to SKBR3-par, despite SKBR3-L cells having decreased expression of CDK1 
compared to SKBR3-par cells. Lapatinib treatment decreases the expression and 
phosphorylation of CDK1 in both cell lines. Thus, at present, the impact of CDK1 
phosphorylation and expression on sensitivity and/or resistance to lapatinib has not been 
elucidated and future work examining additional phosphorylation sites and CDK1 
activity assays and cell cycle assays may more clearly define a role for CDK1 in 
lapatinib resistance. However, validation of the altered phosphorylation of CDK1, 
suggests that the SILAC labelling procedure and phospho-tyrosine enrichment worked 
as identification of an alteration in phospho-tyrosine signalling was detected, suggesting 
that the labelling and enrichment procedure worked but was extremely inefficient.  
In addition to analysing alterations in tyrosine phosphorylation between SKBR3-par and 
SKBR3-L cells changes in total protein expression were analysed using the SILAC-
labelled protein. Several statistically significant changes were detected in the levels of 
proteins in SKBR3-L cells compared to SKBR3-par cells, and also between both of the 
cell lines treated with lapatinib (GAPDH, SET, HER2, EBP1 and SELENBP1) and the 
altered levels of these proteins were confirmed using immunoblotting. 
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8.3.4.1 GAPDH 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an enzyme which plays a 
pivotal role in metabolism and is generally considered a housekeeping gene, however, 
this enzyme is actually very tightly regulated and is involved in numerous cellular 
functions [reviewed in [400]]. GAPDH has also been shown to have both a proapoptotic 
and antiapoptotic role in cell fate. Overexpression of GAPDH in ovarian cancer cells 
resulted in an increase in H202-induced apoptosis, and the phosphorylation of GAPDH 
by AKT2 is an essential step in GAPDH-mediated apoptosis [401]. Knockdown of 
GAPDH in A549 cells results in accelerated cellular senescence with increased 
signalling through the AMPK pathway suggesting a role for GAPDH in the control of 
tumour cell proliferation [402]. SKBR3-L cells have lower levels of GAPDH compared 
to SKBR3-par cells. Whether or not the altered expression of GAPDH is as a result of, 
or indeed plays any role in acquired lapatinib resistance has yet to be determined. 
Interestingly GAPDH interacts with SET protein (see discussion below) both in vitro 
and in vivo and together they regulate cell cycle progression by modulating cyclin B-
CDK-1 activity [403].  
8.3.4.2 SET / I2PP2A 
The SET domain is a 130-amino-acid sequence which was initially identified in the 
protein products of three regulatory genes in Drosophila, whose names account for the 
name SET, i.e, SU(VAR)3-9, enhancer of Zeste [E(Z)], and trithorax (Trx) [404]. SET 
protein, which is named for its SET domain, is also referred to as I
2PP2A and TAF1β.  
SKBR3-par and SKBR3-L cells express SET protein, however SKBR3-L cells treated 
with 1 µM lapatinib have lower levels of SET compared to untreated cells, whereas the 
levels of SET in SKBR3-par cells are unaffected by lapatinib treatment. SET is an 
oncoprotein with diverse cellular functions including cell cycle control, via inhibition of 
CDK1 activity [405], histone acetylation [406], gene transcription [407], apoptosis 
[408], and cell migration [409]. SET interacts with nm23-H1, a metastasis suppressor 
[410]. SET is a potent inhibitor of PP2A [411], a tumour suppressor protein which when 
active, negatively regulates the activity of several proteins including Akt, β-catenin and 
c-Myc and eEF2 [412-414]. Taken together this data suggests that SET plays a key role 
in numerous pathways that lead to more aggressive phenotypes and therefore represents 
an attractive target in the treatment of cancer.  COG112, has been shown to bind SET 
and increase the activity of PP2A and nm23-H1 and also Rac-1 [415]. The role of SET 
as an inhibitor of PP2A is of particular interest in SKBR3-L cells as the phosphorylation 
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of AKT and eEF2 is inhibited in SKBR3-L cells. It is possible that increased PP2A 
activity, mediated by alterations in SET, which is a negative regulator of PP2A activity, 
may play a role in the dephosphorylation of AKT and eEF2 in SKBR3-L cells. Further 
work will be required to elucidate the roles of SET and PP2A in lapatinib resistance. 
 
8.3.4.3 HER2 
The SILAC proteomic experiment revealed increased HER2 expression in SKBR3-par 
cells following lapatinib treatment compared to SKBR3-L cells. Immunoblotting with 
30 µg of protein did not reveal any alterations in HER2 expression. However, by 
reducing the quantity of protein to 5 µg, increased HER2 expression was detected in 
SKBR3-par cells compared to SKBR3-L cells following lapatinib treatment. The 
increased HER2 expression following lapatinib treatment in SKBR3-par cells is 
consistent with previous reports suggesting that lapatinib increases the expression and 
accumulation of HER2 [416, 417].Yet as previously discussed with regard to the 
increased HER2 amplification and expression of HER2 in HCC1954-L cells, this 
alteration in HER2 expression is unlikely to be causative of lapatinib resistance as 
lapatinib inhibits the phosphorylation of HER2 in all cell lines regardless of lapatinib 
sensitivity.  
 
8.3.4.4 EBP1 
Proliferation-associated protein 2G4, also known as ERBB3-binding protein one 
(EBP1), was initially identified as a HER3-binding protein using a yeast two-hybrid 
screen for HER3 interacting proteins [418]. Overexpression of EBP1 inhibits the growth 
of breast cancer cells [419]. Ectopic expression of EBP1 in breast cancer cells reduces 
the levels of HER2 protein, HER2 promoter activity and reduces HER2 protein stability 
[420, 421]. EBP1 also interacts with AKT via the PKC pathway to regulate cell survival 
and suppress apoptosis [422]. There are two different isoforms of EBP1, the longer 
form p48, suppresses apoptosis whereas the shorter from p42 promotes cell 
differentiation. In addition, EGF strongly stimulates p42 binding to HER3, whereas p48 
does not bind to HER3 regardless of EGF treatment [423]. This suggests that EBP1 has 
different effects on cell growth on survival depending on the expression of its isoforms. 
SKBR3-par and SKBR3-L cells express EBP1 and treatment of SKBR3-par cells with 
lapatinib results in a decrease in the expression of EBP1, in contrast there is no change 
in the levels of EBP1 in SKBR3-L when treated with lapatinib. The differential 
expression of EBP1 in response to lapatinib in these cells lines warrants further 
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investigation to determine whether EBP1 is playing a role in acquired lapatinib 
resistance.   
 
8.3.4.5 SELENBP1 
Selenium is an essential trace element which has been proposed to have an anti-cancer 
effect. A link between insufficient selenium and increased risk of cancer has been 
suggested [284, 285]. The anticancer action of selenium is thought to be mediated by 
selenium-binding protein 1 (SELENBP1). However, there is very limited data on the 
significance of selenium binding to SELENBP1 or indeed on the molecular function of 
SELENBP1. Interestingly, the expression of SELENBP1 is reduced in multiple cancer 
types including; gastric [424], prostate [425], lung [426], ovarian [427], thyroid [428], 
colorectal [429], uterine [430], esophageal adenocarcinoma [431] and hepatocellular 
[432], and has been associated with poor survival in gastric [424] and colorectal 
carcinoma [429]. Stable overexpression of SELENBP1 in esophageal adenocarcinoma 
cells resulted in increased sensitivity to cisplatin [431]. It has been proposed that 
SELENBP1 has tumour-suppressor function as the overexpression of 
SELENBP1sensitied colon cancer cells to H2O2-induced apoptosis, inhibited cancer cell 
migration in vitro and inhibited tumour growth in nude mice [433]. The expression of 
SELENBP1 was altered in SKBR3-L cells; SELENP1expression is significantly lower 
in SKBR3-L cells, treated with lapatinib, compared to SKBR3-par cells treated with 
lapatinib. The role that altered SELENBP1 may play in the response of SKBR3-par and 
SKBR3-L cells to lapatinib is yet unknown, this is the first study to report an alteration 
in SELENBP1 in breast cancer or in response to a targeted therapeutic agent.  
 
8.3.4.6  
As previously discussed the tyrosine-phosphorylation protein enrichment procedure was 
disappointing in that the yield of phosphorylated proteins identified for which matched 
SILAC data was calculated was extremely low. When the total proteome of the samples 
was examined using the un-enriched SILAC-labelled samples several alterations in total 
protein expression were identified between the two cell lines. However, several 
alterations which had previously been confirmed using western blotting were not 
detected as being altered between the two cell lines for example, eEF2k, IGF-IR, EGFR, 
HER4 etc. It’s possible that some of these proteins, like the HER receptors, have been 
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harder to detect due to the fact that they are not as readily separated on a 10 % gel as 
lower molecular weight proteins. Thus, if the experiment was to be repeated a gradient 
gel may provide more information than a 10 % gel. However, new developments in the 
field of proteomics are occurring at an accelerated pace and one of the more recently 
developed proteomic techniques is label-free MS. Label-free MS overcomes many of 
the limitations associated with SILAC technology such as increased time and 
complexity of sample preparation, requirement for higher sample concentration, high 
cost of the reagents, incomplete labeling, and the requirement for specific quantification 
software. Thus, label-free MS represents a fast and low-cost method of measuring 
protein expression levels in complex biological samples [434]. 
In summary, SILAC labelling coupled with phospho-tyrosine enrichment produced 
limited results on alterations in phospho-tyrosine signalling between SKBR3-par and 
SKBR3-L cells. However, it was possible to validate an alteration in the 
phosphorylation of CDK1, which was higher in SKBR-L cells compared to SKBR3-par 
cells. CDK1 plays an integral role in cell cycle progression and phosphorylation at 
Tyr15 regulates its activity. The expression of total proteins was analysed using SILAC-
labelled protein and significant alterations in the expression of GAPDH, SET protein, 
EBP1 and SELENBP1 were found. Functional validation of these proteins may reveal 
new targets or biomarkers of acquired lapatinib resistance.  
 
8.4 Innate lapatinib resistance  
In addition to examining alterations in HER family proteins and downstream signalling 
pathways activated by HER2 signalling in acquired lapatinib resistance, the expression 
and phosphorylation of these proteins were examined in innate lapatinib resistance. 
Using a panel of 15 HER2-amplified breast cancer cells, including 5 cell lines with 
innate lapatinib resistance the basal levels of phospho- and total HER2, HER3, EGFR, 
AKT, ERK, p70S6k and eEF2 were examined. Lapatinib sensitivity correlated with 
levels of phospho-HER2, total HER2, phospho-HER3, ERK and p70S6k. While 
lapatinib sensitivity has previously been correlated with the basal expression of HER2 
and the phosphorylation of HER2, HER3 and EGFR [134, 194], a correlation between 
levels of ERK or p70S6k and lapatinib sensitivity has not been reported previously. 
Quantifiable phospho-EGFR was not detected by immunoblotting thus correlations with 
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lapatinib sensitivity were not possible. This is in contrast to the above studies which 
measured phospho- and total EGFR by ELISA which is more sensitive.  
In addition, as the phosphorylation of AKT, ERK, p70S6k and eEF2 in response to 
lapatinib treatment differs between lapatinib sensitive and acquired lapatinib-resistant 
cells, alterations in the phosphorylation of these proteins were examined in a panel of 
HER2-amplifed cell lines. Reduced phosphorylation of HER2, AKT, p70S6k and ERK 
correlated with sensitivity to lapatinib, and increased phosphorylation of eEF2 also 
correlated with lapatinib sensitivity. Innate lapatinib-resistant cells exhibit maintained 
phosphorylation of AKT, ERK and p70S6k and do not exhibit increased eEF2 
phosphorylation in response to lapatinib treatment. The relationship between decreased 
phosphorylation of HER2 AKT, p70S6k and ERK and lapatinib sensitivity have 
previously been reported [134, 194, 390]. However, phosphorylation of eEF2 has not 
previously been correlated with sensitivity to lapatinib. Evaluation of the 
phosphorylation of eEF2, p70S6k, AKT, ERK and HER2 in lapatinib-treated breast 
tumours would be required to test the robust nature of these phospho-proteins as early 
pharmacodynamic biomarkers of lapatinib response. 
Interestingly, our results also suggest that several of the cell lines (SUM190, MDA-MB-
453 and MDA-MB-361) exhibit atypical alterations in the phosphorylation of eEF2, 
p70S6k, AKT and ERK compared to other lapatinib-sensitive/lapatinib-resistant cell 
lines. This suggests that these cell lines should not be utilised in isolation as cell line 
models of lapatinib sensitive and/or lapatinib-resistant cells as the results may not be 
indicative of global alterations. 
 
8.5 Summary and conclusions 
HCC1954-L and SKBR3-L cells represent novel cell line models of acquired lapatinib 
resistance. These cell lines were stably resistant and retained HER2 positivity. A 
summary of the alterations between SKBR3-par and SKBR3-L cells is listed in Table 8-
1. Several alterations were found in HER family members and members of downstream 
signalling pathways which may contribute to lapatinib resistance including, inhibition of 
HER4 expression, decreased levels of phospho-AKT and cross-resistance to EGFR 
targeted therapy in SKBR3-L cells. HCC1954-L cells also exhibited alterations in the 
phosphorylation of AKT and ERK. Published mechanisms of acquired lapatinib 
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resistance were examined in HCC1954-L and SKBR3-L cells. Increased ER expression 
has been reported as a mechanism of resistance to lapatinib however, it is not a 
resistance mechanism in HCC1954-L and SKBR3-L cells as there are ER negative. This 
study also reports upregulation of SRC in HCC1954-L cells only, upregulation of MCL-
1 in SKBR3-L cells only and increased expression of XIAP in HCC1954-L cells 
following treatment with lapatinib. These results suggest that these mechanisms may 
contribute to lapatinib resistance in HCC1954-L and SKBR3-L cells and further 
investigation of these alterations is warranted.  
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Table 8-1: List of alterations in protein phosphorylation and expression in SKBR3-L 
cells compared in SKBR3-par cells. 
Alteration Condition 
↑ phospho-HER2 in SKBR3-L cells  Untreated cells 
↑ phospho- and total EGFR in SKBR3-L cells  Untreated cells 
↑ HER3 in SKBR3-L cells following 1 µM lapatinib treatment 
↓ HER4 in SKBR3-L cells Untreated cells 
↓ phospho-AKT in SKBR3-L cells  Untreated cells 
↓ phospho-ERK in SKBR3-L cells  Untreated cells 
↑ phospho- and total IGF-IR in SKBR3-L cells  Untreated cells 
↑ MCL-1 in SKBR3-L cells Untreated cells 
↓ phospho-eEF2 in SKBR3-L cells Untreated cells 
↑ phospho-eEF2 in SKBR3-par cells only following 1 µM lapatinib treatment 
↑ phospho-eEF2k (Ser359) in SKBR3-L cells Untreated cells 
↓ phospho-eEF2k (Ser359) in SKBR3-par cells following 1 µM lapatinib treatment 
↑ phospho-eEF2k (Ser366) in SKBR3-L cells Untreated cells 
↑ phospho-eEF2k (Ser366) in SKBR3-par cells  following 1 µM lapatinib treatment 
↑ eEF2k in SKBR3-L cells Untreated cells 
↓ phospho-mTOR in SKBR3-L cells  Untreated cells 
↓ phospho-p70S6k in SKBR3-par cells following 1 µM lapatinib treatment 
↑ phospho-CDK1 in SKBR3-L cells  Untreated cells 
↓ CDK1 in SKBR3-L cells  Untreated cells 
↑ GAPDH in SKBR3-L cells Untreated cells 
↓ SELENBP1 in SKBR3-L cells  SILAC LAP vs LAP comparison 
↓ SET in SKBR3-L cells  SILAC LAP vs LAP comparison 
↑ EBP1 in SKBR3-L cells  SILAC LAP vs LAP comparison 
↓ sensitivity to gefitinib in SKBR3-L cells 0.8 ± 0.2 µM versus 4.9 ± 1.1 µM 
 
Lapatinib conditioning of HCC1419 cells revealed a novel potential mechanism of 
lapatinib action – the induction of a senescent-like phenotype. The induction of 
senescence was independent of p53 and p16 expression and associated with high levels 
of p15 and p27 mRNA. The senescent-like phenotype induced by lapatinib was reversed 
when lapatinib was removed from the media. We propose a model whereby lack of p53 
and p16 expression in HCC1419 cells prevented the cells from undergoing terminal 
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senescence in response to lapatinib treatment and thus the de-repression of HER2 
oncogenic signalling, following removal of lapatinib from the media, provided an 
escape from senescence. Therefore lapatinib induced senescence may not only be a 
novel mechanism of lapatinib action but also a novel mechanism of lapatinib resistance. 
These mechanisms warrant further investigation in in vitro and in vivo models of HER2 
positive breast cancer. However, to date this phenotype has not yet been replicated in 
any other models of lapatinib-sensitive cells. Future work will be required to identify 
another model of lapatinib-induced senescence. In addition, model based on p53 and 
p16 expression requires validation using over-expression and knock-down experiments 
in HCC1419 and SKBR3 cells.  
 
In addition, the lapatinib-resistant phenotype of HCC1954-L and SKBR3-L cells were 
examined and characterised using several different screening techniques, including; 
aCGH technology and proteomics.  
Array CGH comparison of HCC1954-L cells to HCC1954-par cells revealed 
amplification of chr17q12, corresponding to several genes including HER2 and 
STARD3. There was amplification of all 4 members of the OATP family of influx 
pumps. The amplification of HER2 and STARD3 at the genomic level also translated 
into increased expression at the protein level. The increased expression of STARD3 is 
particularly interesting as it has not been reported in lapatinib resistance previously. 
Previous phospho-proteomic analysis revealed decreases levels of phospho-eEF2 in 
SKBR3-L cells compared to SKBR3-par cells. The phosphorylation and activity of 
eEF2 was found to be regulated by phosphorylation of eEF2k at Ser359, in an mTOR 
independent manner. This suggests a role for SAPK4 signalling in lapatinib resistance. 
In addition SKBR3-L exhibit maintained phosphorylation of p70S6k following lapatinib 
treatment. Examining the phosphorylation of eEF2 and p70S6k in a panel of HER2 
positive lapatinib resistance cell lines revealed that alterations in the phosphorylation of 
eEF2 and p70S6k, in addition to the alteration in phospho-HER2, phospho-AKT and 
phospho-ERK, correlated with lapatinib sensitivity. Thus suggesting that these 
phosphorylated proteins have the potential to be biomarkers of lapatinib response. In 
addition the basal levels of phospho-HER2, HER2, phospho-HER3, ERK and p70S6k 
predicted lapatinib sensitivity in the panel of cell lines. 
 249 
 
SILAC phospho-tyrosine proteomic analysis of SKBR3-par and SKBR3-L cells 
revealed an alteration in phospho-CDK1, which may play a role in lapatinib resistance. 
In addition, performing total proteomic analysis of the cell lines revealed significant 
alterations in several proteins including, GADPH, SET protein, EBP1 and SELENBP1. 
Many of these protein alterations have not been previously reported in breast cancer 
and/or in lapatinib resistance.  
Further validation of all of the above results, using in vitro and in vivo models of 
lapatinib sensitivity and resistance, will be required to elucidate the roles of these 
alterations in a clinical setting.  
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Figure 9-1: SKBR3-par cells were pre-treated with either 100 nM (A, B and C) or 250 nM (D, E and F) NH125 for 24 hours, after which time NH125 
was removed from the cells and they were treated with either 100 nM lapatinib (A and D), 250 nM lapatinib (B and E) or 500 nM lapatinib (C and F) 
and the percentage growth of the cells was compared cells treated with lapatinib only. Growth is expressed relative to control untreated cells. Error bars 
represent the standard deviation of triplicate experiments. 
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Figure 9-2: SKBR3-par cells were pre-treated with either 100 nM (A, B and C) or 250 nM (D, E and F) NH125 for 24 hours, after which time NH125 
was removed from the cells and they were re-treated with NH125 and with either 100 nM lapatinib (A and D), 250 nM lapatinib (B and E) or 500 nM 
lapatinib (C and F) and the percentage growth of the cells was compared cells treated with lapatinib only. Growth is expressed relative to control 
untreated cells. Error bars represent the standard deviation of triplicate experiments. 
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Figure 9-3: SKBR3-par cells were treated with either 100 nM (A, B and C) or 250 nM (D, E and F) NH125  in combination with either 100 nM 
lapatinib (A and D), 250 nM lapatinib (B and E) or 500 nM lapatinib (C and F) and the percentage growth of the cells was compared cells treated with 
lapatinib only. Growth is expressed relative to control untreated cells. Error bars represent the standard deviation of triplicate experiments. 
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